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ABSTRACT 
Inhibition of CDK2 activity in G1 and S phases of the cell cycle can promote 
selective apoptosis of cancer cells through the E2F1 pathway.  Currently available CDK 
inhibitors target the ATP binding pocket and result in lack of specificity for the cell cycle 
vs. the transcriptional CDKs. It has been shown that a peptide HAKRRLIF derived from 
the tumor suppressor p21 binds to the cyclin binding groove (CBG) and selectively 
inhibits cell cycle CDKs (CDK2/Cyclin A, CDK2/Cyclin E and CDK4/Cyclin D). The 
CBG is unique to cell cycle CDKs hence targeting this site avoids the inhibition of 
transcriptional CDKs can potentially lead to toxicity. The goal of this project is to 
iteratively convert potent cyclin groove inhibitory (CGI) peptides into more drug like 
molecules called FLIPs (Fragment ligated inhibitory peptides) using the REPLACE 
strategy (Replacement with Partial Ligand Alternatives through Computational 
Enrichment).  
FLIPs were constructed by sequentially replacing key peptide binding 
determinants for RRLIF with fragment like small molecules in order to obtain a non-ATP 
competitive inhibitor of cell cycle CDKs with improved drug like properties. Fragment 
alternative capping groups were evaluated by docking, synthesis and testing of FLIPs in 
competitive binding and cellular viability assays.  Partial Ligand Alternatives were 
identified which interacted with the main subsites of the N-terminal tetrapeptide of 
HAKRRLIF and were derivatives of phenyl heterocyclic carboxylic acids, furoic, 
picolinic and benzoic acids. The most effective Ncap was found to be 1-(3,5-
vi 
 
dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid (35DCPT) ligated to RLIF. 
In a further iteration of REPLACE, the C-terminal motif was modified with β-
homoleucine (βLeu) and N-Methyl Phe or 3-Thienylalanine in order to improve 
metabolic stability. The lead compound after Ncap and Ccap optimization was found to 
be 35DCPT-R{βLeu}{3TA}-NH2  (SCCP5964) which has respectable antiproliferative 
activity and is also capable of inducing a G1 cell cycle arrest. The REPLACE strategy 
has therefore been further validated in the development of FLIPs molecules as non-ATP 
competitive CDK inhibitors. These cyclin groove inhibitors represent next generation 
CDK therapeutics having anti-tumor activity consistent with on target inhibition and 
demonstrated potential for drug development. 
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CHAPTER 1 
INTRODUCTION 
 
1.1.Cancer 
Cancer is a group of diseases caused by uncontrolled proliferation of cells. There 
are more than 200 types of tumors originating from various types of cells affecting 
different organs. The major types of cancer are classified into broad categories including 
carcinomas, sarcomas, leukemias, lymphomas and cancers of the central nervous system. 
Carcinomas are types of cancer affecting skin or tissues covering internal organs, 
sarcomas originate in bones, cartilage, fat, muscle, blood vessels or connective tissues, 
leukemias arise in blood and bone marrow, lymphomas affects lympocytes and the CNS 
cancers are related to the brain and spinal cord
1
. Cancer is one of the greatest burdens on 
society and is one of the leading causes of death worldwide. In 2008, the global cancer 
mortality incidence was estimated to be 7.6 million and where this accounted for 13% of 
all deaths in that year. It has been predicted that annually, 13.1 million deaths will occur 
by 2030 due to cancer
2
. In the United States, one in four deaths is due to cancer and more 
than 1.66 million new cases and more than 0.56 million deaths occurred in 2014
2,3,4
.  
The most frequent deaths arise from the cancers of lung, stomach, liver, colon and 
breast. Cancer is caused by various factors which include among others chemicals, 
radiation, food, aging, hormones, infections, and tobacco. Some of the common 
preventable contributing factors include high body mass index, low fiber intake, lack of 
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physical activity, alcohol and smoking account which combined represent 30% of 
cancerdeaths. Tobacco alone contributes to 22% of global cancer deaths and 71% of all 
lung cancers. Cancer treatment methods include surgery, radiation and chemotherapy all 
of which are associated with significant negative outcomes. Surgery is generally not 
useful when cancer has metastasized to various parts of the body whereas chemotherapy 
and radiation therapy are not specific for cancer cells which results in side effects from 
toxicity on normal cells
2,3,5
.  
1.2 History of chemotherapy 
Currently, there are about 200 drugs approved for cancer and hundreds more in 
clinical development
6
. Anti-cancer drug development has undergone many advances 
since the initial development of cytotoxic agents leading to the sophisticated targeted 
therapeutics available now
7
,
8
. The development of chemotherapeutic agents started in the 
era of World War II in 1940s with the nitrogen mustards. At the outset, cancer drugs were 
based on cytotoxics that kill rapidly dividing cells and many of these drugs are widely 
used. The nitrogen mustards were studied and developed at Yale School of Medicine to 
treat non-Hodgkin’s lymphoma. These compounds alkylate DNA on purine bases leading 
to crosslinking of strands and as a result inducing apoptosis
9
. The next step in 
chemotherapeutic agents was the development of antifolate treatments by Sidney Farber 
at the Harvard Medical School and at the Children’s hospital at Boston. Methotrexate is 
an effective drug in the antimetabolite class and which was initially used in the treatment 
of acute lymphoblastic leukemia
10
. Later this drug was found to be effective in breast, 
ovary, bladder and head and neck cancers
7,11,12
. The antifolates bind to and inhibit 
dihydrofolate reductase which acts at the level of the building blocks of DNA and inhibits 
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the synthesis of thymidylate and purines leading to apoptosis
13
. Another example in this 
class is 6-Mercaptopurine (immunosuppressive agent)
14
. Vinca alkaloids are another class 
of drugs that act in mitosis causing spindle poisoning and also inhibit microtubule 
polymerization. These were developed by Eli Lilly and approved by the FDA in 1963. 
Prednisone (modifies gene transcription and affects the synthesis of various proteins) was 
developed in the 1950s and used for acute lymphoblastic leukemia, Non-Hodgkin 
lymphomas and multiple myeloma
7,8
. 
Drug resistance is major problem in cancer treatment as cancer cells mutate and 
become resistant to a single agent. Hence combination therapies were developed through 
the use of multiple drugs with different mechanism of action in attempts to overcome 
drug resistance problem. Combination therapies such as POMP (combination of 
methotrexate, vincristine, 6-MP and prednisone) and MOPP (combination of nitrogen 
mustard, vincristine, procarbazine and prednisone) regimens were validated in 
1960s
15,16,17
. During the era of combination therapies, several natural product drugs such 
as the taxanes
18
 (e.g. paclitaxel, an antimitotic agent) and camphothecins (topoisomerase 
inhibitor) were discovered which were later used for the treatment of ovarian and colon 
cancer respectively. Taxanes were discovered in the 1960s however not approved by the 
FDA until the 1990s
19
.  Cisplatin, a platinum based drug was a serendipitous discovery in 
1960s that was then approved for testicular cancer. Carboplatin was later developed as an 
improved and less toxic version of cisplatin. These drugs bind to DNA and interfere with 
DNA transcription and replication
20
. Many of the cancer therapeutics developed in early 
years of chemotherapy had serious drawbacks due to acute and long term toxicities 
affecting various parts of the body. These arise from the non-selectivity of conventional 
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therapeutics in targeting both cancer and normal cells. Molecular biology and genetics 
approaches helped in understanding the deregulation of signaling pathways and 
molecular defects in tumors. This lead to the development of drugs that target molecular 
pathways specific for cancer cells which marked the beginning of the new generation of 
targeted therapeutics in 1980s
7
.  
1.3 Targeted therapy 
In targeted therapy, drugs are designed to specifically block the function of 
protein molecules that cause molecular defects ultimately leading to tumor growth and 
progression. Such defects are considered as important hallmarks of cancer and are mainly 
observed in proteins involved in signaling pathways and those responsible for regulating 
growth and division of cells. These include regulation of proliferative signaling, control 
of apoptotic pathways, angiogenesis, enabling of replicative immortality, activation of 
invasion and metastasis, deregulation of cellular energetics, control of genome stability 
and processes of tumor promoting inflammation
21,22
. Some examples of targeted drug 
discovery directed towards these pathways are shown in figure 1.1. 
Clinically validated drugs in the category of targeted therapeutics are mostly 
based on small molecule enzyme inhibitors and biologic agents such as monoclonal 
antibodies and vaccines. A number of drugs targeting pathways mentioned above (figure 
1.2) have been approved by the FDA. The first targeted therapeutics approved were the 
estrogen receptor modulators including tamoxifen and toremifene. Trastuzumab 
(Herceptin) was developed in 1998 acts at HER2/neu receptor, used in the treatment of 
breast cancer
23
. Imatinib Mesylate (Gleevac) developed by Novartis was the first small 
molecule drug and the first kinase inhibitor approved for use as targeted therapy and 
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which is capable of killing cancer cells specifically. Imatinib was approved by the FDA 
in 2001 for the treatment of chronic myeloid Leukemia (CML) acting on the tyrosine 
kinase (TYK) BCR-ABL which occurs only in the tumor and therefore provides a 
window of opportunity for selective targeting. Remarkable success was obtained with this 
drug when treating this disease in its early stages and further was shown to be effective in 
treating gastrointestinal tumors. Unfortunately cancers treated with imatinib develop 
resistance due to mutations in the catalytic site of BCR-ABL and which no longer bind 
the drug
24
. Subsequent advances in kinase targeted drug development include the 
epidermal growth factor receptor (EGFR) inhibitors gefitinib (Iressa) and the antibody 
cetuximab were approved by FDA in 2003 for the treatment of non-small cell lung cancer 
(NSCLC) and colon cancer. Erlotinib was then approved in 2005 following the failure of 
gefitinib for NSCLC
25
. 
 
 
Figure 1.1 Therapeutic Targeting of the Hallmarks of Cancer 
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Additional drugs based on inhibition of tyrosine kinase inhibitors developed and 
approved by the FDA later include sorafenib (TYK- VEGFR (vascular endothelial 
growth factor receptor), PGDFR (Platelet derived growth factor)), sunitinib (TYK- 
VEGF, PGDFR, renal carcinoma), nilotinib (CML), pazopanib (VEGF) , vandetanib 
(inhibits EGFR, VEGF and RET), crizotinib (inhibits EML4-ALK), and axtitinib (VEGF, 
renal cell carcinoma). A common feature of these drugs is that they target different 
protein kinases which are deregulated in cancer
26, 27
. There are 519 proteins in this 
family, lack of drug selectivity, emergence of drug resistance may be problematic. 
Furthermore difficulty in drug target validation for particular disease settings may also be 
an issue
28, 29,30
.  
 
Figure 1.2 FDA approved drugs for targeted cancer therapy (NIH data)
26 
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1.4 Protein kinases 
Protein kinases are a group of enzymes involved in phosphorylation of other 
substrates. Members of the kinome family constitute about 2% of all the human 
genes
28,29
. Kinases regulate many cellular pathways including those involved in signal 
transduction regulating growth and division of cells and therefore their deregulation 
frequently is associated with tumor formation. Kinase subfamilies implicated in cancer 
include the receptor tyrosine (RTK), cytoplasmic tyrosine (CTK), serine threonine (STK) 
and lipid kinases (LK)
27
.  RTKs phosphorylate tyrosine residues on substrate proteins and 
generally function in transmembrane signaling. Various members of the RTK family 
have been shown to be mutated in cancer and include the EGF, IGF and PDGF receptors 
among others. Members of the CTKs regulate extracellular signaling e.g. the JAK-STAT 
pathway and include c-SRC, Abl and JAK-2 kinases. PI3K kinases are lipid kinases 
which modulate cell growth, proliferation, and intracellular trafficking, and 
phosphorylate phosphatidylinositol
31, 32
. ST kinases phosphorylate serine and threonine 
residues in various substrates that are required for controlling cell proliferation and 
survival in the presence of abnormal ploidy. Some examples of such enzymes include the 
cyclin dependent kinases (CDKs) that regulate cell cycle check points, the aurora kinases 
which are required for chromosome separation and the polo like kinases involved in 
numerous roles in mitosis and cytokinesis. CDKs play a significant role in cancer 
mechanisms including amplification or overexpression occurring in sarcoma, glioma, and 
melanoma. Mutations in CDK2 are not frequently observed however overexpression of 
its activator cyclin E and the inactivation of p21 and p27 inhibitory proteins can lead to 
excessive CDK2 activity in tumors. Although CDKs are directly and indirectly involved 
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the majority of tumors, CDK inhibitory drugs have yet to be fully approved by the FDA 
as anticancer therapeutics due to issues related to cross reactivity
33
.  
 1.5 Cyclin dependent kinases 
Cyclin dependent kinases (CDKs) are heterodimeric complexes of a CDK 
catalytic subunit and a cyclin acting as a positive regulatory subunit. The different 
CDK/cyclin complexes known to date have key roles in regulating both cell cycle check 
points and transcription events
33,34
. Most CDKs are activated by associating with a 
particular cyclin and further through phosphorylation of the catalytic subunit on a 
threonine residue adjacent to the active site.  Prior to activation, the ATP binding site of 
CDKs is hidden by the T-loop. Binding of cyclin leads to a conformational change 
including movement of T-loop from the active site entrance. These structural changes 
also arrange the ATP binding residues in the correct confirmation to allow catalysis at the 
active site and which is completed through phosphorylation by CDK7 (CDK activating 
kinase, CAK) on the T-loop threonine. The fully activated CDK/cyclin complexes are 
then able to phosphorylate threonine and serine residues on CDK substrates
35,36
. For the 
cell cycle CDKs it is known that key substrates require recruitment prior to 
phosphorylation. This occurs through a shallow and mainly hydrophobic binding site 
known as the cyclin binding groove (CBG). The CBG is also involved in regulation of 
CDK catalytic activity by endogenous cell cycle inhibitory proteins which act as CDK 
inhibitors (CDKIs)
37
. The CDKIs are classified in two families known as the INK4 and 
Cip/Kip proteins that bind to catalytic sub unit or the whole CDK/cyclin complex 
respectively. Members of INK4 family include p15, p16, p18 and p19 which inhibit 
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CDK4 and CDK6 whereas the Cip/Kip includes p21, p27 and p57 that can inhibit each of 
the cell cycle CDK complexes
38,39
. 
There are at least 13 CDKs and 11 cyclins that have been identified so far 
40,41
. 
CDKs are mainly classified into two groups based on their roles in the cell cycle as (i) 
check point regulators and (ii) transcriptional regulators. The complexes of CDK4/cyclin 
D1, CDK6/cyclin D1 and CDK2/cyclin E regulate G1/S transition by phosphorylating the 
retinoblastoma protein (Rb). Further action of CDK2/cyclin A modulates the progression 
of S phase and CDK1/cyclin B controls the G2/M transition and entry into mitosis. 
CDK7/cyclin H, CDK9/cyclin T and CDK8/cyclin C function in regulating transcription 
through phosphorylation of RNA polymerase II thereby facilitating initiation and 
elongation of RNA transcripts3
33,42
. A summary of the roles of CDK/cyclin complexes is 
depicted in figure 1.3. 
 
Figure 1.3 Role of CDK/cyclin complexes in cell cycle progression and transcription 
1.6 Deregulation of cyclin D-CDK4/6-p16
INK
4-Rb pathway in cancer  
The retinoblastoma protein Rb is a key regulator of the G1 to S phase transition. 
Its function in transcriptional repression is inactivated by sequential phosphorylation by 
CDK4/cyclin D, CDK6/cyclin D and CDK2/cyclin E. CDK4/6/cyclin D assists in 
10 
 
progression through G1 by phosphorylation of the Rb-E2F complex. INK4 family protein 
p16
INK4
 associates with CDK4/6 to regulate G1 progression by the release of cyclin D. 
CDK4/cyclin D and CDK6/cyclin D also binds to the CDK2 inhibitors p21
CIP1
 or p27
KIP1
, 
p57
KIP2
 sequestering these from CDK2. Mitogenic signals stimulate the synthesis of the D 
cyclins and release of CDK4 and CDK6 from p16
INK4
. Cyclin D associates with CDK4/6 
which subsequently forms an assembly with Cip/Kip proteins. CDK4/cyclin D relieves 
the assembly of Cip/Kip with CDK2/cyclin E, thus activating it and leading to further 
phosphorylation of the Rb-E2F1 complex. Full activation of E2F results in gene 
expression and production of proteins required for progression through S phase. During 
this process, cyclin E gene is produced, binds to CDK2 by antagonizing Cip/Kip 
inhibitory proteins and creating a positive feedback loop. Late in S phase, CDK2/cyclin 
A maintains Rb in its inactive state and also phosphorylates E2F, releasing it from the  
DNA after gene transcription for S-phase progression is complete (figure 1.4). The Rb 
and Cip/Kip proteins play significant roles in maintain cells in a quiescent state
33,34
.  
In general the cyclinD-CDK4/6-p16
INK4
/Rb pathway is disrupted in many forms 
of cancer. Cyclin D is particular is overexpressed in many tumors including breast cancer 
(due to gene rearrangement), multiple myeloma (due to translocation) and mutation of 
cyclin D is found in esophageal cancer. Gene amplification of cyclin D is observed in 
mantle cell lymphoma. Loss of the tumor suppressor p16
INK4 
occurs in many cancers due 
to gene deletion, point mutation or transcriptional silencing ultimately resulting in 
increased activity of CDK4/cyclin D. Due to the overexpression of cyclin D or the loss of 
p16
INK4
, excessive CDK4 kinase activity results, further leading to up-regulated 
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CDK2/cyclin E and in turn generating higher activity levels of the E2F transcription 
factor
43
.  
 
Figure 1.4 Role of cyclin D-CDK4/6-p16
INK
4-Rb in cell cycle 
1.7 Selective apoptosis of cancer cells by the inhibition of CDK2/cyclin A through 
E2F1 pathway 
The Rb protein when in its hypo phosphorylated state acts as a transcriptional 
repressor (i.e. bound to E2F) and is converted to a transcriptional activator when 
phosphorylated resulting in its dissociation from E2F. E2F is then released to bind to the 
DP1 protein and form a dimeric complex. The E2F1-DP1 heterodimer initiates gene 
transcription through its DNA binding transcription factor activity. After replication is 
complete, the activity of E2F1 must be neutralized prior to exit from S phase. 
CDK2/cyclin A is responsible for this function through interaction with the N-terminus of 
E2F and ultimately phosphorylates both E2F and DP1 to release the complex from DNA. 
Since many tumors have high base line levels of E2F1 due to a deregulated Rb pathway, 
inhibition of CDK2/cyclin A activity can lead to accumulation of E2F1 and persistent 
12 
 
activity. The result of this is to surpass the threshold required for the induction of 
apoptosis in a p53 independent fashion. Inhibition of CDK2/cyclin A in the context of 
normal cells has a much lower effect due to the lower levels of E2F1 activity and the 
cells proceed with S phase (figure 1.5). Hence inhibition of CDK2/cyclin A should 
promote selective apoptosis of cancer cells and as a result should be considered as an 
important target for cancer
34
.  
 
Figure 1.5 Role of CDK2/cyclin A in cancer cell apoptosis through E2F1 pathway 
1.8 Strategies for the inhibition of CDK/Cyclin complex  
The general strategies for the inhibition of CDK/Cyclin complexes include direct 
and indirect modulation such as (i) ATP competitive and (ii) non-ATP competitive 
inhibition respectively
44
.  Direct modulators mainly antagonize ATP binding whereas 
indirect mechanisms act in other ways.  These include blocking substrate recruitment 
through the cyclin binding groove, inhibition of kinase activation by interfering with 
formation of the complex with the cyclin, and also stabilizing an inactive conformation of 
13 
 
the complex
45
. The ATP binding pocket and cyclin binding groove are shown in figure 
1.6. 
 
Figure 1.6 CDK2/cyclin A complex showing CBG 
 and ATP binding site
46
 
The majority of identified protein kinase inhibitors and FDA approved drugs are 
based on these come under the category of direct modulators that block the binding of 
ATP binding. The ATP binding site is highly conserved among the family of 519 kinases 
and therefore limits the selectivity of these molecules. The non-specificity of ATP 
competitive inhibitors can lead to cross reactivity with other members of the kinome 
potentially resulting in off target side effects and toxicities
44
. The first generation of CDK 
inhibitors included flavopiridol and roscovotine and exhibited limited activity and 
unacceptable toxicities in clinical trials. These molecules were not specific for the desired 
CDK2 target and were found to be capable of inhibiting several CDK/cyclin complexes 
in addition to other kinome members. One side effect of Flavopiridol is hyperacute tumor 
lysis syndrome and damage to the photoreceptor layer in eyes. Roscovitine has been used 
in the treatment of NSCLC in phase I-II stage of clinical trials, where the reported side 
effects are nausea, vomiting, elevations in serum creatinine levels and hypokalemia. 
Other CDK inhibitors developed subsequent to these first generation inhibitors include 
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R547, AT7519, and AZD5438. Most of these compounds have good preclinical activity 
but also are non-specific and are pan CDK inhibitors. This results in effects through 
inhibition of transcription is a likely reason for the observed toxicities. A list of CDK 
inhibitors that have been clinically investigated are shown in figure 1.7. The drug PD-
0322991(Palbociclib) has been given breakthrough status is in phase III clinical trials for 
post-menopausal estrogen receptor positive breast cancer. It is the most selective CDK 
inhibitor so far since it acts only on CDK4 and CDK6 thus inhibiting Rb 
25,33,42,47
.  
 
Figure 1.7 CDK inhibitors in clinical trials  
Non-ATP competitive CDK inhibitors developed to date include substrate derived 
peptides (p53 and Rb derived peptides). The tumor suppressor p53 derived peptides 
target the docking site of p53 tetramerization domain on CDK2 surface. A 20 mer peptide 
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derived from this site is known as CIP and inhibits phosphorylation. A GEF-CIP fusion 
protein induces cell death in A375 melanoma cell lines by reducing p53 activity along 
with suppression of p21.  As discussed in section 1.6 and 1.7, the Rb protein is very 
important for regulation of the G1/S transition and S phase. A 39 residue peptide in cell 
permeable form derived from Rb (Spa310) has been shown to induce apoptosis via 
G0/G1 arrest by the inhibition of CDK2 activity. Inhibitors of the interaction between 
CDK and the cyclin have been recently discovered. C4, an inhibitor of the CDK2 cyclin 
A interaction is a 22mer peptide derived from the α5 helix of cyclin A. This peptide 
adopts a α-helical structure and mimics hydrophobic interactions between CDK2 and 
cyclin A leading to an inactive conformation of CDK2/cyclin A complex. This peptide is 
specific for the inhibition of CDK2 activity when introduced into MDA-MB-231 breast 
cancer cell lines as a TAT fusion peptide. NBl1 is a hexapeptide which targets a cleft 
present in the monomeric cyclin A, affecting the interactions of CDK2/cyclin A and also 
the stability of the complex. This peptide inhibits most of the cell cycle CDK complexes 
including CDK2/cyclin A, CDK2/cyclin E, CDK6/cyclin D and CDK1/cyclin E.  Cellular 
studies of an NBl1-TAT fusion peptide on cell lines including HCT116, HT29, T98G, 
and A2780 showed that it also inhibits CDK2/cyclin A. Fluorescence polarization studies 
showed that this peptide also inhibits CDK1/cyclin B1, CDK6/cyclin D3 however does 
not affect other serine/threonine kinases such as glycogen synthase kinase and mitogen-
activates kinase
45
. As can be seen, the majority of molecules in the category of non-ATP 
competitive inhibitors is peptide based and are in the stage of early pre-clinical 
development.  
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In general, peptides are not suitable for drug development due to their non-drug 
like characteristics including lack of cell permeability and susceptibility to proteolytic 
degradation
48
. In this project an alternative approach for non-ATP competitive inhibition 
has been pursued by targeting the cyclin binding groove (CBG). The CBG is primarily a 
hydrophobic groove that is distant from ATP binding site and is present in cyclins A, D 
and E
46
. It has been shown that a consensus sequence derived from CDK substrates and 
inhibitory proteins interacts with the CBG and inhibits the cell cycle CDKs i.e. those that 
associate with cyclins A, D and E. The overall goal of this project is to convert an 
optimized CBM peptide to a non-peptidic inhibitor using the REPLACE drug design 
strategy
49
.  
1.9 Cyclin binding motif  
Substrates of the cell cycle CDKs include the E2F and Rb proteins and these in 
addition to the tumor suppressor inhibitory proteins (e.g. p21, p27, p57 and p53) contain 
a conserved sequence (CBM) essential for the regulation of CDK activity and for 
substrate recruitment. This motif is comprised of the ZRXL sequence (figure 1.8) in 
which “Z” and “R” are basic residues. The residue “Z” is most frequently Lys and “X” is 
a strictly conserved Arg residue (figure 1.8). Previous studies have shown that 
CDK4/cyclin D and CDK2/cyclin E phosphorylation can be inhibited by the 20 mer 
peptide (residues 141-160) derived from the C-terminus of p21. The same sequence of 
peptides did not inhibit the phosphorylation of histone H1, hence has no effect on the 
activity of CDK1/cyclin B further illustrating that early cell cycle CDKs can be 
selectively blocked in this manner.  
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Figure 1.8 CBM sequences present in tumor suppressors and substrates  
that interact with CDK2/cyclin A, CDK2/cyclin E and CDK4/cyclin D 
The sequence of p21
WAF
 (DFYHSKRRLIF) determined to be the most active in 
cyclin binding and CDK inhibition was found to be from residues 149 to 160. A 
structure-activity relationship (SAR) study was carried out by exchanging each of the 
residues within this sequence for alanine and therefore probing the contribution of each 
side chain. It was found that the replacement of Ser153 resulted in potency gains in both 
CDK4/cyclin D (IC50-10µM) and CDK2/cyclin E (IC50-0.004±0.005µM) (figure 1.9)
50
.  
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Figure 1.9 Alanine scan of p21
WAF1
 (149-160) sequence 
Further studies on the consensus cyclin binding motif (ZRXL) indicated that the 
flanking residues (Ala on the N-teminus and Phe on C-terminus) make hydrophobic 
interactions shown to be important for binding. Octapeptides including those from p21 C-
terminus (HAKRRLIF), E2F1(PVKRRLDL) and p107 (SAKRRLFG), were tested for 
kinase inhibition against CDK2/cyclin A, CDK2/cyclin E and CDK4/cyclin D and for 
competitive binding with cyclin A. Of the peptides tested, HAKRRLIF was found to be 
the most potent with an IC50 value of 0.028µM which is comparable to full length human 
recombinant p21WAF1 (IC50 = 0.011µM) in competitive binding assay of CDK2/cyclin 
A. Hence the CBM was optimized to the octapeptide, HAKRRLIF and which was further 
minimized to a pentapeptide RRLIF (IC50-1.4µM in CDK2/cyclin A). The 
crystallographic structure of CDK2/cyclin A/p27
KIP1 
shows how the CBM (SACRNLFG) 
interacts with the CBG. Similarly the modeled structure of CDK2/cyclin A/p21
WAF1
 was 
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generated and in which HAKRRLIF interacts with the CBG
46,50
. It has been shown that 
CBM peptides derived from E2F linked to the transfection sequence of HIV-TAT induces 
a cytotoxic effect on tumor cells including U2OS and MDA-MB-435, cell types which 
possess deregulated cyclin D-CDK4/6-p16
INK4
-Rb. At the same time, CBM peptides 
exert little effect on non-transformed cells including HaCaT and rat 1A fibroblasts. A 
further study investigated a 20mer peptide from the C-terminus of p21
WAF1 
conjugated to 
a 16 residue sequence from the homeodomain of Antennapedia protein (penetratin) and 
E2F derived peptides linked to Tat. These permeable peptides were tested in cancer lines 
and flow cytometry suggested that cell death was due to nuclear condensation and sub 
diploid DNA suggestive of apoptosis
51,52
. 
1.10 Cyclin binding groove 
The CBG is primarily a hydrophobic groove, distinct and distant from ATP 
binding pocket, found only in cell cycle CDKs, through which cyclins recruit substrates 
and inhibitory proteins. Targeting CBG leads to selective inhibition of CDK2/cyclin A 
and CDK4/cyclin D over other members of the CDK family. The structure of the CBG is 
somewhat different between cyclin A and cyclin D however in general consists of three 
sub sites interacting with binding determinants from the octapeptide HAKRRLIF (figure 
1.10). These sub sites include a primary hydrophobic pocket and a smaller secondary one 
separated by a ridge of negatively charged residues
49
. 
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Figure 1.10 Structure of CBG 
 HAKRRLIF binds at the CBG in such a way that the N-terminal tetrapeptide 
interacts with the secondary pocket and acidic residues while the C-terminal region 
contacts the primary pocket (figure 1.11). The types of interactions occurring between 
HAKRRLIF and CBG include ion-pairing, hydrogen bonding and hydrophobic effects 
through van der Waals interactions. The basic residues of HAKRRLIF undergo ion-
pairing interactions with the acidic residues of the CBG and include Glu220, Glu224 and 
Asp283. The backbone amides of His1, Ala2, Lys3 and Arg4, form hydrogen bond (H-
bonds) with Glu224, Trp217, Gln254 and Ile 281 respectively. The methyl side chain of 
Ala2 fills the secondary pocket while the side chains of Leu6 and Phe8 occupy the 
primary lipophilic pocket. These interactions are listed in detail in figure 1.11 and table 
1.1. 
 
Figure 1.11 Binding and interactions of HAKRRLIF in CBG 
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Table 1.1 List of interactions of HAKRRLIF with CBG 
 
1.11 Comparison of CBG in cyclin A and cyclin D 
Previous studies were conducted in the McInnes laboratory in order to investigate 
the structural differences between the CBG of cyclins A and D1. The major differences in 
the residues of the cyclin groove include the exchange of Ile132, Val60 and Thr62 for 
Tyr286, Leu214 and Asp216 in cyclin A respectively. The superposition of cyclin A and 
D1 structures reveals that these variations are accompanied by movement of a helix-loop 
segment from residues 119 to 136 resulting in conformational differences between the 
cyclins (figure 1.12). This conformational variation results in cyclin D having a shallower 
but extended primary pocket. Furthermore, a narrow secondary pocket and fewer acidic 
residues occur in cyclin D relative to cyclin A (figure 1.13).  These variations could 
potentially be exploited in the design of selective inhibitors of CDK4/cyclin D if these 
were desired
53
. 
Type of interaction N-terminal and central region C-terminal region 
Ion-pairing Basic amino acids (H,K,R,R) with acidic 
residues(Glu224, Glu220 and Asp283) 
NA 
H-bonding Amide backbones of  HAKRR (Glu224, 
Trp217, Ile281, Gln254) 
NA 
van der Waals 
hydrophobic effect 
Ala methyl side chain with the secondary 
hydrophobic pocket 
Leu, Phe side chain with 
the primary pocket 
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Figure 1.12 Comparison of CBG residues of cyclin A and cyclin D 
Left- Overlay of crystal structures of cyclin D1 (orange carbon atoms; PDB code 
2W96) and cyclin A2 (PDB code 1OKV) The Leu and Phe residues of the CBM 
interacting with the primary hydrophobic pocket are shown. E220 and D216 
comprise the acidic region, and the secondary hydrophobic pocket is to the left of 
W217.   
Right - Ribbon representation of the overlay highlighting the differences in the 
cyclin box helices. Cyclin D1 is shown in yellow and the CGI peptide in blue. The 
region displaying the largest structural differences after superimposing the 
backbone atoms is labeled (residues 116_136 of cyclin D1) 
 
 
Figure1.13 Comparison of CBG of cyclin A and cyclin D 
Comparison of the solvent accessible surface of the cyclin grooves of A2 (left) and 
D1 (right). The following regions displaying structural differences in cyclin binding 
determinants are labeled: (left) The more acidic region of cyclin A compared to 
cyclin D1, which results in differential interactions with Arg4 (peptide sequence 
HAKRRLIF).  
Right-The primary hydrophobic extension of cyclin D1 (top right); the shallower 
cyclin D1 primary hydrophobic pocket (the Leu214_Val60 interchange, bottom 
right); and the narrower cyclin D1 secondary hydrophobic pocket (bottom left). 
Each of these structural features explains the differential requirements for cyclin 
groove inhibitor binding. 
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1.12 Rationale and hypothesis 
Data supports the hypothesis that inhibition of cell cycle CDKs (CDK2 and 
CDK4) by CBM peptides will lead to selective apoptosis of cancer cells. The structure of 
the CBG in complex with CBM peptides (i.e. HAKRRLIF and RRLIF) have been 
utilized in the development of non-ATP competitive CDK inhibitors. Furthermore the 
REPLACE (REplacement with Partial Ligand Alternatives through Computational 
Enrichment) strategy has been applied in order to convert optimized peptides into non-
peptidic and more pharmaceutically appropriate molecules. Truncation of key peptide 
determinants and substitution of these with PLAs (Partial Ligand Alternatives) in the 
context of the truncated p21WAF peptide, RRLIF has been undertaken in order to 
construct more drug-like FLIPs (Fragment ligated inhibitory peptides). The resulting 
FLIP molecules should retain the potency and interactions of the parent peptide however 
with improved physicochemical properties more akin to drug-likeness. Based on this 
rationale the following hypothesis and major goals of this project were proposed: 
“REPLACE is a viable strategy to generate more drug-like inhibitors that selectively 
inhibit cell cycle CDK/cyclin complexes and induce apoptosis in cancer cells” 
In order to confirm the hypothesis and achieve the project goals, PLAs were 
identified by computational and synthetic methods. The N-terminus of the RRLIF was 
replaced fragment like small molecules to generate FLIPs  based on derivatives of phenyl 
heterocyclic scaffolds (chapter 2), heterocyclic fragments substituted with basic groups 
(chapter 3), phenylacetic acid systems (chapter 3) and benzoic acid derived moieties 
(chapter 5) in order to mimic key interactions of the peptide. In addition to N-cap 
optimization, the hydrophobic C-terminal motif was replaced with residues designed to 
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impart enhanced proteolytic stability and cell permeability (chapter 4). The competitive 
binding efficiency of generated FLIPs was determined by a fluorescence polarization 
assay developed in the McInnes laboratory and lead compounds were tested for their anti-
proliferative activity in U2OS and DU145 cell lines
52,54
.  
In summary, the REPLACE strategy has been successfully utilized in the 
development of FLIPs with improved drug like properties and results demonstrate 
significant progress towards the overall goal of generating next generation and cell cycle 
CDK inhibitors targeting the CBG and leading to selective apoptosis of cancer cells. 
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CHAPTER 2 
OPTIMIZATION OF CDK/CYCLIN GROOVE INHIBITORS THROUGH 
REPLACE MEDIATED FRAGMENT ASSEMBLY 
 
2.1 Introduction 
REPLACE (REplacement with Partial Ligand Alternatives through 
Computational Enrichment) is a fragment based approach developed for the design of 
inhibitors targeting protein-protein interactions
49
.  In simple terms REPLACE is an 
iterative strategy useful for the conversion of a peptide inhibitor into a more drug-like 
molecule in order to make protein-protein interaction targets more broadly accessible.  
REPLACE combines techniques at the interface of chemistry and biology including both 
computational and both solution and solid phase synthetic chemistry to generate non-
peptidic compounds which are then evaluated in binding and cellular assays is shown in 
figure 2.1. Peptides in general do not make good drugs due to their lack of membrane 
permeability, and metabolic instability
48
.  In this study the iterative conversion of a 
peptidic cyclin groove inhibitor has been undertaken by replacing key N and C-terminal 
binding determinants with more drug-like fragments. After a generation of FLIPs which 
are N and/or C-terminally capped, these will be much less susceptible to proteolysis. 
Reduction in polar surface area and molecular weight of an inhibitor should lead to 
greater cell permeability thereby improving drug likeness.
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Figure 2.1 REPLACE methods 
In REPLACE we utilize the structure activity relationship (SAR) combined with 
interactions of HAKRRLIF in its receptor in the Discovery studio 3.0 to design capping 
groups. The pentapeptide RRLIF is used as stating point to design FLIPs in which the N-
terminal Arg is truncated.  A library of commercially available molecules or molecules 
designed in our lab is used for docking in the hollow region created by truncation of Arg. 
Partial ligand alternatives (PLAs) or N-caps are selected such that these molecules would 
retain most of the interactions of truncated binding determinants. Such a library is docked 
(computationally placed in the binding site) using molecular modeling software (e.g. 
LigandFit
55
 within Discovery studio 3.0) after which the docked poses are prioritized 
based on the scoring function which is an assessment of their ability to bind. Top scoring 
virtual hits are then obtained from commercial sources or synthesized so as to be 
evaluated as capping groups. To do this they are ligated to the truncated peptide sequence 
by solid phase synthesis in order to generate FLIP molecules
56
. These are tested in an in 
vitro assay (e.g. FP
57
 assay to determine their competitive binding efficiency) to 
determine if the activity of the parent peptide has been recapitulated however in a more 
drug-like molecule. If so, FLIPs can be further evaluated in order to determine if any 
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cellular activity has been achieved. An overview of the REPLACE strategy is illustrated 
in scheme 2.1. 
 
Scheme 2.1 Schematic representation of REPLACE strategy 
The REPLACE strategy has been utilized to convert the peptidic inhibitor RRLIF 
into a more drug like non-ATP competitive CDK inhibitor acting through the cyclin 
groove. The initial objective of this project is to identify low molecular weight non-
charged fragment alternatives for N-terminal arginine residue. Since arginine is the most 
basic amino acid, it makes strong electrostatic interactions with the acidic region of CBG 
but also potentially limits cell permeability. In order to improve drug likeness, several 
uncharged fragment molecules based on phenyl heterocyclic carboxylic acids were 
investigated.  These were designed based on a previously reported N-capping group, 1-
(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide (35DCPT) ligated to 
RLIF. The crystal structure of this N-cap confirmed that the 35DCPT takes up the same 
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position occupied by the N-terminal tetrapeptide of the p21 parent peptide (HAKRRLIF). 
 
Figure 2.2 Binding mode of 3,5-DCPTRLIF in CBG 
Binding of 3,5-DCPTRLIF is shown with hydrogen bonding interactions (depicted 
in green dotted lines) with N-atom of Trp217 and Gln254 
 
The 3,5-dichlorophenyl ring makes hydrophobic contacts through van der Waals 
interactions with the secondary hydrophobic  pocket replacing those of the peptide Ala2 
methyl side chain. Further, the N-2 atom of the triazole ring and the amide carbonyl of 
the capping group accept hydrogen bonds with the side chains of Trp217 and amide 
bonds of Gln254 respectively (figure 2.2). The 35DCPT N-capped peptide (FLIP) 
successfully recapitulated the activity of the intact pentapeptide providing proof of 
concept for the REPLACE strategy
49
. In this study, the triazole core structure was 
substituted with other heterocyclic isosteres (including pyrazole, furan, pyrrole, imidazole 
and thiazole) to investigate the effect of alternate heteroatoms on binding. In addition to 
this the phenyl ring was derivatized with methyl, methoxy and halogen substituents to 
probe with the binding affinity of the secondary pocket. A structure activity relationship 
(SAR) was carried out for this diverse set of heterocyclic core structures with 
substitutions on phenyl ring was studied to establish the optimal requirement of 
functional groups for binding. Along with improving binding affinity, optimization of the 
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Ncapping group was investigated to improve the physicochemical properties (clogP, 
polar surface area) and metabolic stability that determine drug likeness of the inhibitors. 
2.2 Results 
2.2.1 Synthesis of N-caps 
In order to probe the structure-activity relationship of the 35DCPT Ncap scaffold, 
a number of variants of this substructure were synthesized. These included 5-methyl-1-
phenyl-1H-1,2,4-triazole-3-carboxylic acid (phenyltriazole), 5-methyl-1-phenyl-1H-
pyrazole-3-carboxylic, acid (phenylpyrazole), 1-phenyl-1H-pyrrole-3-carboxylic acid 
(phenylpyrrole), 2-phenyl-2H-imidazole-4-carboxylic acid (phenylimidazole), 5-
phenylfuran-2-carboxylic acid (phenylfuran), and 2-phenylthiazole-4-carboxylic acid 
(phenylthiazole). Each of these was modified by including a variety of substitutions on 
the phenyl ring as shown in table 3.1.  
Scheme 2.2 Preparation of phenyltriazole N-capping groups 
 
The phenyltriazole carboxylic acid derivatives were synthesized by reacting the 
diazonium salt of an appropriately substituted aniline with ethyl 2-chloroacetoacetate and 
subsequent cyclization to the 1,2,4-triazole using acetaldehyde oxime, triethylamine in 
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toluene. The resulting ester was subjected to base hydrolysis to generate the final capping 
group product of about 80% yield (scheme 2.2)
58,59
. The phenylpyrazole capping groups 
were prepared by the reaction of substituted phenyl hydrazines with ethylacetopyruvate 
in triethylamine/ acetonitrile to generate the cyclized product as an ester with a yield of 
21%. Base hydrolysis was then employed to convert to the free carboxylate obtained in 
quantitative yield (scheme 2.3)
60
. Initial attempts at this reaction used base catalysis 
however led to the formation of two isomers (figure 2.3) in equal amounts (these could be 
separated by flash chromatography). The structure of the desired isomer was confirmed 
by one dimensional nuclear overhauser effect (1D-NOE) NMR experiments. In this 
experiment, irradiation of the methyl group in pyrazole ring lead to the enhancement of 
two ortho aromatic proton signals. Further variants of this reaction showed that acid 
catalysis of the cyclization reaction protonated the hydrazine leading to suppression of 
the formation of the undesired isomer.  The phenyl ring of the pyrazole substructure was 
derivatized as 3,5-dichloro, 3 and 4-chloro, 3-fluoro, 3 and 4-methoxy  derivatives in 
order  to study the effect of these substitutions on the interactions with secondary pocket. 
 Scheme 2.3 Preparation of phenylpyrazole N-capping groups 
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Figure 2.3 Ethyl 1-(substituted phenyl)-5-methyl-1H-pyrazole-3-carboxylate 
To generate phenylfuran derivatives, appropriate aniline was diazotized with 
sodium nitrite and hydrochloric acid. The intermediate diazonium salt was then reacted 
with furoic acid through catalysis with copper chloride (scheme 2.4)
 61. 
The yield of the 
final product was about 28%. In this series the 3-chloro and 3,5-dichloro derivatives were 
successfully synthesized. Phenylpyrrole capping groups were prepared by reaction of a 
substituted aniline (4-chloro and 3,5-dichloro) with 3,5-
dimethoxytetrahydrofurancarboxaldehyde through refluxing in acetic acid to generate the 
cyclized  phenylpyrrole as an aldehyde precursor with 94% yield. To obtain the final 
capping group, this was oxidized to carboxylic acid (65% yield) using silver nitrate and 
sodium hydroxide (scheme 2.5)
12
 . All the N-caps were ligated to RLIF by solid phase 
synthesis and tested in FP assay.    
Scheme 2.4 Preparation of phenylfuran N-capping groups 
 
Scheme 2.5 Preparation of phenyl pyrrole N-capping groups 
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2.2.2 Structure activity relationship of phenyl heterocyclic isosteres as N-caps 
As comparators for the Ncapped peptides that were generated through application 
of REPLACE, the potency of both the parent peptide (HAKRRLIF and RRLIF) were 
evaluated in the FP competitive binding assay. It was found the HAKRRLIF (IC50 values 
of 0.13 µM; CDK2/cyclin A, 0.22 µM; CDK4/cyclin D) shows better inhibitory potential 
compared to RRLIF (1.4 µM; CDK2/cyclin A and 16.1 µM; CDK4/cyclin D). 
HAKRRLIF is therefore about 10 fold more potent compared to RRLIF in the cyclin A 
and 70 fold in cyclin D context. RRLIF has a higher affinity for cyclin A compared to 
cyclin D. As mentioned above, the crystal structure of 35DCPT Ncapped peptides have 
been previously solved. These structures reveal that this capping group only partially 
mimics the interactions of N-terminal residues. The FP assay results of all heterocyclic 
core structures with different phenyl substituents were compared and the isosteres 
exhibited significant differences in potency as shown in table 3.1
63
.  
The SAR of FLIPs containing phenyl heterocyclic carboxylic acids was carried 
out for understanding the importance of heteroatoms (N and O) with binding at CBG and 
also the substituents on phenyl ring for van der Waals interactions with second pocket. In 
the SAR of phenyl heterocyclic scaffolds, the most potent core structure incorporated into 
a FLIP was found to be the starting phenyltriazole derivative followed by phenylpyrazole 
and phenylfuran containing FLIPS. FLIPs having the phenylpyrrole, phenylthiazole and 
phenylimidazole scaffolds displayed marginal or no activity. FLIPs 5773 (35DCPT-
RLIF) and 5774  (1-(4-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide-RLIF) 
were shown to be the most potent compounds with IC50 values for CDK2/cyclin A of 4 
μM and 11.5 μM respectively and in cyclin D was 27.3 µM and 12.0 µM respectively.  
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Thus, 5773 has better activity in the CDK2/cyclin A assay whereas the potency of 5774 is 
reversed in that it has greater affinity towards CDK4/cyclin D. The activity of 5906 (1-(3-
chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide containing FLIP, IC50 5.7 µM) 
was comparable to 5773 and 5907 (3-methylphenyl)-5-methyl-1H-1,2,4-triazole-3-
carboxamide-RLIF, IC50-13.8 µM) was comparable to 5774 in the cyclin A context in the 
FP assay. The unsubstituted phenyltriazole FLIP, 5843 showed the lowest activity (cyclin 
A-16.2 µM, cyclin D-49.2 µM) among the phenyltriazole series.  
Table 2.1 Structure activity of phenyl heterocyclic N-terminal Partial Ligand 
Alternatives 
 
For the pyrazole isosteric FLIP series which have one less nitrogen heteroatom in 
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the five membered ring, comparison of the 3,5-dichloro (5763, IC50-21.8 μM) and 4-
chloro (5765, IC50-21.8 μM) substituted derivatives with 5773 shows a relative loss of 
activity by about 3-5 fold against CDK2/cyclin A. Similar to results obtained for the 
phenyltriazole series, the 3,5-dichloro substituted analog (5763, IC50>100 µM) shows 
lower potency compared to 4-chloro substituent (5765, IC50 -54.7µM) of pyrazole in the 
CDK4/cyclin D assay.  Although the size of a methyl group is similar to that of a chlorine 
atom, the 3-substituted methylphenyltriazole derivative (5907) is about 3.5 fold less 
potent compared to 5773 and 5906. The same trend was observed in the phenylpyrazole 
series in that the 3,5-dichloro, 3-chloro and 3-fluoro derivatives show greater affinity for 
CDK2/cyclin A2. The other FLIP showing detectable activity in this series is 3-
fluorophenylimidazole-RLIF (5852), the activity of which is comparable to 
corresponding phenylpyrazole (5771) in both CDK2/cyclin A2 and CDK4/cyclin D1. 
From these results it is evident that the presence of nitrogen atom in the heterocycle (for 
H-bonding with Trp217) is required for good activity.  
The inhibitory activity of a FLIP molecule capped with 3-fluorophenylpyrazole 
(5771) was determined to be 29.6 μM for CDK2/cyclinA and 65.9 μM in CDK4/cyclin 
D. Substitution of the 4-position on the phenyl ring provides improved binding relative to 
the 3-position for CDK4/cyclin D as evidenced by the results for the phenyltriazole and 
phenylpyrazole capped peptides. Binding of the unsubstituted phenylpyrazole containing 
FLIP (5762, 40.3 μM for CDK2/cyclin A2; 54.2 μM for CDK4/cyclin D1) was similar to 
the 4-chloro derivative. The increased steric bulk of the methoxy groups relative to 
chorine and fluorine contributes to the potency drop for both 3- (5766) and 4-methoxy 
(5767) phenylpyrazole derivatives. 
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2.2.3 Docking of phenyl heterocyclic isosteres as N-capping groups 
A docking analysis was carried out for all the isosteric phenyl heterocyclic series 
to correlate with the binding potencies of FLIPs obtained from the FP assay. 
Computational studies of these Ncaps were performed using the parameters obtained in 
the validation of the use of the LigandFit program (docking validation and parameters are 
explained in chapter 4) for high- throughput docking of ligands into the cyclin groove of 
cyclin A (2UUE). The potential Ncapping groups shown in table 3.2 were docked and 
subsequently analyzed and prioritized based on superimposability with the crystal 
structure of 35DCPT, hydrogen bonding (with the side chains of Trp217 and Gln254), 
and also PLP1 and consensus scoring. Consensus scoring is a combination of all the 
seven scoring functions in LigandFit and it gives more accurate estimate of the various 
interactions between the receptor and ligand.  
Table 2.2 Docking results of phenyl heterocyclic N-terminal 
Partial Ligand Alternatives 
Core 
structure 
Highest PLP1 
score 
Consensus 
score 
H-bond length with 
Trp217(Å) 
Triazole 57.29 5-7 1.38 to 2.34 
Pyrazole 55.28 5-7 1.24 to 2.43 
Furan 53.04 4-7 >2.5 
Imidazole 50.20 3-6 >2.5 
Thiazole 47.3 1-4 >2.5 
Pyrrole 47.1 0-3 NA 
 
Phenyltriazole (PLP1-57.29) derivatives were found to have the highest PLP1 
score and this was followed by phenylpyrazoles (PLP1-55.28), phenylfurans (PLP1-
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53.04), phenylimidazoles (PLP1-50.20), phenylthiazoles (47.3) and phenylpyrroles 
(PLP1-47.1). For the most part, the consensus score was predictive for capping groups 
with substitutions at 3-position and 3,5-position. High consensus score values (between 5 
and 7) were obtained for poses that have 3-chloro or 3,5-dichloro substituents on the 
phenyltriazole and phenylpyrazole and which were the most potent in the CDK2/cyclin A 
context. The exception to this was methoxy derivatives of the phenylpyrazole FLIP series 
where both high PLP1 score (>58) and consensus score (7) values were obtained for 
incorrect poses and which did not interact well with the secondary pocket. Despite the 
high scores, the incorrect binding mode is consistent with lack of activity of 5966 and 
5967.  
2.3 Discussion and conclusion 
In this study protein-protein interactions at CBG are being targeted through 
application of the REPLACE strategy
49
. REPLACE is a novel strategy for converting 
peptidic molecules into more drug like molecules by sequential replacement of residues 
of peptidic inhibitors with small molecule capping groups. FLIPs are peptidic molecules 
where key determinants have been substituted with fragments that potentially have 
increased drug likeness compared to the parent peptides and retain important interactions 
of the truncated residues. Hence the goal in this section was to focus on the structure 
activity relationship through optimizing interactions with the secondary pocket and 
mimicking hydrogen bonding contacts observed with the peptide and in a previous study 
where preliminary heterocyclic N-caps were identified.  
A library of phenyl heterocyclic N-capping group derivatives was designed in 
order to replace the N-terminal arginine residue of RRLIF and to potentially exploit 
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additional interactions of the N-terminal tetrapeptide of HAKRRLIF. These include ion-
pairing interactions with acidic residues of the cyclin groove, hydrophobic interactions of 
Ala2 with secondary pocket and backbone hydrogen bonds with various side chains of 
the CBG. The N-caps were based on phenyltriazolecarboxylic acid derivatives identified 
using REPLACE which were then used to construct FLIP molecules. X-ray 
crystallographic analysis of 35DCPT ligated to RLIpfF-NH2 and in complex with 
CDK2/cyclin A(PDB ID 2UUE) revealed that the 1,2,4-triazole core occupies the 
position of Arg4 backbone  on the ridge that separates both the hydrophobic pockets 
while the dichlorophenyl group occupies the hydrophobic secondary pocket and provides 
affinity through van der Waals interactions. The N-2 atom of the 1,2,4,-triazole ring and 
the amide carbonyl oxygen act as hydrogen bond acceptors for the indole N-atom of 
Trp217 and amide N-atom of Gln254 respectively.  
For the library design, information from another recent study examining the 
structural differences of the cyclin groove between cyclin A and cyclin D was exploited 
(explained in more detail in chapter 1, section 1.11)
53
. Peptide analog SAR was used to 
delineate the key variations in the major and minor hydrophobic pockets and in the acidic 
regions between the two cyclins. Using the SAR revealed in these studies, a library of 
isosteric heterocyclic  N-caps were designed in order to retain similar interaction of 3,5-
DCPT and also to probe the contributions of this fragment replacement to cyclin groove 
binding.  An extensive SAR study was carried out by generating isosteres in which the 
triazole core was replaced with other heterocyclic systems including pyrazole, furan, 
pyrrole, imidazole and thiazole rings. Furthermore the SAR of the phenyl ring attached at 
N1 of the triazole was explored through introduction of a variety of substitutions at 
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positions 3, 4 and 5. The SAR of heterocyclic isosteres was carried out to provide insight 
into the contributions of H bonding with indole N-atom of Trp217.  The incorporation of 
different heteroatoms in the appropriate position where an H bond is contributed by the 
N2 of the triazole ring was undertaken through synthesis of the corresponding isostere 
(nitrogen:  pyrazole, thiazole and imidazole also oxygen: furan).  Substitution of the 
phenyl ring of the phenyl heterocycle with halogens (Cl, F), methyl or methoxy groups 
was undertaken to identify groups that provide better interactions and complementarity 
with the secondary pocket.  
A common feature of all the molecules in the synthesized library is the presence 
of carboxylate group which when ligated to the truncated peptide forms an amide bond  
mimicking the  H- bonding to the side chain amide N-atom of Gln254 as observed in the 
peptide crystal structures. A docking study was carried out to determine if the N-caps in 
this library were capable of making H bonding with Gln254 (figure 2.4) and with Trp217 
as proposed. The results showed that this indeed was the case however variable lengths 
and strengths of H-bonds would be expected. 
 
Figure 2.4 Overlay of docked structures of N-caps 
The interaction filters (Trp217 & Gln243) are indicated as green spheres and 
hydrogen bonding are indicated in green dotted lines on the surface of cyclin A 
(PBD ID2UUE) 
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The results obtained from binding of the FLIPs to CDK2/cyclin A revealed that the 
heterocyclic core is a critical determinant for potency. Since both the two ring structures 
expected to have the strongest H-bond (triazole and pyrazole) were the most potent, the 
conclusion was drawn that the H-bond is essential for the activity of this isosteric FLIP 
series. Comparison of the N-caps having a 3,5 dichloro substitution strongly indicated the 
importance of having an atom capable of acting as an H-bond acceptor to the NH group 
of indole ring in Trp217. In the phenylfuran containing FLIPs, the N-atom is replaced 
with an oxygen atom. Since oxygen is more electronegative (3.44, Pauling’s scale) than 
the nitrogen (3.04, Pauling’s scale) 64 and the oxygen lone pairs of electrons participates 
in the furan aromatic system, a much weaker H-bond interaction would be expected 
compared to the triazole and pyrazole. Although the five membered ring of triazole and 
pyrazole is also aromatic and the lone pairs participate in the aromaticity there are 
however three and two lone pairs present respectively and at least any one pair of 
electrons are more available for H bonding. These factors provide a strong reasoning for 
the inactivity of the phenylfuran analogs and increased relative activity of the 
phenyltriazole and phenylpyrazole containing FLIPs. Since only one phenyl imidazole 
FLIP was generated, this could not be directly compared with the phenyltriazole series. 
The 3-fluoro derivative was available however and could be compared with 3-
fluorophenylpyrazole.  The comparable activity of these two FLIPs indicates that similar 
H-bonding contributions are made to the phenylpyrazole FLIP.  The phenylpyrrole 
isosteres do not exhibit good activity because the pyrrole ring does not have H-bond 
acceptor to interact with the indole group of Trp217 and that the two H atoms may even 
clash with each other. The docking results obtained support these results in terms of 
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PLP1 score and hydrogen bond length. In case of phenyltriazole and phenylpyrazole 
derivatives the hydrogen bond length between N-2 nitrogen atom and Trp217 varies 
between 1.24 to 2.43Å whereas the hydrogen bond length between the weak hydrogen 
bond acceptors in the phenylfuran and Trp217 is greater than 2.7Å. 
Comparison of the binding activity results suggests that the phenyltriazole 
containing FLIPs are considerably more potent that the phenylpyrazole containing ones 
by 3 to 5 fold. These results suggest that the N-2 nitrogen atom is not the only binding 
determinant in the heterocyclic ring and that the triazole N-4 atom plays an additional 
role in binding. This observation was initially difficult to explain in structural terms since 
no interactions between N-4 and the cyclin groove are observed in the crystal structures. 
A modeling study was carried out in which a water molecule was placed between N-4 
atom of the triazole (5773) and carboxylate side chain of Asp283 (cyclin A) or Asp129 
(cyclin D). This water molecule can thus form a bridging hydrogen bond between N-4 
atom of triazole and carboxylate group of the acidic residue (figure 3.3) thereby 
suggesting a reason for the potency increase of the phenyltriazole series. Since the 
phenylpyrazole derivatives cannot make such an interaction this potentially explains the 
lower activity potential of this series. As a whole the SAR of phenyl heterocyclic Ncaps 
demonstrates the importance of hydrogen bonding with the cyclin groove and 
furthermore highlights the structural differences contributing to diversity in activity 
profile.  
The contributions of the substitutions on the phenyl ring to their interaction with 
the secondary hydrophobic pocket were studied from the SAR of the phenyltriazole and 
phenylpyrazole containing FLIPs. The activity profile of appropriate phenyl substituents 
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could be correlated in both triazole and pyrazole based FLIPs. The phenyl group makes 
hydrophobic contacts through van der Waals interaction with the secondary pocket and 
appropriate substitution in phenyl ring provides better interaction. As mentioned earlier 
3,5-dichloro derivative was the most potent compound (comparable potency with 3-
chloro derivative) followed by 4-chloro and 3-methyl derivatives in CDK2/cyclin A. 
Substitution at the 3-position offers better activity for inhibition of CDK2/cyclin A. Of all 
the substituents incorporated into the phenyl ring in these two isosteric series, chlorine 
was found to be the most effective in binding to cyclin A and cyclin D in their respective 
CDK complexes. The FP results also showed that the position of the substituents on the 
phenyl ring determines specificity towards a particular cyclin. A 3-chloro substituted 
phenyl ring (5906, 5907, 5764 and 5771) and 3, 5-dichloro substitution (5773, 5763) in 
both the triazole and pyrazole context have  better activity in binding to cyclin A 
compared to cyclin D. The 4-chloro substituted analogs however (5774 and 5765) have a 
reverse potency order with respect to binding to the two cyclins. This observation can be 
explained by the structural differences of secondary hydrophobic pocket between cyclin 
A and cyclin D. In cyclin A this pocket in shallower and larger whereas it is smaller and 
deeper in cyclin D. Hence larger volume of this sub site in cyclin A can accommodate 3 
and 3,5 dichloro substituents with a better complementarity. As a result of the smaller 
hydrophobic sub site in cyclin D, the 3 and 3,5-disubstituted phenyl group is displaced 
relative to cyclin A and is further out of the secondary pocket. The 4-chloro substituent 
binds deeper in the secondary pocket of cyclin D, allowing better van der Waals 
interactions of the phenyl and furthermore allowing interaction with Glu66 and Glu70. 
An overlay of modeled structure of 5773 in complex with CDK4/cyclin D1 and 
42 
 
CDK2/cyclin A2 shown in figure 2.5 explains the binding modes of 3,5-disubstuted 
phenyl ring in the second pocket of cyclin A and cyclin D
63
.  
  
Figure 2.5 Modeled structure of 5773 in cyclin A & cyclin D  
 
Showing bridging hydrogen bond between the ligand and the receptor 
Modeled structure of SCCP 5773 in complex with CDK4/cyclin D1 (tan carbon 
atoms) overlaid with the crystal structure of the same N-cap bound to CDK2/cyclin 
A2 (yellow carbon atoms). A Connolly surface representation of cyclin A is shown 
along with the putative water molecule contributing bridging hydrogen bonds. 
 
The difference in the potency between 3-chloro and 3-fluoro substituents could be 
observed with the phenylpyrzaole containing FLIP series is indicated by increased 
complementarity of the larger chloro substituent with the secondary pocket.  In 
comparison with the fluoro substituent, the chloro also allows closer contact of the phenyl 
ring in the pocket (figure 2.6). Decreased potency of the 3-methyl substitution could be 
due to less favorable interactions of the slightly larger group with the secondary pocket in 
comparison with 3-chloro substituent. The methoxy groups in turn are too large due to 
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the extra connecting atom (oxygen) and it is displaced outside of the minor hydrophobic  
pocket due to the resulting steric clash also leading to loss of hydrogen bonding with 
Trp217 in 4-methoxyphenylpyrazole derivative (figure 2.7).  
 
 
Figure 2.6 Comparison of complementarity of 3-Chloro and  
 
3-Fluoro substituents on phenyl ring of pyrazole 
Complementarity of 3-chlorophenyl pyrazole (left) and 3-fluorophenyl pyrazole 
(right) derivatives in the second pocket are shown as CPK structures on the surface 
of cyclin A 
 
 
Figure 2.7 Comparison of binding modes of chloro substituents and  methoxy 
substituents on the phenyl ring of pyrazole 
 
Binding mode and complementarity of 3-chlorophenyl pyrazole, 3,5-dichlorophenyl 
pyrazole (left) and 3-methoxy phenyl pyrazole and 4-methoxy phenyl pyrazole 
(right) derivatives in the second pocket are shown on the surface of cyclin A.  
 
In conclusion, the phenyltriazole Ncapping series was found to be the best 
heterocyclic isostere and substitution at the 3 and 5 positions resulted in the most potent 
FLIP molecule (5773) through the most favorable interactions and providing the best 
complementarity with the secondary pocket. The position of chloro substituent of the 
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phenyl ring determined specificity towards a particular cyclin with the 3-chloro and the 
3,5-dichloro binding better to CDK2/cyclin A and the 4-chloro substitution  resulting in 
high affinity for CDK4/cyclin D. In this study one of the most important N-terminal 
residues Arg of RRLIF was successfully replaced with phenyl heterocyclic based small 
molecules. Through this SAR studies on phenyl heterocyclic capping groups, the 
important interactions of N-capping groups that are key for binding have been explored. 
H bonding with Trp217 and Gln254 are crucial for binding and the size of substituents in 
the phenyl ring also contributes to complementarity and proper positioning of N-capping 
groups on top of secondary pocket. In addition, the drug likeness of the most potent 
molecule 5773 has been considerably improved compared to RRLIF. Physical properties 
such as clogP and total polar surface area (tPSA) helps in determining drug likeness and 
efficiency of the molecules to cross cell membranes. The clogP and polar surface area of 
5773 is (+2.42 and 243) is better than RRLIF (-2.86, 303.52). The standard values for 
clog P are between -0.4 to 5.6 and tPSA is less than 140 Å based on Lipinski’s rule of 5 
for orally available drugs
65,66
. The FLIP molecule 5773 could be further improved for 
drug likeness with modifications on C-terminus with non-natural amino acids such as (β-
Leu for Leu and Ile, NMePhe or 3thienylAla for Phe), as is discussed in detail in chapter 
5.  These observations related to the optimization of functional groups for binding and 
physicochemical properties of 5773 were utilized in the design of improved N-capping 
groups and converting the peptide RRLIF into more drug like molecule.  
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2.4 Experimental section 
2.4.1 Synthesis 
2.4.1.1 Materials and method  
All solvents and reagents were used as obtained. 
1
H NMR and 
13
C NMR spectra 
were recorded with a Varian Mercury 300 and 400 Spectrometer, respectively. Mass 
spectra were measured with Micromass QTOF:  Tandem quadruple-time of flight mass 
spectrometer electrospray ionization (ESI) and VG 70S:  Double-focusing magnetic 
sector mass spectrometer (EI). Analytical purities of evaluated compounds were >95% 
unless stated otherwise. The following analytic method (unless stated otherwise) was 
used on a Waters Alliance 2695 HPLC with a 2996 diode-array detector and equipped a 
C18 (2) 100 A, 250 x 4.6mm, 5µ column (Phenomenox Luna). A gradient from 100% 
water (0.1% trifluoroacetic acid) to 60% acetonitrile (0.1% trifluoroacetic acid) was run 
over 30 mins and held for 4 mins. The chromatograms were extracted at 226 and 254 nm.  
2.4.1.2 Synthesis of N-caps 
The N-caps 1-(4-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid, 1-
(4-methylphenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid, 2-(3,5-dichlorophenyl)-
1H-imidazole-5-carboxylic acid, 2-(3-chlorophenyl)-1H-imidazole-5-carboxylic acid 
were obtained commercially and the compound 2-(4-chlorophenyl)thiazole-5-carboxylic 
acid was synthesized in our lab. The NMR and MS spectra chromatograms for 
representative N-capping groups are shown in appendix. The analytical characterization 
data for all the FLIPs are shown in appendix table 1. 
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Preparation of phenyltriazole N-capping groups
57,58
 (5843, 5773, 5774, 5906, 5907) 
Ethyl 2-chloro-2-(2-(3,5-dichlorophenyl)hydrazono)acetate (1a) 
To a solution of 3,5-Dichloroaniline (1.62g, 10mmol) in 10 ml methanol, 10 ml of 
6 N Hydrochloric acid was added while maintaining the temperature at 0°C. Sodium 
nitrate (1.38g, 20mmol) was then slowly added as a solid. The reaction mixture was 
stirred for 15 mins at 0°C after which sodium acetate was added as a solid to adjust the 
reaction to pH 5. Subsequent to this, a solution of ethyl 2-chloroacetoacetate (1.64, 
10mmol) in methanol was slowly added while maintaining the temperature at 0°C, after 
which the reaction mixture was allowed to warm to ambient temperature and stirred for 
12 h. The reaction was monitored by TLC using 25% ethyl acetate in hexanes, for 
completion. Methanol was then removed under reduced pressure, diethyl ether was added 
and the organic layer was separated and washed with saturated sodium bicarbonate and 
water prior to drying over sodium sulfate. The organic layer was concentrated and the 
product crystalized from ethanol to give an orange solid 2.29g (77.7%). 
1
H NMR (methanol-d4, 300 MHz) δ (ppm) 7.2 (s, 3H), 7.0 (s, 1H), 4.32-4.39 (q, J=3.52, 
3H) 1.35-1.4 (t, J=3.41Hz, 3H). EI+ 294 
Ethyl 2-chloro-2-(2-(3,5-dichlorophenyl)hydrazono)acetate (1b) 
1
H NMR (chloroform-D, 300 MHz) δ (ppm) 7.27-7.25(m, 1H), 7.22(d, J-8.28Hz, 1H), 
7.05(s, 1H), 7.02(d, J=10.56Hz, 1H), 6.99(d, J=7.92Hz, 1H), 4.39(q, 21.54Hz, 2H), 
1.40(t, J=6.99Hz, 3H) EI+260 
Ethyl 1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylate (2a) 
The step 1 product, Ethyl 2-chloro-2-(2-(3,5-dichlorophenyl)hydrazono)acetate 
(1) (2.29g, 7.7mmol), and acetaldehyde oxime (0.473g, 7.7mmol) were dissolved in 
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toluene and heated to reflux for 2h after which triethylamine (0.81g, 7.7mmol) was 
added. The reaction was monitored by TLC using 25% ethyl acetate in hexanes. After 
completion, the reaction mixture was then concentrated and partitioned between ethyl 
acetate and water. The layers were separated and the aqueous layer was washed with 
ethyl acetate. The combined organic layers were washed with water and brine, dried with 
sodium sulfate, filtered, and then concentrated. The residue was crystallized from 
diethylether/hexanes to give the product as fine, tan needles weighing 1.97g (84.5%). 
1
H NMR (chloroform-D, 300 MHz) δ (ppm) 7.45 (s, 2H), 7.49 (s, 2H) 4.46-4.53 (q, 
J=3.36Hz, 2H) 2.62 (s, 3H), 1.41-1.46 (t, J=3.35Hz, 3H) ES+ 300 
Ethyl 1-(3-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylate (2b) 
1
H NMR (chloroform-D, 300 MHz) δ (ppm) 7.54(s,1H), 7.48-7.42(m, 3H), 4.50(q 
J=6.93Hz, 2H), 2.58(s, 3H), 1.44(t, J=7.14Hz, 3H) EI+265 
1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid (3a) 
The step 2 product, Ethyl 1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-
carboxylate (2)  (1.9g, 6.33mmol) was refluxed in sodium hydroxide (2.02g, 50.64mmol), 
19ml of ethanol and 19ml of water for 2h and the reaction was monitored by TLC (35% 
ethyl acetate in hexanes). After the completion of reaction, the reaction mixture was 
cooled, the alcohol was evaporated and diluted with water. The reaction mixture was 
acidified with 1N hydrochloric acid and stirred to precipitate the product.  
1
H NMR (chloroform-D, 400 MHz) δ (ppm) 7.86 (t, J=1.04Hz) 7.8 (d, J= 1.12Hz3H) 
2.54 (s, 3H) 
13
C NMR (Dimethyl sulfoxide-D6, 400 MHz) δ (ppm) 160.6, 154.5, 154.11, 138.5, 
135.1, 134.7, 129.0, 123.8 
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HRMS EI+ observed 270.9914, calculated 270.9915, 0.4ppm 
1-(3-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid (3b) 
1H NMR (Dimethylsulfoxide, 400 MHz) δ (ppm) 7.80(s,1H), 7.64 (s, 2H), 2.51(s, 3H) 
13C NMR (Dimethyl sulfoxide, 400 MHz) δ (ppm) 160.80, 154.21, 154.00, 137.87, 
133.69, 131.20, 129.29, 124.73, 123.55, 12.81 
EI+237 
Preparation of phenylpyrazole N-capping groups
59
 (5762-5767, 5771) 
Ethyl 1-(3,5-dichlorophenyl)-5-methyl-1H-pyrazole-3-carboxylate (4a) 
1 g (4.68mmol) of 3,5-dichlorophenyl hydrazine was dissolved in 25 ml of acetonitrile in 
a  100 ml round bottom flask, triethylamine (0.47g, 6.9mmol) and ethyl aceto pyruvate 
(0.74g, 4.68mmol) were added to the reaction mixture under stirring and left to continue 
overnight. The reaction was monitored by TLC (25% ethyl acetate in hexanes) for 
completion. After the reaction was complete, the reaction mixture was diluted with 
dichloromethane and washed with water. The organic layer was separated, dried over 
sodium sulfate and concentrated. The crude mixture was then purified by flash 
chromatography (Biotage SP4) using a SNAP 100g column with a gradient run starting 
from 6% ethylacetate: 94% hexanes to 50% ethyl acetate and 50% hexanes over 15 
column volumes to yield a white solid  0.39g (21% yield).  
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.431 (s, 3H), 6.744 (s, 1H), 4.49-4.44 (t, 
J=7.0Hz, 2H), 2.39 (s, 3H), 1.39-1.42 (t, J=2.54Hz, 3H), EI+298 
Ethyl 1-(4-chlorophenyl)-5-methyl-1H-pyrazole-3-carboxylate (4b) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.37(q, J=8.61Hz, 4H), 6.81(s,1H), 4.23(q, 
J=7.14Hz, 2H), 2.34(s,3H), 1.26(t, J=7.29Hz, 3H) EI+265 
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Ethyl 1-(3-chlorophenyl)-5-methyl-1H-pyrazole-3-carboxylate (4c) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.52(t, J=8.48Hz, 1H), 7.22(t, J=7.08, 3H), 
6.88(s,1H), 4.42(q, J=7.02Hz, 2H), 3.86(s,3H), 1.40(t, J=7.29Hz, 3H) ES-263 
Ethyl 1-(3-fluorophenyl)-5-methyl-1H-pyrazole-3-carboxylate (4d) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.49(t, J=8.40Hz, 1H), 7.21(t, J=7.01, 3H), 
6.78(s,1H), 4.38(q, J=7.02Hz, 2H), 3.76(s,3H), 1.34(t, J=7.18Hz, 3H) EI+249 
Ethyl 1-(3-methoxyphenyl)-5-methyl-1H-pyrazole-3-carboxylate (4e) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.36(t, J=7.92Hz, 1H), 6.99(t, J=4.32, 3H), 
6.95(s,1H), 4.41(q, J=6.96Hz, 2H), 3.86(s,3H), 2.32(s, 3H), 1.39(t, J=7.17Hz, 3H) 
EI+261 
Ethyl 1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-3-carboxylate (4f) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.45(d, J=8.79Hz, 2H), 7.07(d, J=8.79, 2H), 
4.26(q, J=7.19Hz, 2H), 3.81(s,3H), 2.49(s, 3H), 1.27(t, J=7.19Hz, 3H) EI+ 261 
ethyl 5-methyl-1-phenyl-1H-pyrazole-3-carboxylate (4g) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm)7.41(s, 5H), 6.79(s, 1H), 4.19(s, 2H), 2.35(s, 
3H), 1.22(s, 3H) EI+231 
1-(3,5-dichlorophenyl)-5-methyl-1H-pyrazole-3-carboxylic acid (5a) 
The ester obtained from step1, ethyl 1-(3,5-dichlorophenyl)-5-methyl-1H-
pyrazole-3-carboxylate (4) (0.39g, 1.3mmol) was dissolved in 10 ml methanol. The ester 
solution was treated with a 10 ml solvent mixture of tetrahydrofuran, 20% potassium 
hydroxide and methanol (1:1:1). The solution was stirred at room temperature overnight 
and after completion, as evidenced by TLC (25% ethylacetate in hexanes), methanol was 
evaporated and the reaction solution was partitioned between ethylacetate and water. 
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After washing with ethyl acetate, the aqueous layer was collected and acidified to pH 2 
using 1N hydrochloric acid. The acidified aqueous layer was then partitioned between 
dichloromethane and additional water. The organic layer was dried over sodium sulfate 
and concentrated to get solid product 0.23g (100%). 
1
H NMR (dimethyl sulfoxide-D6, 400MHz) δ (ppm) 7.78-7.79 (t, J=0.937Hz,) 7.8 (d, 
J=1.14, 1H), 6.74 (s, 1H), 2.50 (s, 3H) 
13
C NMR (dimethyl sulfoxide-D6, 400MHz) δ (ppm) 162.9, 144.5, 141.4, 140.8, 134.5, 
128.0, 123.5, 11.9 
HRMS EI+ Observed 269.9959, calculated 269.9963, 1.5ppm 
1-(4-chlorophenyl)-5-methyl-1H-pyrazole-3-carboxylic acid (5b) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.45(q, J=9.30Hz, 4H), 6.79(s, 1H), 
2.36(s,3H) ES- 235 
1-(3-chlorophenyl)-5-methyl-1H-pyrazole-3-carboxylic acid (5c) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.42(t, J=8.52Hz, 1H), 6.98(t, J=7.19Hz, 
3H), 6.54(s,1H), 3.81(s, 3H), 2.32(s,3H) EI+ 237 
1-(3-fluorophenyl)-5-methyl-1H-pyrazole-3-carboxylic acid (5d) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.48(t, J=8.71Hz, 1H), 7.02(t, J=7.45Hz, 
3H), 6.74(s,1H), 3.92(s, 3H), 2.46(s,3H) EI+ 221 
1-(3-methoxyphenyl)-5-methyl-1H-pyrazole-3-carboxylic acid (5e) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.38(t, J=8.55Hz, 1H), 7.00(t, J=7.17Hz, 
3H), 6.77(s, 1H), 3.84(s, 3H), 2.36(s,3H) EI+ 233 
1-(4-methoxyphenyl)-5-methyl-1H-pyrazole-3-carboxylic acid (5f) 
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1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.43(d, J=8.76Hz, 2H), 7.04(d, J=8.76Hz, 
2H), 3.86(s, 3H), 2.38(s, 3H) EI+ 233 
5-methyl-1-phenyl-1H-pyrazole-3-carboxylic acid (5g) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.57 (s,1H), 7.44(s, 2H), 7.38(s, 1H), 
6.80(s, 1H), 2.38(s,3H) ES- 201 
Preparation of phenylfuran N-capping groups 
60
 (5768, 5769) 
Synthesis of 5-(3,5-dichlorophenyl)furan-2-carboxylic acid (6a) 
A mixture of 3,5-dichloro aniline (0.84g, 5mmol), hydrochloric acid (15%, 3ml ) 
and water (4.5ml), was heated until a clear solution was obtained. This solution was then 
cooled to 0
o
C, diazotized with aqueous sodium nitrite (30%, 1.2ml) and filtered. To the 
filtered solution, water (2.5ml) and furoic acid (0.56g, 5mmol) were added. An aqueous 
solution of cupric chloride (0.125g in 10 ml water) was added dropwise and stirred for 4h 
at room temperature and kept aside for 16h. The resulting solid was filtered off, 
suspended in water and purified by flash chromatography (Biotage SP4) using a SNAP 
100g column with a gradient 0% to 40% ethylacetate for 5 column volumes, the 
concentration of ethyl acetate at 40%  was kept constant for 2 column volumes and then 
increased to 100% in 5 column volume. The purified product obtained weighed 0.36g 
(28%) 
1
H NMR (dimethyl sulfoxide-D6, 400MHz) δ (ppm) 7.85 (d, 2H), 7.65 (t, 2H), 7.36 (d, 
J=3.88Hz, 1H), 7.40 (d, 3.96, 1H) 
13
C NMR (dimethyl sulfoxide-D6, 400MHz) δ (ppm) 159.0, 152.9, 145.0, 134.9, 132.2, 
128.0, 122.7, 119.7, 110.5 
HRMS EI+ Observed 255.9698, calculated 255.9694, 1.6ppm 
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Synthesis of 5-(3,5-dichlorophenyl)furan-2-carboxylic acid (6b) 
1
H NMR (dimethyl sulfoxide-D6, 300MHz) δ (ppm) 7.80(d, J=8.64Hz, 2H), 7.53(d, 
J=12.36Hz, 2H), 7.30(d, J=4.53Hz, 1H), 7.17(d, J=3.69Hz, 1H) ES-221 
Preparation of phenylpyrrole N-capping groups 
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 (5775, 5776) 
1-(4-chlorophenyl)-1H-pyrrole-3-carbaldehyde (7a) 
4-chloroaniline (0.51g, 4 mmol), 2,5-dimethoxytetrahydrofuran-3-carbaldehyde 
(0.76g, 4.8 mmol), acetic acid (16ml) were stirred in a round bottom flask until a red 
colored solution was observed. The reaction mixture was then refluxed at 120
o
C for 15 
mins and a dark reddish brown solution was obtained. The reaction was monitored by 
TLC (25% ethyl acetate: 75% hexanes) and worked up when complete. The reaction 
mixture was cooled, extracted with ethyl acetate and the organic layer was washed with 
saturated sodium bicarbonate, dried over sodium sulfate and concentrated to get 0.77g 
(94%) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 9.85 (s, 1H), 7.62-7.63 (t, J=1.8Hz, 1H), 
7.44-7.47 (d, J=9Hz, 2H), 7.34-7.37 (d,J=9.3Hz, 2H) 7.05 (t, J=0.9Hz, 1H), 6.57-6.58 (q, 
J=1.5Hz, 1H) EI+204 
1-(3,5-dichlorophenyl)-1H-pyrrole-3-carbaldehyde (7b) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 9.86(s,1H), 7.64(s, 3H), 7.34(s, 1H), 
7.06(s,1H), 6.82(s,1H) ES+ 240 
1-(4-chlorophenyl)-1H-pyrrole-3-carboxylic acid (8a) 
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1-(4-chlorophenyl)-1H-pyrrole-3-carbaldehyde(7) (0.76g, 3.58mmol) obtained from step 
1, silver nitrate (1216.26mg, 7.16mmol), 6 N sodiumhydroxide (15ml) and methanol 
(5.8ml) were refluxed for 5h and the reaction was monitored by TLC for completion. The 
reaction mixture was filtered through celite and the aqueous layer was acidified to get a 
white precipitate. The precipitate was filtered off, dissolved in ethyl acetate, and dried 
over sodium sulfate to get the product 0.6g (65%) 
1
H NMR (dimethyl sulfoxide-d6, 400 MHz) δ (ppm) 7.95 (t, J=0.93, 1H), 7.71-7.73 (d, 
J=4.6Hz, 2H), 7.53-7.56 (d, J= 4.7Hz, 2H), 7.43-7.44 (t, J= 1.33Hz1H), 6.61-6.62 (q, 
J=0.88Hz, 1H) 
13
C NMR (dimethyl sulfoxide-d6, 400 MHz) δ (ppm) 165.0, 137.9, 130.5, 129.5, 123.9, 
121.7, 120.7, 118.6, 111.5 HRMS  
EI+ observed 221.0242, calculated 221.0244, 0.9ppm 
1-(4-chlorophenyl)-1H-pyrrole-3-carboxylic acid (8b) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.64(s,1H), 7.34(s,3H), 7.06(s,1H), 
6.82(s,1H) ES+ 256 
2.4.2 Fluorescence Polarization Binding Assay  
CDK4D1 FP assay: This assay was performed using black 384-well plates using a 
previously described procedure
2
 with the following modifications. To each well were 
added: 5 µl CDK4D1 (0.3 µg/well purified recombinant human kinase complex from 
Invitrogen), 5 µl compound solution, 5 µl 30 nM fluoresceinyl-Ahx-Pro-Val-Lys-Arg-
Arg-Leu-(3ClPhe)-Gly tracer peptide. Compounds and kinase complexes were diluted 
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using assay buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, 1mM 
dithiothretiol (DTT). Plate was centrifuged for 1 min at 500 rpm and then incubated with 
shaking for 45 mins at room temperature. Fluorescence polarization was read on DTX880 
multimode detector (Beckman Coulter, Brea, CA) fitted with 485 nm/535 nm 
excitation/emission filters and a dichroic mirror suitable for fluorescein. Relative mp was 
calculated for each concentration tested using the equation showing below. IC50 values 
were determined by logarithmic regression by correlating relative mps and testing 
concentrations. 
Relative mp = 
mP(compound)-mP(DMSO, protein, tracer)
mP( DMSO, protein)-mP(DMSO, protein, tracer)
 
CDK2A2 FP assay: This assay was performed using black 384-well plates. To 
each well were added: 5 µl CDK2A2 (0.3 µg/well purified recombinant human kinase 
complex), 5 µl compound solution, 5 µl 30 nM fluoresceinyl-Ahx-Pro-Val-Lys-Arg-Arg-
Leu-Phe-Gly tracer peptide. Compounds and kinase complexes were diluted using assay 
buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, 1mM dithiothretiol 
(DTT). Plate was centrifuged for 1 min at 500 rpm and then incubated with shaking for 
45 mins at room temperature. Fluorescence polarization was read on DTX880 multimode 
detector (Beckman Coulter, Brea, CA) fitted with 485 nm/535 nm excitation/emission 
filters and a dichroic mirror suitable for fluorescein. Relative mp was calculated for each 
concentration tested using the equation showing below. IC50 values were determined by 
logarithmic regression by correlating relative mps and testing concentrations. 
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2.4.3 Docking
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All the N-capping groups were docked in the cyclin A/CDK2 crystal structure 
(PDB ID 2UUE) using 1-(3,5- dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-
carbaldehyde as control ligand. The parameters of the LigandFit (Discovery Studio 3.0, 
Accelrys) were PLP1 energy grid, minimization sphere “on”, number of poses 10. All the 
docked poses analyzed with PLP1 scoring function, hydrogen bonding and were 
subjected to visual analysis for complementarity with second pocket. 
2.5 Acknowledgement 
I thank Dr. Shu Liu for testing all the compounds in FP assay. Dr. Michael Walla 
and Dr. William Cotham in the Department of Chemistry and Biochemistry at the 
University of South Carolina for assistance with mass spectrometry, Helga Cohen and Dr. 
Perry Pellechia for NMR spectrometry.  
This chapter is written based on the following article with permission from the publisher 
Shu Liu, Padmavathy Premnath (joint first author), Joshua Bolger and Campbell 
McInnes, Optimization of CDK/cyclin groove Inhibitors through REPLACE mediated 
Fragment Assembly, Journal of Medicinal Chemistry, 2013, 56 (4), 1573–1582 
 
56 
 
CHAPTER 3 
FRAGMENT BASED DISCOVERY OF ARGININE ISOSTERES THROUGH 
REPLACE: TOWARDS NON-ATP COMPETITIVE CDK INHIBITORS 
 
3.1 Introduction 
In the chapter 2, the design, SAR and optimization of fragment alternatives based 
on phenyl heterocyclic carboxylic acids was described. These were designed from a 
phenyltriazole Ncap that was discovered during proof of concept for the REPLACE 
strategy
49
. Despite the search for replacements for the critical Arg4 residue, this capping 
group only retained the interactions of the Ala2 methyl side chain and hydrogen bonding 
interactions with Trp217 and Gln254
49
. The ion-pairing contacts of Arg4 were not 
observed in this for any of the subsequent phenyl heterocyclic isosteres. As next step, the 
design of N-capping groups retaining hydrophobic contacts with the secondary pocket 
and H-bonding interactions observed in the previous series but adding basic functionality 
were explored to identify surrogates for arginine and more completely mimic the contacts 
of the native peptide. The REPLACE strategy was used to identify FLIPs synthesized 
from derivatives of phenyl acetic, furoic and picolinic acids as N-capping groups. These 
fragment alternatives were identified through molecular docking studies. The LigandFit
55
 
method was used after validation that it was predictive for similar known fragment 
ligands that were docked into the binding site for Arg4 after its deletion from the 
structural complex. Virtual fragment hits were obtained and used to generate Fragment  
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Ligated Inhibitory Peptides (FLIPs)
56
 and tested in the previously mentioned assay to 
study their competitive binding efficiency
57
. 
3.2 Results 
3.2.1 Validation of LigandFit docking method 
The first step for any in silico screening method is to assess its predictive 
capability. LigandFit
55
 is an accurate, fast and shape based method which can identify 
and generate poses of ligands that are complementary to the active site of the protein of 
interest. The procedure involves two main steps: (i) cavity detection for the identification 
of active site and (ii) docking of ligands at the active site. In the case of an unknown 
binding site, LigandFit utilizes a cavity detection algorithm for detecting a potential 
ligand interacting site and in case of a known active site through the crystal structure of a 
protein-ligand complex, the ligand structure is used to define the active site points.  A 
shape based comparison filter combined with a Monte Carlo conformational search is 
employed for generating ligand poses that have shape complementarity to the active site. 
Furthermore, a grid based method is employed to generate more realistic protein-ligand 
interactions for poses minimized based on the active site
55
. 
As mentioned above, parameters used in any docking protocol should be 
optimized prior to docking of unknown ligands to ensure that these will be predictive. To 
do this a ligand with known orientation in the cyclin groove is redocked to assess if 
correct binding modes are reproduced by the algorithm. To accomplish this, docking was 
carried out in CBG of CDK2/cyclin A (PBD ID:2UUE) by varying the parameters of the 
docking protocol using the ligands (1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-
carbonyl (35DCPT) and 1-(4-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carbonyl) 
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(4CPT) as positive controls and 5-chloro-2-phenyl-1,8a-dihydroimidazo[1,2-a]pyridine-
3-carbaldehyde as a negative control. These molecules were used as controls based on 
previous studies in which 35DCPT and 4CPT were shown to occupy the position of Arg4 
at CBG in their respective crystal structures (PBD ID: 2UUE, 2V22).  FLIPs N-capped 
with 35DCPT and 4CPT bind to CBG and inhibit CDK2/cyclin A whereas the negative 
control containing FLIP had very poor inhibitory activity
49
. The structures of positive and 
negative control are shown in figure 3.1. Important parameters of the LigandFit protocol 
affecting the generated binding mode were optimized and include the type of energy grid 
and minimization algorithm and also the number of poses generated and scoring function 
used to differentiate good from bad poses.  
 
Figure 3.1 Structures of positive and negative controls 
The energy grid is the force field for calculating ligand-receptor interaction and 
three types are available within LigandFit: the Dreiding force field with Gasteiger 
charges, the CFF (Consistent Force Field) and PLP1 (Piecewise linear potential). The 
first step in the validation study was to evaluate each of these energy grids and then select 
the one that generates the highest number of accurate poses. After finding a suitable 
energy grid, the use of a minimization algorithm was studied by turning it on or off 
during LigandFit docking. It can be used to generate poses with relaxed conformations 
and also to remove steric overlap that occurs during docking and results in bad poses. The 
next step in the validation exercise is to determine which overall force field is optimal. 
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CHARM and CFF are two examples of those available to generate atom types and to 
assign partial charges to the atoms of the simulation and ultimately to estimate the 
binding affinity as sum of the strength of intermolecular van der Waals and electrostatic 
interaction between atoms of the ligand and receptor. Docking time is a concern when 
evaluating thousands of compounds and thus it is very important to set an optimal value 
for the number of poses generated for each ligand docked determines length of the 
calculation.  For this validation, the number of poses generated was varied between 5, 10 
and 20 to determine the optimal number required in order to reduce the docking time.  
The last step in the docking validation is to determine which scoring function is able to 
correctly assess experimental binding modes for a known ligand. Scoring functions are 
used to rapidly estimate the binding affinity of a docked ligand pose based on the 
geometry of the conformation and its non-covalent interaction with the target receptor. 
Ligscore1_Dreiding, Ligscore2_Dreiding, PLP1, PLP2, PMF, DOCKSCORE and Jain 
scoring functions were evaluated.  
The LigandFit parameters were optimized based on the number and accuracy of 
poses for the known ligands docked into the cyclin groove i.e., maximum number of 
correct poses of the positive control ligands and minimum or no poses of negative control 
ligand in top scoring poses. A correct pose is one that binds in the receptor in a very 
similar orientation to the true ligand and thus superimposes well with true ligand binding 
mode and interactions with the defined interaction filters. A close pose is one where the 
positive control ligand binds in similar orientation to the correct pose and has RMSD 
(root mean square distance) of less than 2.0 Å compared to the true ligand binding mode. 
Optimized parameters obtained in the validation exercise will then be selected for 
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docking of the library of unknown fragments.  
The binding modes of the 35DCPT Ncap have been previously characterized by 
X-ray crystallography and were used for the generation of site points. The volume 
occupied by the ligand at the binding site determines the site points. In this study, site 
points cover the interaction of the phenyl ring (attached to N-1 atom of triazole) in the 
secondary hydrophobic cleft of the CBG and those of the H-bonds of the triazole N-2 
atom with indole nitrogen of Trp217 and carbonyl oxyen with the amide side chain of 
Gln254. Along with these interactions, the correct orientation of the carbonyl group was 
studied because this is required for the formation of an amide bond to the peptide in FLIP 
synthesis. As the crystal structure is a tetrameric complex of two CDK2/cyclin A 
heterodimers, both cyclin subunits were evaluated in the validation by docking the 
positive and negative control ligands into the CBG (PBD ID 2UUE).  
Table 3.1 Determination of the optimal cyclin subunit (2UUE)  
 
Docking results for B subunit showed that 10 and 14 correct/close poses 
respectively were obtained for 35DCPT and 4CPT respectively whereas for the D 
Energy Grid Dreiding CFF PLP1
Sub units Subunit B Subunit D Subunit B Subunit D Subunit B Subunit D
No. of correct poses 
of 3,5-DCPT
2 - 4 - 6 -
No. of correct poses 
4-DCPT
- - - - 8 -
No. of  closer poses 
(<2.0Å) of 3,5-
DCPT
3 - 4 - 4 -
No. of  closer poses 
(<2.0Å) of 4-DCPT
15 - 8 - 6 11
-ve controls in top 
25 
18 - 15 - - -
Best scoring 
functions 
LigScore2
_Dreiding
-
PLP1, 
PLP2
-
PLP1, 
PLP2
Ligscore1_ 
dreiding, 
Ligscore2_ 
dreiding, PLP1
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subunit, 11 close poses of 4-CPT and no correct poses for 3,5-DCPT resulted from the 
calculations. There were no poses of the negative control ligand in the top 25 poses for 
either subunit. As a result, the B subunit was considered for further parameter 
optimization (Table 3.1). For each energy grid evaluated, the number of correct/close 
poses in top 25 based on ranking of the scoring function (Ligscore1_Dreiding, 
Ligscore2_Dreiding, PLP1, PLP2, Jain, PMF and DOCKSCORE) was determined. The 
energy grids, Dreiding, CFF and PLP1 generated 2, 4 and 6 correct poses respectively for 
35DCPT. In top 25 scoring poses, there were 18 and 15 poses of negative ligands 
observed for Dreiding and CFF respectively but there were no negative ligand poses 
found for PLP1. After confirming that the PLP1 energy grid was the most effective, it 
was used for further validation runs where scoring functions were analyzed individually. 
The best scoring function was found to be PLP1 which generated 6 correct and/or close 
poses of 35DCPT and 4CPT in the top 25 ranked poses. Results for the docking 
parameter optimization are shown in Table 3.2.  
Table 3.2 Optimization of LigandFit docking parameters for the cyclin A groove 
 
Energy Grid Dreiding CFF PLP1
No. of correct poses 3,5-
DCPT
2 4 6
No. of correct poses 4-
DCPT
- - 8
No. of -negative controls in 
top 25 
-PLP1(4), -PLP2(4), 
Jain (4), PMF(4), 
DOCK SCORE(6)
-PMF (7), DOCK 
SCORE (6)
No –ve control poses 
in all the scoring 
functions
Best scoring functions LigScore2_Dreiding PLP1, PLP2 PLP1, PLP2
3,5-DCPT(rank of top 25 
correct/closer poses for the 
best scoring function)
4,5 (for all the scoring 
functions)
PLP1(9-12,25), 
PLP2(13-16,25)
PLP1(7-14,25), 
PLP2(11-18)
4-DCPT (rank of top 25 
correct/closer poses for the 
best scoring function)
-
PLP1(1-8), 
PLP2(17-24)
PLP1(1-6) PLP2(20-
25)
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Having minimization sphere “on” minimizes the ligands to their lowest energy 
conformations after docking. Hence 10 was considered an optimal number for number of 
poses generated because it generated sufficient number of poses for interpreting the 
results while saving the docking time.  The conclusion of this docking validation study is 
that the optimized parameters were found involve the use of the PLP1 energy grid the 
minimization sphere, and the generation of 10 poses. The docking carried out for the 
known ligands showed that the experimental binding modes of ligands can successfully 
be reproduced and therefore the method should be predictive. 
3.2.2. Docking of the virtual capping group library.  
To more completely exploit the interactions of high affinity peptidic cyclin 
groove inhibitors, a library of compounds based on the crystal structure ligand (1-(3,5-
dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxaldehyde 35DCPT) and using SAR 
of the parent peptide (HAKRRLIF) was designed. The criteria used in the library design 
included (i) molecular weight less than 400, (ii) presence of a carboxylic acid group for 
the formation of amide bond with the peptide sequence, (iii) incorporation of alkyl/aryl 
substitutions for van der Waals interactions with the secondary pocket, (iv) basic 
functionality for ion-pairing interaction with acidic residues and (iv) synthetic feasibility/ 
commercial availability. This library was built using the following cores strucures: 5-
membered heterocyclic ring substituted with a carboxylate, phenyl acetic acids and 6-
membered heterocyclic ring substituted with a carboxylate.  
1. 5-membered heterocyclic rings: These include 1,2,4- triazole, pyrazole, furan, 
pyrrole, and thiophene  rings. The latter were linked to another 5-membered 
heterocyclic structure (imidazole, pyrazole and thiophene). In addition to these, the 
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furoic acids were substituted with diethylaminomethyl and piperazinylmethyl groups. 
Some examples are shown in figure 3.2. These basic groups were included to exploit 
ion-pairing interactions with the acidic residues (Glu220, Glu224 and Asp283; cyclin 
A numbering) made by Lys3 and Arg4 (HAKRRLIF). The heteroatoms in the 5-
membered ring were included to interact with H bond donors in the cyclin groove 
(e.g. the indole nitrogen of Trp217). 
 
Figure 3.2 Examples of structures 5-membered  
heterocyclic structures docked 
 
2. Phenyl acetic acids: These were substituted with alkoxy groups at the 3 position and 
were expected to interact with the secondary pocket occupied by the Ala2 methyl side 
chain in the peptide. 
3. Picolinic acids: These were substituted with alkyl groups at the 3 position for 
interacting with the secondary pocket and with basic groups at the 4 position for ion-
pairing interactions (piperazinylmethyl, guanidomethyl and dimethylaminomethyl 
groups). 
Each potential Ncap was docked as an aldehyde into the cyclin groove of  
CDK2/Cyclin A (PBD ID 2UUE) using the validated LigandFit docking method in order 
to predict the correct orientation. Presence of carboxylic acid group would be hindrance 
and interfere with interaction filter. Hence the molecules were docked as aldehydes.  
Docked molecules were prioritized based on high PLP1 score, shape complementarity 
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and consensus scoring. Consensus scoring is a way of assessing poses that score well in 
multiple scoring functions (in this case, the seven scoring functions used) with the aim of 
obtaining a more accurate estimate of the various interactions between the receptor and 
the ligand. The PLP1 scoring and the shape complementarity of top scoring poses were 
comparable with the true ligands 3,5-DCPT and 4-CPT. The structures and PLP1 scoring 
values of virtual hits are shown in table 3.3. 
Table 3.3 Hit molecules with their PLP1 scoring 
 
3.2.3. Structure activity relationship of N-capping groups  
In Chapter 3, phenylheterocyclic carboxamido FLIPs, were described and the 
structure-activity was explored for interactions with the secondary pocket and H-bonding 
residues of the cyclin groove (e.g. Trp217 and Gln254)
63
. Residues of the N-terminal 
Structure PLP 1 Structure PLP 1
54.28 48.83
42.61 53.12
52.1 49.18
48.4 45.32
45.35 46.7
43.84 45.92
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tetrapeptide of HAKRRLIF make ion-pairing interactions with acidic side chains 
surrounding the secondary pocket. Arg4 of HAKRRLIF occupies the ridge of the cyclin 
groove that separates both the major and minor lipophilic pockets and makes ion-pairing 
interactions with Glu220 and Glu224 thus providing a significant portion of the affinity 
for the peptide. Here, groups capable of ion-pairing interactions were incorporated onto 
various scaffolds. Some of these scaffolds were designed to be capable of H-bonding and 
hydrophobic interactions. The heterocyclic carboxylic acids substituted with basic 
functionality were designed to make ion-pairing interactions with the acidic residues 
(Glu220 and Glu224) and H-bonding contacts with cyclin groove side chain atoms 
(Trp217 and Gln254). 5 and 6 membered nitrogen and oxygen heterocycles were 
hypothesized to facilitate H-bonding interactions observed in the 35DCPT capping group 
(to the indole nitrogen of Trp217). The amide group present in all the compounds makes 
hydrogen bonding with Gln254. Phenylacetic and picolinic acid derivatives were 
substituted with alkyl/alkoxy groups to further explore SAR of the minor hydrophobic 
pocket. 
After scoring the docked ligands, potential capping groups were further 
prioritized based on commercial availability and/or ease of synthesis and subsequent to 
this incorporated into FLIPs (appended onto the RLIF sequence).  Of all of the FLIPs 
synthesized and derived from furoic acids (table 4.4), only 5581 (CDK2/cyclin A- 43.4 
µM, CDK4/cyclin D-41.9µM) and 5589 (CDK2/cyclin A- 50.3 µM, CDK4/cyclin D-43.2 
µM) possessed significant activity and exhibited similar potency in binding to both 
CDK2/cyclin A and CDK4/cyclin D. All the other FLIPS from this series and those 
derived from thiophene carboxylic acids showed weak activity (table 3.4). 
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Table 3.4 SAR of 2-Furoic acid and Thiazole-4 carboxylic acid based FLIPs 
 
An additional scaffold which was explored and verified computationally was the 
picolinic acid based fragment. The 6 position was substituted with alkyl, alkyloxy and 
piperazinylmethyl groups and these were incorporated as Ncaps into either the RLIF or 
RLNpfF peptide. Thus, unsubstituted, 6-methoxy, 6-ethoxy derivatives were ligated to 
RLNpFF while 6-methyl and 5-piperazinylmethyl analogs (5856) were appended to the 
RLIF sequence. The compound having a piperazinyl methyl substitution at the 5 position, 
5856 shows moderate activity in binding to CDK2/cyclin A (>100µM) and greater 
SCCP ID R
CDK2/cyclin A IC50 
(mM)
CDK4/cyclin D1 
IC50 (mM)
5581 1 - 43.5±1.2 41.9±3.1
5585 1 - >100 >100
5586 1 - >100 >100
5589 1 - 50.3±1.3 43.2±5.0
5761 1 - >100 >180
5582 - 2 56.2±1.2 >180
5584 - 2 >180 >180
Core
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potency for inhibition of the cyclin groove of CDK4/cyclin D (21.9 µM) with roughly 
equal activity compared to RRLIF (CDK4/cyclin D- 16.4 µM). The results are shown in 
table 3.5.  
Table 3.5 SAR of Picolinic acids based FLIPs 
 
Phenylacetic acid derivatives were a third scaffold that was studied and analogs 
were designed to explore the effect of the incorporation of methylene bridge between the 
phenyl ring and the carboxyl group, on the lipophilic interactions with the secondary 
pocket. Three analogs 3-ethoxy (5854), 3-propoxy (5853) and 3-isobutyloxy (5855) 
phenylacetic acid were synthesized by alkylation of 3-hydroxyphenylacetic acid using the 
appropriate alkyl bromide followed by base hydrolysis of the ester which occurs due to 
concomitant alkylation of the carboxylate (scheme 4.1)
67
. These N-capping groups were 
then ligated to RLIF with the exception of 530 where 3,4- diethoxyphenyl acetic acid was 
SCCP ID R2
CDK2/cyclin A IC50 
(mM)
CDK4/cyclin D1 IC50 
(mM)
525 H 1 - 29.2±1.3 48.4±1.2
5845 Me - 2 >100 85.7±1.9
524 OMe 1 - 36.4±1.2 >100
523 OEt 1 - 39.7±1.2 >100
5856 - 2 >100 21.9±1.1
Core
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obtained commercially and appended to RLNpfF. This bis-substituted analog showed the 
best activity in this phenylacetic acid derived series with IC50 values of 5.2 µM and 3 µM 
in CDK2/cyclin A and CDK4/cyclin D respectively. All other compounds were 
marginally or completely inactive. The activity of the phenylacetic acid based FLIPs are 
shown in table 3.6. 
Scheme 3.1 Synthesis of phenyl acetic acid derivatives 
. 
Table 3.6 SAR of Phenylacetic acid based FLIPs 
 
SCCP ID R1 R2
CDK2/cyclin A 
IC50 (mM)
CDK4/cyclin D1 
IC50 (mM)
5854 H OEt >100 >100
5853 H n-OPr >100 >50
5855 H t-OBu >100 >100
530 OEt OEt 5.2±1.3 3.0±2.12
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3.3 Discussion and conclusion 
Optimizing docking parameters is a mandatory step for every receptor-ligand 
complex as interactions vary considerably with each target. For every target we need to 
find the optimal set of parameters that will reproduce experimental binding modes and 
thus will be customized to that particular target. Validation of the LigandFit method was 
carried out to ensure that the method is able to reproduce experimental binding modes for 
known ligands of the cyclin groove and therefore show that the docking results of 
unknown compounds will be predictive. The PLP1 energy grid and scoring function were 
selected as optimal parameters that were effective in reproducing the binding modes of 
native ligands (35DCPT, 4CPT). Energy grid PLP1 was able to reproduce maximum 
number of correct or closer poses compared to Dreiding and CFF. Scoring functions in 
general are calculated based on assessment of a combination of electrostatic, van der 
Waals and hydrogen bonding energies. Of all the seven scoring functions (Jain, 
Ligscore1, Ligscore2, PLP1, PLP2, DOCKSCORE and PMF) studied PLP1 was found to 
be the most successful as this includes hydrogen bonding terms and hydrophobic 
interactions. In this study the binding efficiency at the cyclin groove – substrate protein-
protein interaction interface is being evaluated and thus is comprised of a variety of 
interactions with H-bonding being a major contributor to affinity of CGI ligands. A 
library of small molecules based on 5-furoic acid, thiazole-4-carboxylic acid, 5 and 6 
substituted picolinic acids, and also 3 and 4 substituted phenylacetic acids were docked to 
evaluate for their ability to completely interact with cyclin groove. Among the docked 
molecules, 16 molecules were synthesized as FLIPs and tested in FP assay.  
Among the Ncap series based on furoic acids, FLIPs having furoic acid with basic 
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substituents (5-((diethylamino)methyl)furan-2-carboxylic acid - 5581 and 5-((4-
methylpiperazin-1-yl)methyl)furan-2-carboxylic acid - 5589) showed greater activity 
towards both cyclin complexes than 5-((1H-imidazol-1-yl)methyl)furan-2-carboxylic acid 
- 5585 and 5-((1H-pyrazol-1-yl)methyl)furan-2-carboxylic acid - 5586. The basic groups 
in the Ncaps will be protonated and thus positively charged at physiological pH. This 
activity observed for 5581 and 5589 is most likely because of the ion-pairing interaction 
of the charged basic groups with acidic residues in the cyclin groove (Glu220 and 
Glu224; cyclin A and Glu66; cyclin D).  In addition to their ion-pairing interactions, 
docked poses indicate that the ethyl groups of 5581 and the piperazine ring carbons of 
5589 interact with the secondary pocket occupied by the Ala side chain of the parent 
peptide and also mimicking the van der Waals interactions of the phenyl ring of the 
35DCPT capping group. Among the thienyl FLIP analogs (5-(thiophen-2-yl)furan-2-
carboxylic acid - 5584) and (5-(thiophen-3-yl)furan-2-carboxylic acid -5582), 5582 
possessed the greatest affinity for cyclin A in complex with CDK2 most likely because it 
has a larger secondary pocket to accommodate the thiophene ring.  
As previously discussed in chapter 3, the oxygen atom in the furan ring is a poor 
hydrogen bond acceptor compared to nitrogen containing heterocycles (i.e. 1,2,4-triazoles 
and pyrazoles) resulting in weak binding affinity of FLIPs containing this ring system
63
. 
This is a likely reason for the overall weak affinity of this series relative to the 
phenyltriazole capping groups discussed in chapter 3.  But 5581 and 5589 exhibit better 
binding affinity towards CBG compared to other phenylfuroic acid derivatives as a result 
to the presence of basic groups. Therefore, it is likely that appending the basic 
substituents evaluated in furoic acid series onto the 1,2-4 triazole should result in 
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significant improvements in binding. The interactions of selected results are shown in 
figure 3.3. In addition, benzoic acid derived capping groups incorporating basic groups 
were evaluated and are discussed in chapter 5.  
Picolinic acids derivatives were designed to incorporate a heteroatom capable of 
mimicking H- bonding interactions (Trp217, Gln254) observed in the 35DCPT capping 
group and in the peptide context. This was confirmed by the respectable activity of the 
unsubstituted picolinamide capped peptide (525). In addition to H-bonding, the methyl or 
alkoxy group at the 6 position was hypothesized to provide hydrophobic complementarity 
with the second pocket while the piperazinylmethyl group should offer both ion-pairing 
and van der Waals interactions (5856). This did not prove to the case since the designed 
FLIP was inactive in binding to the CDK2/cyclin A complex. The considerable binding 
activity of 5856 for cyclin D/CDK4 is likely the result of closer positioning of the free 
piperazine N-atom for ion-pairing with Glu66. Minimal activity of the 6-methoxy (524) 
and 6-ethoxy (523) derivatives relative to the unsubstituted compound (525) indicate that 
these substitutions are not appropriately positioned to interact with the pocket. Since the 
picolinamide capping group is a six membered ring system, placing larger substituents in 
the 6-position may lead to a steric clash leading to weaker interaction with Trp217. 
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Figure 3.3 Interactions of 5581, 5585, 5589 and 5856 at the 
Arg binding site of CBG 
 
The binding of hit molecules at the Arg binding site of CBG is shown. The 
interaction filters NH-atom of Trp217 and Gln254 are shown as green spheres; 
hydrogen bonds with the interaction filters are shown as green dotted lines. The 
closer acidic residues and interaction filters are shown in three letter codes. Ion-
pairing interactions with GLu220 and Glu224 are depicted in green lines 
The loss of activity for the mono substituted phenylacetic acid derivatives could 
be a result of the absence of the potential hydrogen bonding interaction with Trp217. The 
increased potency of the diethoxy analog (530) is likely due to the presence of the 
additional substituent at 4 position enabling better placement of the 3-ethoxy group in the 
secondary pocket
68
. The activity of this type of substitution was explored in the context 
of benzoic acid derivatives which do not have the methylene bridge and these results are 
discussed in chapter 5.  
Validation of the LigandFit docking method was useful for predicting binding 
interactions of unknown compounds at the protein-protein interface. The results obtained 
 
5581 (PLP1- 52.1)  
IC
50 
(CDK2/cyclin A- 43.5±1.2µM  
  CDK4/cyclin D-41.9±3.1µM) 
5585 (PLP1- 42.61) 
IC
50
 (CDK2/cyclin A> 100µM  
         CDK4/cyclin D>100µM 
5856 (PLP1-35.03) 
IC
50
 (CDK2/cyclin A- >100 µM 
CDK4/cyclin D – 21.9 ±1.1 µM) 
5589 (PLP1-54.28) 
IC
50
 (CDK2/cyclin A- 50.3±1.3µM, 
CDK4/cyclin D-43.2±5.0µM) 
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from FLIP CGI compounds derived from furoic, thiazole, picolinic and phenylacetic acid 
derivatives as N-capping groups suggests that these groups are good substituents for N-
terminal Arg. The results correlated from docking analysis and binding assay of FLIPs 
confirms validation of docking parameters. In addition to hydrogen bonding interactions, 
basic groups substituted in furoic acid and picolinic acid provided insights on ion-pairing 
interactions. Overall these FLIP molecules developed in this series contribute to 
validation of REPLACE strategy for the development of drug like molecules and also 
provides a platform for further investigation of ion-pairing interactions with acidic region 
of CBG through the use of more optimal scaffolds. 
3.4 Experimental section 
3.4.1 Validation of LigandFit 
The parameters of the LigandFit (Discovery Studio 3.0, Accelrys) docking 
method were validated using ligands from cyclin A/CDK2 crystal structures. The 
crystallographic ligands 1-(3,5- dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-
carbaldehyde (3,5-DCPT) (PDB ID:2UUE) and 1-(4- chlorophenyl)-5-methyl-1H-1,2,4-
triazole-3-carbaldehyde (4-CPT) (PDB ID:2V22) were used as positive controls and 5-
chloro-2-phenyl-1,8a-dihydroimidazo[1,2-a]pyridine-3-carbaldehyde was evaluated as a 
negative control. The three ligands were docked successively into the cyclin grooves of 
two structures (2V22, 2UUE) and 20 poses were generated for each. This was repeated 
by variation of  the LigandFit parameters including the forcefield used for the energy grid 
(Dreiding, CFF and PLP1), use of minimization sphere (on or off) and different scoring 
functions (Ligscore1_Dreiding, Ligscore2_Dreiding, PLP1, PLP2, PMF, DOCKSCORE) 
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to determine which generated a calculated binding energy most predictive of the 
experimental binding mode. For each parameter and scoring function, the number of 
correct poses of the positive controls in the top 25 ranked binding modes (out 25 of 60 
possible, 20 for each of the three ligands) was determined. A library of 20 potential 
fragment alternatives was manually built using ChemDraw for Excel (Perkin Elmer) and 
subsequently imported into DiscoveryStudio 3.0 (Accelrys). For docking of unknown 
compounds, 10 poses were generated since this was sufficient to generate correct poses 
for the control ligands. 
3.4.2. Synthesis 
3.4.2.1 Material and methods 
All the starting materials, solvents and reagents were used as obtained without 
further purification. Analytical thin layer chromatography was performed on silica gel 
(GF-254 plates). 1H NMR and 13 C NMR spectra were recorded with a Varian Mercury 
300 and 400 Spectrometer, respectively. Mass spectra were measured with a Micromass 
QTOF (Tandem quadruple-1 time of flight mass spectrometer), electrospray ionization 
(ESI) and VG 70S (Double-focusing magnetic sector mass spectrometer, EI). Analytical 
purities of evaluated compounds were >95% unless stated otherwise. The following 
analytical method (unless stated otherwise) was used on a Waters Alliance 2695 HPLC 
with a 2996 diode-array detector and equipped with a C18 (2) 100 A, 250 x 4.6mm, 5μm 
column (Phenomenox Luna). A gradient from 100% water (0.1% trifluoroacetic acid) to 
60% acetonitrile (0.1% trifluoroacetic acid) was run over 30 mins and held for 4 mins. 
The chromatograms were extracted at 226 and 254 nm. 
75 
 
3.4.2.2 Synthesis of capping groups 
Furoic acid, picolinic acid and 2-(3,4-dihydroxyphenyl)acetic acid N-terminal 
capping groups were all  obtained commercially (Chembridge, Matrix Scientific and 
UKROrgSyth). 3-alkoxy phenyl acetic acid derivatives were synthesized using the 
following procedure: 
Step 1: Synthesis of ethyl 2-(3-ethoxyphenyl) acetate (9a)
 67
 
3-hydroxyphenylacetic acid (0.76 g, 5 mmol), ethyl bromide (0.25 g, 23 mmol) 
and potassiumcarbonate (0.13 g, 16.5 mmol) were refluxed in 5 ml of DMF for 12-18 hrs. 
The reaction was monitored by TLC (Ethylacetate: Hexanes= 35:65), after the reaction 
was complete, the reaction mixture was cooled to room temperature; water was added to 
dissolve potassium carbonate. The aqueous layer was extracted with ethyl acetate and the 
combined organic layers were washed with saturated sodium bicarbonate, brine, dried 
over sodium sulfate and evaporated to yield reddish oil (0.31 g, yield-30.0%). 
1
H NMR (Chloroform-D, 300MHz) δ (ppm) 7.13(t, J=7.32Hz, 1H), 6.75(t, J=8.73Hz, 
3H), 4.06(q,24 J=7.80Hz, 2H), 3.93(q, J=6.75Hz, 2H), 3.50(d, J=7.26Hz, 2H), 1.31(t, 
J=6.87Hz, 3H), 1.16(t,25 J=7.02Hz, 3H)  
 EI 208 
 propyl 2-(3-propoxyphenyl)acetate (9b) 
Reddish oil (yield-28.2%) 
1
H NMR (Chloroform-D, 300MHz) δ (ppm) 7.25-7.19(m, 1H), 
6.83(t,29 J=8.07Hz, 3H), 4.05(t, J=6.78Hz, 2H), 3.91(t, J=6.39Hz, 2H), 3.59(d, 
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J=6.96Hz, 2H), 1.80(q, 30 J=7.35Hz, 2H), 1.64(q, J=6.00Hz, 2H), 1.03(t, J=7.32Hz, 3H), 
0.91(t=7.33Hz, 3H) 
EI 224 
isobutyl 2-(3-isobutoxyphenyl)acetate (9c) 
Reddish oil (yield-24.2%) 
1
H NMR (Chloroform-D, 300MHz) δ (ppm) 7.22(t, J=8.34Hz, 
1H), 6.85-4 6.79(m, 3H), 3.89(d, J=6.48Hz, 2H), 3.71(d, J=6.93Hz, 2H), 3.60(s, 2H), 
2.12-2.03(m, 1H), 1.97-5 1.88(m, 1H), 1.03(d, J=6.18Hz, 6H), 0.92(d, J=6.60Hz, 6H) 
EI 264 
Step 2: 2-(3-ethoxyphenyl) acetic acid (10a)
3
 
The ethyl 2-(3-ethoxyphenyl) acetate (1.41g, 5mmol) obtained from step 1 was 
treated with sodium hydroxide (2.8 g, 70 mmol) and a solution of 15 ml ethanol and 15 
ml water. The reaction mixture was refluxed for two hours and the reaction was 
monitored by TLC (Ethylacetate: Hexanes= 35:65). After the completion of reaction, the 
reaction mixture was cooled; the alcohol was evaporated and diluted with water. The 
reaction mixture was acidified with 1N hydrochloric acid and stirred to precipitate the 
product as white solid (0.73 g, Yield-81.2%). 
1
H NMR (chloroform-D, 500MHz) δ (ppm) 7.28-7.24(m, 1H), 6.88-6.83(m, 3H), 4.05(q, 
J=6.80Hz, 2H), 3.63 (s, 2H), 1.42 (t, J=7.25Hz, 3H) 
 
13
C NMR (chloroform-D, 125MHz) δ (ppm) 177.15, 159.14, 134.61, 129.60, 121.55, 
115.65, 113.41, 63.41, 41.01, 14.80 
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EI 180 
2-(3-propoxyphenyl)acetic acid (10b) 
White solid (yield-85.2%) 
1
H NMR (chloroform-D, 300MHz) δ (ppm) 7.21(d, J=7.44Hz, 
2H), 6.83(t,22 J=7.86Hz, 2H), 3.90(t, J=6.03Hz, 2H), 3.61(s, 2H), 1.79(q, J=6.42Hz, 2H), 
1.02(t, J=7.05Hz, 3H) 
EI 194 
2-(3-isobutoxyphenyl)acetic acid (10c) 
White solid (yield-82.8%) 
1
H NMR (chloroform-D, 300MHz) δ (ppm) 7.22(d, J=8.19Hz, 
1H), 6.83(t, 26 J=8.70Hz, 3H), 3.70(d, J=7.26Hz, 2H), 3.62(s, 2H), 2.11-2.00(m, 1H), 
1.01(d, J=6.69Hz, 6H) 
EI 208 
Analytical data (NMR and MS) of representative N-caps are shown in appendix. 
Characterization data for FLIPs are shown in appendix table 2. 
3.4.3 Fluorescence polarization assay
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CDK4D1 FP assay: This assay was performed using black 384-well plates using a 
previously described procedure with the following modifications. To each well were 
added: 5 µl CDK4D1 (0.3 µg/well purified recombinant human kinase complex from 
Invitrogen), 5 µl compound solution, 5 µl 30 nM fluoresceinyl-Ahx-Pro-Val-Lys-Arg-
Arg-Leu-(3ClPhe)-Gly tracer peptide. Compounds and kinase complexes were diluted 
using assay buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, 1mM 
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dithiothretiol (DTT). Plate was centrifuged for 1 min at 500 rpm and then incubated with 
shaking for 45 mins at room temperature. Fluorescence polarization was read on DTX880 
multimode detector (Beckman Coulter, Brea, CA) fitted with 485 nm/535 nm 
excitation/emission filters and a dichroic mirror suitable for fluorescein. Relative mp was 
calculated for each concentration tested using the equation showing below. IC50 values 
were determined by logarithmic regression by correlating relative mps and testing 
concentrations. 
Relative mp = 
mP(compound)-mP(DMSO, protein, tracer)
mP( DMSO, protein)-mP(DMSO, protein, tracer)
 
CDK2A2 FP: assay This assay was performed using black 384-well plates. To each 
well were added: 5 µl CDK2A2 (0.3 µg/well purified recombinant human kinase 
complex), 5 µl compound solution, 5 µl 30 nM fluoresceinyl-Ahx-Pro-Val-Lys-Arg-Arg-
Leu-Phe-Gly tracer peptide. Compounds and kinase complexes were diluted using assay 
buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, 1mM dithiothretiol 
(DTT). Plate was centrifuged for 1 min at 500 rpm and then incubated with shaking for 
45 minutes at room temperature. Fluorescence polarization was read on DTX880 
multimode detector (Beckman Coulter, Brea, CA) fitted with 485 nm/535 nm 
excitation/emission filters and a dichroic mirror suitable for fluorescein. Relative mp was 
calculated for each concentration tested using the equation showing below. IC50 values 
were determined by logarithmic regression by correlating relative mps and testing 
concentrations. 
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CHAPTER 4 
STRUCTURE ACTIVITY RELATIONSHIP LEADING TO CONVERSION OF 
CYCLIN BINDING GROOVE PEPTIDES TO DRUG LIKE CDK INHIBITORS 
THROUGH REPLACE  
 
4.1 Introduction 
In this chapter, structure-activity relationships of peptidic cyclin groove inhibitors 
derived from the p21
WAF
 CDK inhibitory protein and the Rb like substrate, p107 are 
described. This was carried out towards the overall aim of targeting substrate recruitment 
through the cyclin binding groove (CBG) present in cell cycle CDK/cyclin complexes. 
The Cyclin Binding Motif (CBM) has been studied in detail and shown to be comprised 
of the consensus sequence, ZXRLYY’ where Z, X are basic residues (Lys, Arg), L is 
leucine and Y, Y’ are non-polar residues with a requirement for Phe at one of these two 
positions. Ala scanning of the p21
WAF
 sequence from residues 149 to160 has been carried 
out showing that the sequence, DFYHAKRRLIFS was a potent inhibitor of CDK4/cyclin 
D and CDK2/cyclin E in kinase assays. Minimization studies showed that the peptide 
octamer, HAKRRLIF was a highly potent inhibitor of CDK2/cyclin A when tested in 
competitive binding assay and also that the activity was comparable to the intact human 
recombinant p21
WAF
( IC50 = 0.028µM vs. 0.011µM). This octamer was further truncated 
to RRLIF (IC50-1.4µM in CDK2/cyclin A) showing that respectable levels of potency 
could be retained with a MW more akin to drug-likeness. Overall these results show that 
potent and selective inhibition of cell cycle CDKs can be obtained in p21 derived
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peptides that are non-ATP competitive compounds. Similarly another octapeptide derived 
from the retinoblastoma like protein p107, SAKRRLFG binds to the CBG and results in 
potent inhibition of cell cycle CDKs (IC50 - 0.035µM in CDK2/cyclin A)
 46
. Because of 
their lack of cell permeability and metabolic instability, peptides in general do not make 
good drugs
48
. The first aim of this study is to investigate the SAR of the CBM in greater 
depth in order to replace peptide residues that prevent it from crossing the cell membrane 
and to incorporate substitutions to improve metabolic stability. The liabilities of the CBM 
peptides include the basic residues (Lys, Arg) that limit cell permeability and the 
susceptibility of the amide backbone to proteolytic degradation. Furthermore, the goal 
was to iteratively convert the peptide RRLIF into drug like FLIP molecules utilizing 
REPLACE strategy.  Based on the SAR data, a variety of modifications were included to 
replace Arg5 and to stabilize the C-terminal motif against degradation. These were then 
then converted into more pharmaceutically appropriate compounds through addition of 
the 35DCPT as the most effective Ncap identified to date.   
4.2 Results 
A detailed structure activity relationship was carried out for peptides derived from 
p21
WAF
 and p107 with several modifications of the key residues to determine how the key 
determinants of binding could be replaced and based on the results allow conversion to 
more drug like molecules. Three series of CGI peptides were selected for a detailed study 
of their structure activity relationships. Two of these include the p21WAF
 
derived 
peptides HAKRRLIF and its truncated variant RRLIF. The third series is from the Rb 
like protein substrate, p107 and has the sequence SAKRRLFG. Previous SAR 
information revealed that the residues His1, Lys3, Arg4 and Arg5 make ion-pairing 
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interactions with the acidic regions and are therefore important or critical for activity
44
.  
Furthermore Ala3, Leu6 and Phe8 contact the two hydrophobic pocket regions through 
van der Waals interactions and these are essential determinants for binding to the CBG. 
Inclusion of the Ile spacer residue between Leu and Phe in the p21
WAF
 peptide 
(HAKRRLIF) improves potency relative to the p107 peptide (SAKRRLFG) 
69
. An 
extensive SAR investigation was therefore carried out so as to find residue alternatives 
that might reduce peptide length and consequently improve the drug likeness.  
 
Figure 4.1 Structure of non-natural amino acids 
For the octapeptides, HAKRRLIF and SAKRRLFG, modifications of the C-
terminus were attempted. For RRLIF, Arg 4 was substituted with non-natural amino acids 
or fragment capping groups designed to further probe its contributions and Arg5 was 
replaced with isosteric residues. These modifications were carried out to study SAR 
which then would help in investigating the effect of substituted residues in retaining the 
inhibitory activity but with improved stability and drug likeness. The isosteric residues 
incorporated are shown in figure 4.1. Modified peptides were synthesized by standard 
solid phase chemistry
56
, and then tested for their ability to bind to the cyclin groove of 
CDK2/cyclin A and CDK4/cyclin D1. Furthermore the experimental binding affinity was 
correlated with the calculated interaction energies for peptides modeled in complex with 
CDK2/cyclin A. 
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4.2.1 Structure activity relationship of SAKRRLFG (p107) and HAKRRLIF 
(p21
WAF
) based peptide analogs  
Peptides derived from p107 and p21
WAF
 have been shown to exhibit potent non-
ATP competitive inhibitory activities against CDK2/cyclin A and CDK4/cyclin D. The 
key residues that contribute to binding and inhibitory activity need to be investigated to 
extend the structure-activity relationships.  As discussed, the CBG has three major 
subsites including an acidic region and a major (primary) and a minor (secondary) 
hydrophobic pocket. Lys3 and Arg4 in the N-terminal tetrapeptide of the octapeptides 
interact with acidic residues (Glu220, Glu224 and Asp284) and whereas Ala2 interacts 
with the secondary hydrophobic pocket. Leu6 and Phe (7 or 8) in the C-terminal region of 
the octomer bind to the primary lipophilic pocket
49,70
 . In this first instance, these C-
terminal determinants were exchanged to determine their contributions with the major 
hydrophobic pocket and also the consequences of the structural differences of cyclin A 
and cyclin D on affinity of these inhibitors. The competitive binding efficiency 
determined by FP assay of a number of octapeptide variants based on SAKRRLFG and 
HAKRRLIF are shown in table 4.1. 
C-terminal modifications of SAKRRLFG were designed to examine (i) effect of 
C-terminal functional group (CONH2 or COOH), (ii) extension of the C-terminus to 
probe interaction with the major hydrophobic pocket (iii) replacement of Arg5 and (iv) 
modification of the motif interacting with the major hydrophobic  pocket by deletion and 
substitution of key residues. Modification of the C-terminal functional group was 
assessed by synthesizing SAKRRLFG as its C-terminal amide (SAKRRLFG-NH2, 457). 
Compared to the corresponding C-terminal acid peptide (5815), 457 showed similar 
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binding to both CDK2/cyclin A (0.05 µM, 0.07 µM) and CDK4/cyclin D (0.66 µM, 0.88 
µM). Extension of the peptide with methionine (SAKRRLFGM, 5564) shows 
comparable results with 5815 (CDK2/cyclin A- 0.07 µM, CDK4/cyclin D-0.70 µM). 
5814 with the 3TA Phe replacement shows a 3 fold decrease in potency in CDK2/cyclin 
A (0.18 µM) and 2 fold decrease in CDK4/cyclin D (1.67 µM) compared to 5815. 
Replacement of Leu with betahomoleucine (β-Leu) leads to 2-3 fold potency 
improvement (5820, CDK2/cyclin A- 0.02 µM, CDK4/cyclin D- 0.29 µM) compared to 
5815. CBM peptides of p21 with LIF sequence on C-terminus are more potent than p107 
peptides that have LFG sequence. The isoleucine of HAKRRLIF (5816) acts as spacer 
residue and thus adding the extra carbon in the β-Leu (compared to leucine) provides for 
more optimal spacing to allow adaptation of the Phe to the pocket. In order to determine 
the effect of the β-Leu residue in the 3TA context, both Leu and Phe were replaced with 
these residues respectively (5813). These substitutions were found to be the most 
effective in this series with a 20 fold enhancement in potency compared to 5814 in both 
cyclin A and cyclin D context (CDK2/cyclin A- 0.01 µM, CDK4/cyclin D- 0.04 µM). 
Previous studies have indicated that Arg5 is less important for activity than Arg4 and 
which makes critical contributions to binding. . When Arg5 was substituted with Asn 
(5557, 5558) the activity decreased 3-4 fold for binding to both cyclins (CDK2/cyclin A- 
0.19 µM, CDK4/cyclin D- 4.15 µM). Similarly replacement of Arg5 with Ala (5559) 
resulted in reduced potency. HAKRRLIF (444) exhibited comparable binding activity 
(CDK2/cyclin A-0.02 µM) with a peptide in which Phe was replaced with 
cyclohexylalanine(HAKRRLI(CHA), 5816).  
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Table 4.1 Structure activity relationship of p21 and  p107 derived peptide analogs 
 
 
4.2.2 Structure activity relationship of RRLIF (p21
WAF
) based peptide analogs 
Previous SAR studies resulted in the identification of RRLIF as the minimal 
cyclin groove binding sequence with CDK inhibitory activity. Hence RRLIF was used as 
a starting point to convert the peptide to a more drug like molecule. A variety of peptide 
analogs derived from RRLIF (IC50 = 1.01 μM and IC50 = 25.12 μM for CDK2/cyclin A 
and CDK4/cyclin D respectively) were designed to introduce replacements for each of 
these residues and to probe their contributions and potential for replacement with more 
drug-like moieties. Results obtained from the SAR studies of RRLIF modifications are 
shown in tables 5.2, 5.4 and 5.5 and discussed in the following sections.  
4.2.2.1 Arg replacements 
Substitutions of both the N-terminal arginines were carried out to examine the 
sensitivity and binding requirement for each one. Previous studies have indicated that 
Arg4 critical for activity while Arg5 is less so. Both arginine residues were replaced with 
SCCP ID Structure
CDK2/cyclin A 
IC50 (µM)
CDK4/cyclin D1 
IC50 (µM)
457 SAKRRLFG-NH2 0.07±0.02 0.88±0.34
5815 SAKRRLFG-OH 0.05±0.02 0.66±0.21
5814 SAKRRL3TA G-OH 0.18±0.07 1.67±0.53
5564 SAKRRLFGM 0.07±0.04 0.70±0.30
5820 SAKRR{βLeu}FG-OH 0.02±0.00 0.29±0.07
5813 SAKRR{βLeu}3TAG-OH 0.01±0.00 0.04±0.07
5557 SAKRNLFGM 0.19±0.06 4.15±1.36
5558 SAKRNLFG-NH2 0.24±0.11 3.09±2.00
5559 SAKRALFGM 0.81±0.10 4.92±0.34
5816 HAKRRLI{CHA} 0.02±0.00 0.18±0.04
444 HAKRRLIF 0.02±0.01 0.12±0.05
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citrulline as shown in 5812 (Cit-RLIF) and 5831(RCitLIF) to study the effect of non-
charged isostere urea in place of highly basic group guanidine. Activity data shows IC50 
values of 5812 in CDK2/cyclin A as 43.17 μM and CDK4/cyclin D as 40.46 µM 
indicating a potency drop of 42 and 1.6 fold respectively. For 5831, the IC50 values were 
found to be 5.19 μM and 15.76 μM in CDK2/cyclin A and CDK4/cyclin respectively 
which showed 5 fold less activity in CDK2/cyclin A and slightly improved potency in 
CDK4/cyclin D. Substitution of Arg5 with isosteric residues including N,N-
dimethyllysine (Figure 4.1, 5925- R(dimethyllys)LIF, IC50 1.70 µM) and 
Nmethylarginine (Figure 4.1, 5918 R(NMeArg)LIF, 20.62 µM) results in potency 
decreases in binding to CDK2/cyclin A. 5925 retains similar activity while  5918 
undergoes a 20 fold decrease in binding activity. 5918 shows slight decrease in the 
activity for CDK4/cyclin D (IC50 33.76 µM) while 5925 is about 2.7 fold more potent 
than RRLIF (IC50 9.19µM) in this context. 
Further subsitutions for Arg5 included the neutral residues Gly, Ala and Pro to 
study the loss of ion-pairing interactions with the acidic region. Peptides incorporating 
these replacements resulted in very weak or no binding to both CDK/Cyclin complexes 
evaluated. Proline substitution (RPLIF 5832) was proven to be detrimental to the activity 
with IC50 values of greater than 180 μM for both CDK2/cyclin A and CDK4/cyclin D. 
Glycine substitution for this residue (RGLIF-5873- >180 μM for CDK2/cyclin A and 
CDK4/cyclin D) resulted in a similar loss of binding. The activity of the alanine surrogate 
(RALIF 5833) significantly decreased with respect to the native residue by 20 fold with 
respect to CDK2/cyclin A (IC50 of 20.36 μM) but had no dramatic loss of binding to 
RRLIF in CDK4/cyclin D (IC50 > 28.76 μM). A molecular modeling study was carried 
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out in order to examine the structural basis for the potency loss of these Arg replacement 
analogs.  After formation of the peptide cyclin complex by mutation of RRLIF (from the 
crystal structure 1OKV) and subsequent energy minimization, interaction energies were 
calculated for all of the Arg5 alternatives of RRLIF. The competitive binding efficiency 
of each peptide was compared with the interaction energy for its complex modeled with 
CDK2/cyclin A. A trend in the relationship between the interaction energy and the 
competitive binding data was observed with R
2
 correlation coefficients of 0.85 and 0.87 
for potential and electrostatic energy respectively (table 4.3, figure 4.2).  
Table 4.2 N-terminal modifications with R substitutions 
 
X1- DMAM peptoid, X2-DMAMAla, NCAP1-2-(3-methoxyphenyl)acetic acid, 
NCAP2- 4-(piperidin-4-yloxy)benzoic acid 
 
 
 
SCCP ID Structure
CDK2/cyclin A IC50 
(µM)
CDK4/cyclin D1 IC50 
(µM)
5811 RRLIF 1.01±0.17 25.12±2.97
5812 Cit-RLIF 43.17±8.77 40.46±1.07
5831 RCitLIF 5.19±1.56 15.76±1.94
5918 R(dimethyllys)LIF 20.62±2.57 33.76±10.72
5925 R(NMeArg)LIF 1.70±0.76 9.19±2.18
5832 RPLIF >180 >100
5833 RALIF 20.36±7.57 28.76±12.86
5873 RGLIF >180 >100
5877 R-X1-LIF >180 >100
5879 R-X2-LIF >180 >100
5878 NCAP1-X1-LIF >180 >100
5895 NCAP2-X1-LIF >180 >100
Non-
natural 
amino 
acids
Natural 
amino 
acids
Peptoid
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Table 4.3 Interaction energy calculated for the peptide analogs 
 
0 .0 0 .5 1 .0 1 .5 2 .0
-2 5 0
-2 0 0
-1 5 0
-1 0 0
In te ra c tio n  E n e r g y  V s  IC 5 0
L o g  IC 5 0
P o te n tia l e n e rg y  R
2
-  0 .8 5 5 2
E le c tro s ta t ic  e n e rg y  R
2
-  0 .8 7 4 5
 
Figure 4.2 Correlation of interaction energy with binding affinity  
Further to these exchanges for the second arginine, peptoid substitutions were 
utilized to attempt Arg5 replacement (Figure 4.3). Peptoids are peptidomimetics that have 
side chains attached to the amide N-atom and these are resistant to proteolysis. Two 
different peptoid residues were generated and incorporated. These included 
dimethylaminomethyl glycine and dimethylaminomethyl alanine which were included as 
Arg5 replacements in the RRLIF context (5877, 5879).  5878 and 5895 incorporated 3-
methoxyphenylacetamide and 4-piperidiyloxybenzamide as Ncapping group 
replacements respectively for Arg4. Peptoid incorporation was not successful as shown 
by the inactivity for CDK2/cyclin A (Table 4.2). The loss of activity for these analogs 
suggests that shift of the side chains to the α-nitrogen from the α-carbon may not provide 
RRLIF 0.004 -195.25 -47.03 -148.21
CitRLIF 1.635 -162.61 -47.97 -114.64
RCitLIF 0.715 -169.05 -48.02 -121.02
RALIF 1.309 -155.52 -43.6 -111.92
RGLIF 2.255 -155.03 -43.49 -111.54
R(NMeArg)LIF 0.23 -191.38 -47.15 -144.23
Peptide 
sequence
LogIC50
Van der Waals 
Energy(kcal/mol)
Electrostatic 
Energy(kcal/mol)
Potential Energy 
(kcal/mol)
89 
 
favorable contacts with CBGs.  
 
Figure 4.3 Structure of FLIPs containing peptoids 
4.2.2.2 C-terminal modifications of RRLIF 
As previously described, Leu6 and Phe8 of the RRLIF sequence are critical 
residues for binding through the hydrophobic effect and van der Waals interactions with 
the primary pocket. Previously SAR modifications have not been extensively probed in 
the pentapeptide context for binding to both CDK/cyclin complexes, were further 
investigated. The C-terminus was modified by deletion of the isoleucine (RRLIF 
sequence) or glycine (RRLFG sequence) residues and also through substitution with 
rationally selected non-natural amino acids (table 5.4). Ile7 (RRLIF) is a spacer residue 
that enables proper positioning of both Leu and Phe for optimal hydrophobic contacts. 
Deletion of this residue (RRLF, 5874) leads to a 35 fold decrease in potency for 
CDK2/cyclin A (IC50 35.651μM) and almost complete loss of activity for CDK4/cyclin 
D. Adding glycine to this sequence generates the p107 pentapeptide (5871- RRLFG) and 
results in a 2 fold improvement in binding to CDK2/cyclin A. Its IC50 of 18.88 μM is still 
almost 20 fold higher compared to RRLIF however. Incorporation of the non-natural 
residues, β-Leu and N-MePhe previously investigated in the octapeptide context showed 
promising results with respect to activity improvements. Substitution of Leu with βLeu 
resulted in recovery of binding activity that was lost with the removal of Ile spacer 
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residue.  RRβLF (5875) is only 2 fold less potent than RRLIF in the CDK2/cyclin A 
context (5811, 2.81 µM) and has similar binding in the CDK4/cyclin D context (21.17 
µM). Extension of this sequence with Gly resulted in improved activity only in binding to 
CDK2/cyclin A (RRβLeuFG – 5876, 1.73 μM, CDK2/cyclin A; 20.24 μM CDK4/cyclin 
D). Replacement of Phe with N-MePhe in both C-terminal acid and amide contexts 
shows drop in the activity CDK4/cyclin D compared to RRLIF however has comparable 
binding activity to CDK2/cyclin A. 5941, RR{βLeu}NMeF-NH2 and 5930, 
RR{βLeu}NMeF had IC50 values of 1.74 µM and 5.82 µM in CDK2/cyclin A and 45.58  
µM and 81.13  µM  in CDK4/cyclin D respectively. βLeu and N-MePhe were 
incorporated in the same peptide for the purpose of improving drug-likeness by 
enhancing metabolic stability. In addition, the C-terminal amide functionality of 5941 
helps in reducing the total polar surface area (to 271.42 vs. 303.52 (RRLIF)). 
Table 4.4 C-terminal modifications with LIF substitutions 
 
5.2.2.3 Combination of optimal Ncapping groups with SAR information to improve 
drug likeness of RRLIF derivatives.  
In previous chapters, N-capping groups designed to exploit H-bonding (with 
Trp217, Gln254), van der Waals (secondary pocket) and ion-pairing interactions (acidic 
region) of CBG were described. An extensive SAR study of phenyl heterocyclic 
ID Sequence CDK2A IC50 (µM) CDK4D IC50 (µM)
5811 RRLIF 1.01 ± 0.17 25.12±2.97
5871 RRLFG 18.88±4.45 >100
5874 RRLF 35.65±10.51 >100
540 RRLNpfFG 0.70±0.19 9.26±2.07
5875 RR{βLeu}F 2.81±0.76 21.17±2.99
5876 RR{βLeu}FG 1.73±0.46 20.24±5.37
5930 RR{βLeu}{NMeF) 1.35±1.38 45.58±5.63
5941 RR{βLeu}{NMePhe}-NH2 5.82±3.12 81.13±3.78
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carboxylic acids and Arg alternatives based on furoic, picolinic, thiazole and phenylacetic 
acid derivatives was undertaken/ These results indicated that 1-(3,5-dichlorophenyl)-5-
methyl-1H-1,2,4-triazole-3-carboxylic acid (35DCPT) was among the most effective and 
drug-like N-caps. As a result, this fragment was combined with the substitutions 
described above that removed some of the metabolic liabilities of RRLIF while retaining 
its potency. Synthesized derivatives included 35DCPTCit {βLeu}NMeF (5962), 35DCPT 
Arg{βLeu}NMeF(5963), 35DCPT Arg{βLeu}3TA (5964) whose structures and 
activitites are shown in figure 4.5 and table 4.4 respectively. As a result of the citrulline 
substitution, FLIP 5962 has no activity in CDK2/cyclin A and CDK2/cyclin D. The other 
35DCPT capped peptides containing arginine, 5963 and 5964 have respectable activity 
for CDK2/cyclin A with IC50s of 8.95 µM and 5.70 µM respectively. Although these 
FLIPs have decreased compared to RRLIF, they possess greater drug likeness as 
evidenced by calculation of their physicochemical properties including of clog P 
(partition coefficient) and pTSA (total polar surface area).  
 
Figure 4.4 FLIPs with modification on N-terminus and C-terminus 
As a further step to improve drug likeness, Arg5 was substituted with alkylated 
guanidine derivatives shown in a previous context to improve ion-pairing interactions 
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while potentially imporving cell permeability properties. Arg5 was replaced in the 5964 
scaffold with alkylated arginine isosteres including monomethyl (6030); monoethyl 
(6028) and dimethyl (6029) derivatives and also the cyclic guanidine variant (6027) 
(figure 5.4). The IC50 values are 4.50 µM (6030), 16.39 µM (6029), 3.69 µM (6028) and 
46.75 µM (6027). Testing of this set revealed that monalkyl derivatives had decreased 
binding compared to 5964 whereas the dimethyl and cyclic guanidine derivatives 
displayed similar affinity.  
Based on the calculation of key properties (clog P and tPSA), it was concluded 
that these 35DCPT capped peptides had improved pharmaceutical like properties relative 
to RRLIF while potentially increasing permeability and stabilization against proteolytic 
degradation. These FLIPs were therefore evaluated for their ability induce anti-
proliferative effects in U2OS (osteosarcoma) and DU145 (prostate cancer) cell lines as 
evidence for cell permeability and anti-tumor activity. In line with its decreased activity 
in the binding assay,  5962 did not show any growth inhibitory activity when evaluated in 
the MTT assay whereas the cyclin groove inhibitory FLIPS, 5963 and 5964 had 
respectable cellular activity on U2OS cells (IC50 30.7 M, 18.3 M respectively) and 
DU145 (IC50 36.5 M, 21.8 M respectively). Comparison of the anti-proliferative 
activities of 5963 and 5964 was suggestive of consistency between the binding affinity 
on CDK2/cyclin A and the cellular activity since a roughly 2 fold difference was 
observed in both. The modified guanidine derivatives all exhibit weaker cellular activities 
compared to 5964. Inhibition of cell cycle CDKs should lead to G1 arrest and therefore to 
determine if these FLIPs act by this mechanism, cell cycle distribution analysis was 
carried out by fluorescence activated cell sorting. The FLIP 5964 causes cell cycle arrest 
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at G1 compared to DMSO control and it is mechanistically distinct from Flavopiridol 
which leads to accumulation of cells in the G2/M phase (figure 4.5).  
Table 4.5. FLIP Modifications to the N and C-terminii 
 
 
 
Figure 4.5 Cell cycle analysis by FACS 
4. 3 Discussion and conclusion 
As indicated previously, the CBG is comprised of two hydrophobic pockets and 
an acidic region. Key interactions of CBM peptides include ion-pairing interactions with 
acidic region, hydrogen bonding with backbone amides of the cyclin and van der Waals 
interactions with hydrophobic regions. The critical residues of the CBM include Arg4, 
CDK2/cyclin A CDK4/cyclin D1 clogP tPSA* U2OS DU145
5811 RRLIF 1.4 ± 0.42 16.1±1.73 -1.64 303.52 NA NA
5962 35DCPT-Cit{βLeu}{NMeF}-NH2 >100 >100 5.142 242.57 >100 >100
5963 35DCPT-R{βLeu}{NMeF}-NH2 8.95±4.15 78.25±11.09 4.947 249.35 30.7±2.7 36.5±2.6
5964 35DCPT-R{βLeu}{3TA}-NH2 5.70±3.55 >100 2.573 220.25 18.3±1.5 21.8±0.32
6027 35DCPT-G10-{βLeu}{3TA}-NH2 46.75±10.68 >100 3.32 208.76 >100 >100
6028 35DCPT-G11-{βLeu}{3TA}-NH2 3.69±0.23 >100 3.8 194.77 75.6±1.2 102±14
6029 35DCPT-G12-{βLeu}{3TA}-NH2 16.39±3.72 >100 3.85 208.76 108±4 130±27
6030 35DCPT-G19-{βLeu}{3TA}-NH2 4.50±0.74 >100 2.34 194.77 60.5±3.3 81.0±8
SCCP ID Structure
FP assay IC50 (µM) Physical properties MTT assay IC50 (µM)
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Arg5, Leu7 and Phe8 are conserved in the three parent peptides in this SAR study. The 
main objective in this chapter was to further investigate critical residues of the CBM and 
then determine ways to convert the CBM pentapeptides RRLIF to more drug like 
molecule through further application of REPLACE.  
Contacts between species containing opposite formal charges are the strongest 
among non-bonded interactions. Since Arg4 and 5 of the CBM involve ion pairing 
interactions with negatively charged residues in the cyclin groove, both are important for 
binding of HAKRRLIF and its minimized counterpart. The decrease in potency observed 
when these were substituted with isosteric residues can be therefore attributed to 
decreased ion-pairing interactions in these analogs. Results obtained for citrulline 
substitution indicated that ion pairing contacts of Arg4 are more significant than those of 
Arg5, an observation consistent with the number of negatively charged residues of the 
cyclin contacting them. Citrulline which has an uncharged urea group in place of 
guanidine in Arg that leads to loss of ion-pairing interactions. Arg 4 makes multiple ion-
pairing interactions at CBG unlike Arg5 hence replacing Arg4 with its uncharged isostere 
causes major activity loss. The difference in activity between cyclin A and cyclin D most 
likely arises from the structural differences between the cyclins and the variation in the 
CBM contacting residues in these two proteins. When bound to cyclin A, the Arg4 
residue interacts with Asp283 through ion pairing. This residue occurs as Thr62 in cyclin 
D and results in fewer ion-pairing interactions
53
. Replacement of Arg with citrulline 
therefore is tolerated better in the cyclin D context. This is consistent with the results 
obtained for replacement of Arg5 with N,N-dimethyllysine (5918) which undergoes a 20 
fold  reduction in potency for binding to CDK /cyclin A and a decrease of 1.3 fold for 
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CDK4/cyclin D. Although 5918 has a basic residue available for ion paring interaction, 
the hindered methylated tertiary amine may prevent interaction with the Asp283 side 
chain. Methylation of the amide backbone nitrogen is a common strategy to stabilize 
peptides and make them resistant to proteolysis
71,72
. Incorporation of N-Me Arg in place 
of Arg5 lowers the potency less than 2 fold suggesting that N-methylation would be 
beneficial to increase proteolytic stability while preserving binding activity. Uncharged 
alternatives for the Arg5 were incorporated (Gly, Ala and Pro) and for the most part led 
to poor binding due to loss of ion-pairing and H-bond interactions. The peptide 
containing proline would undergo perturbation of its conformation (as observed in the 
modeled structure of RPLIF) along with the loss of H-bonding interactions from the 
backbone amide. Similarly RGLIF and RALIF suffer from loss of ion pairing. As a whole 
calculated interaction energies from the modeled complexes correlate very well with the 
IC50 values determined in FP assay. Consistent with the results obtained for 
pentapeptides, potency levels observed for the octapeptide Arg5 replacements decreased 
significantly.  
Peptoids are peptide replacements based on N-substituted glycine residues i.e. 
where the side chain is attached to the -N atom instead of α C-atom. Since these 
compounds are tertiary amides and non-natural, they are resistant to proteolysis
73
. In the 
peptoid series, Arg5 was substituted with dimethylaminomethyl glycine (DMAM) and 
dimethylaminomethyl alanine (DMAMAla) peptoid residues. Loss of activity for the 
peptoid series can be explained by these compounds adopting a different conformation 
leading to loss of hydrogen bonding and van der Waals interactions. 
In order to explore substitutions for the key residues (Leu, Phe) contacting the 
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primary hydrophobic pocket and to imbue cyclin groove inhibitors with greater metabolic 
stability and cell permeability while further minimizing the size, β-Leu and non-natural 
residues were incorporated. Deletion of the Ile spacer residue (RRLF) leads a dramatic 
loss of binding to CDK2/cyclin A.  The majority of the potency loss could be recovered 
by the addition of a methylene spacer in Leu of RRLF i.e, substituting β-Leu for Leu as 
seen in RR β-LeuPhe-NH2 (5941) Incorporation of β-Leu has the advantage of improving 
stability of the peptide and also reducing the peptide length. Along with this, β-Leu 
provides similar van der Waals interaction from its side chain while the extra methylene 
also acts as a spacer offering flexibility to the Phe sidechain for improved 
complementarity with the primary hydrophobic pocket
69,70
. This was confirmed by 
testing of the octapeptides 5920 and 5813, both were among the most potent in 
competitive inhibition of CDK2/cyclin A and CDK4/cyclin D and further corroborated 
by the binding potency for 5975 (RR{βLeu}F) and 5976 (RR{βLeu}FG) with 
CDK2/cyclin A. Results from both penta and octapeptide analogs suggest that 3TA is an 
effective replacement for Phe while also potentially improving drug likeness. N-
methylation of the Phe residue did not lead to potency loss and therefore suggests that its 
inclusion into the peptide or FLIP would result in stabilization against proteolysis. 
Incorporation of β-Leu and N-MePhe/3TA (in place of LIF) results in a smaller peptide 
while retaining the majority of interactions. Apart from this, presence of the amide group 
on the C-terminus improves the tPSA compared to RRLIF. The tPSA and clog P are 
parameters that determine the exposed hydrophilic surface and overall hydrophobicity of 
a molecule. These should be in a balance if used in a predictive sense for estimating if a 
molecule will be useful as for drug development. According to Lipinski’s rule of 5 and 
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other guidelines for drug likeness, the tPSA is typically less than 140 Å and clog P is 
between -0.4 to 5.6 for orally available drugs
65,66
. 
In previous chapters, the REPLACE strategy was described in the identification 
and optimization of N-capping groups as suitable ligand alternatives for Arg4. The 
molecule 1-(3,5-dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxamide was found to 
be most potent N-capping group. As a result, FLIPs were synthesized combining this 
capping group with the C-terminal modifications in an attempt to improve drug likeness 
while retaining affinity of the original peptide. In order to provide insights into the cell 
permeability and anti-tumor effects of these FLIPs, cellular viability studies were 
undertaken. The results indicated that both cyclin groove inhibitors have antiproliferative 
effects on DU145 and U2OS cancer cell lines
52,54
. As these cell lines have deregulated Rb 
pathways, it is probable that the growth inhibitory effects of 5963 and 5964 are through 
inhibition of cell cycle CDKs and specifically through E2F1. In the MTT cell viability 
assay 
74
, the 3TA analog (5964) was observed to be 2 fold more potent compared to N-
MePhe analog (5963) which is in accordance with the binding assay. Modifications to the 
guanidine side chain were attempted by addition of linear or cyclic alkyl groups. 
Although some of these have similar cyclin groove binding ability, their weaker cellular 
suggests that the modified guanidine group interferes with cellular permeability. This 
could result from steric hindrance of the modified guanidine group precluding interaction 
with negative charges of the lipid bilayer and therefore preventing permeability. Results 
from the binding assay and cell cycle analysis strongly indicate that 5964 is a lead 
compound in that it binds to and inhibits CDK2/cyclin A thereby inducing G1 cell cycle 
arrest and anti-proliferative effects in tumor cells.  These results are consistent with on 
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target inhibition of the cell cycle CDKs and pave the way for more in depth studies with 
these FLIPs. Development of FLIPs with cellular activity is an important milestone in 
this project and contributes overall to the development of anti-tumor therapeutics using 
REPLACE strategy. Future studies will focus on the mechanism of action of the lead 
FLIP molecule 5964 in cancer cell lines and will be further optimized to improve its 
cellular activity.  
4.4 Materials and methods 
4.4.1. Peptide & FLIP Synthesis
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All N-terminally capped FLIPs were synthesized and purified using standard 
Fmoc chemistry by GenScript (Piscataway, NJ).  HPLC and MS were used to confirm the 
purity and structure of each peptide. Peptides were assembled by using standard solid-
phase synthesis methods. A sample procedure is given as follows: 5 equivalents of the C-
terminal amino acid were coupled to Rink resin at the first place using 1 DIEA (0.082 
mL) and HBTU (189.6 mg) in 2 mL of DMF for 1 h. The Fmoc of the C-terminal amino 
acid was removed using 20% piperidine in 3 mL of DMF for 10 min before addition of 5 
equiv of the next amino acid using DIEA (0.082 mL) and HBTU (189.6 mg) in 5 mL of 
DMF. Wash cycles (5 x 10 mL of DMF + 5 x 10 mL of DCM) were applied to each step 
in between coupling and deprotection of Fmoc. Upon completion of assembly, side chain 
protecting groups were removed, and peptides were cleaved from Rink resin using 90:5:5 
mixtures of TFA/H2O/TIPS. Crude peptides were purified using reverse-phase flash 
chromatography and semi preparative reverse-phase HPLC methods. Pure compounds 
were lyophilized and characterized using mass spectrometry and analytical HPLC (see 
Supplementary Table 3). 
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4.4.2 Energy minimization and Interaction energy calculation 
Energy minimization was performed in Discovery studio 3.0 in the Cylin A (PBD 
ID: 1OKV) at the cyclin binding groove. Prior to minimization, the heavy atoms of the 
protein were set as constraints, CHARMm force field was applied to the receptor ligand-
complex. The minimization protocol was used for calculating the energy minimization. 
The parameters used were Smart minimizer Algorithm with 2000 steps and 0.1 as RMS 
gradient, GBSW (Generalized Born with a Simple Switching) implicit solvent model 
using Dielectric constant as 1 and implicit solvent dielectric constant as 80. The other 
parameters non-bonded radius and electrostatics were set as default. 
 The interaction energy between the protein and each ligand was calculated with 
interaction energy protocol in Discovery studio 3.0. Default parameters were used for (i) 
In-Situ Ligand Minimization, (ii) Ligand Conformational Entropy (iii) Non-bonded 
radius (iv) Electrostatics (v) Advanced and (vi) Parallel processing. The implicit solvent 
model was set to GBSW (Generalized Born with a Simple Switching) along with 
dielectric constant as 1 and implicit solvent dielectric constant as 80.  
4.4.3 Cell culture
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U2OS osteosarcoma cells and DU145 human prostate cancer cells were obtained 
from ATCC (Manassas, VA). All cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM , Fisher Scientific) supplemented with 10% Fetal Bovine Serum (FBS, 
USA Scientific) and 100µg/ml of Streptomycin (strep)/ 100 U/ml of Penicillin (pen). 
Cells were incubated at 37ºC with 5% CO2. 
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4.4.4 Viability assay 
Cells were seeded in 96-well plates at (2 × 10
3 
cells/ml) and allowed to adhere 
overnight in DMEM growth media containing 10% NU serum and 1% Pen/Strep. The 
compounds 5962, 5963, and 5964 were dissolved in DMSO and added in a dose 
dependent manner (1 µM to 100 µM). The diluted compounds were added to the cells in 
triplicate and incubated for 72 hours at 37
o
C with 5% CO2. The cell viability was 
determined using MTT (3-(4,5-Dimethylthiazol-2YI)-2,5-Diphenyl tetrazolium 
Bromide)  assay
4
.  Absorbance readings were obtained using a DTX880 multimode 
detector fitted with 595nm filter. Cell viability results were represented as the ratio of the 
absorbance reading in treated vs. untreated cells. IC50 values were obtained using a 
nonlinear regression line with 5.0 Graghpad Prism. Experiments performed in triplicates. 
4.4.5 Cell Cycle Analysis 
Cells were plated at 150,000/ml overnight in six well plates. CDK2 inhibitors 
were added in a dose dependent fashion for 48 hrs. The cells were then fixed with 70% 
Ethanol overnight at -20 degrees. The cells were centrifuged and ethanol was removed. 
The cells were washed twice with 1X PBS following staining with DAPI(4’,6’ diamino-
2-phenylindole) and analyzed using BD LSR II (Becton Dickenson) with a blue filter. 
Experiments were performed in triplicates. 
4.4.6 Fluorescence Polarization Binding Assay  
CDK4D1 FP assay: This assay was performed using black 384-well plates using 
a previously described procedure
57
 with the following modifications. To each well were 
added: 5 µl CDK4D1 (37 µg/ml purified recombinant human kinase complex from 
Invitrogen), 5 µl compound solution, 5 µl 12 nM fluoresceinyl-Ahx-Pro-Val-Lys-Arg-
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Arg-Leu-(3ClPhe)-Gly tracer peptide. Compounds and kinase complexes were diluted 
using assay buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, BSA 
1mg/ml, 20mM dithiothretiol (DTT). Plate was centrifuged for 1 min at 500 rpm and then 
incubated with shaking for 45 mins at room temperature. Fluorescence polarization was 
read on DTX880 multimode detector (Beckman Coulter, Brea, CA) fitted with 485 
nm/535 nm excitation/emission filters and a dichroic mirror suitable for fluorescein. 
Relative mp was calculated for each concentration tested using the equation showing 
below. IC50 values were determined by logarithmic regression by correlating relative mps 
and testing concentrations. 
Relative mp = 
mP(compound)-mP(DMSO, protein, tracer)
mP( DMSO, protein)-mP(DMSO, protein, tracer)
 
CDK2A2 FP assay :This assay was performed using black 384-well plates. To 
each well were added: 5 µl CDK2A2 (18 µg/ml purified recombinant human kinase 
complex), 5 µl compound solution, 5 µl 12 nM fluoresceinyl-Ahx-Pro-Val-Lys-Arg-Arg-
Leu-(3ClPhe)-Gly tracer peptide. Compounds and kinase complexes were diluted using 
assay buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, BSA 1mg/ml, 
20mM dithiothretiol (DTT). Plate was centrifuged for 1 min at 500 rpm and then 
incubated with shaking for 45 mins at room temperature. Fluorescence polarization was 
read on DTX880 multimode detector (Beckman Coulter, Brea, CA) fitted with 485 
nm/535 nm excitation/emission filters and a dichroic mirror suitable for fluorescein. 
Relative mp was calculated for each concentration tested using the equation showing 
below. IC50 values were determined by logarithmic regression by correlating relative mps 
and testing concentrations. 
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CHAPTER 5 
OPTIMIZATION OF BENZOIC ACID DERIVED INHIBITORS OF THE 
CYCLIN GROOVE OF CDK2 USING THE REPLACE STRATEGY 
 
5.1 Introduction 
As described, the pentamer RRLIF was found to be the minimal CBM sequence 
with sufficient potency to inhibit CDK2/cyclin A and CDK4/cyclin D. Chapters 3 and 4 
describe the identification and optimization of arginine isosteres as N-terminal capping 
groups
63,68
 and further peptide SAR.  Extensive information was obtained for these Ncaps 
based mainly on substituted 5 membered heterocyclic rings. These fragment alternatives 
were designed to mimic peptide interactions with the secondary pocket and with cyclin 
residues interacting with the peptide backbone. The heteroatoms in these fragments 
provided H-bond acceptors observed in the peptide context with Trp 217 of the cyclin 
groove
63
. Interactions with the negatively charged residues (Glu220, Glu224, and Asp 
283) observed in the peptide/cyclin complex were largely absent in the phenyltriazole 
Ncaps. Further series of Ncaps incorporating basic functionality in furoic and picolinic 
acid derivatives resulted in FLIPs with moderate activity therefore leaving considerable 
scope for improvement
68
.  A literature precedent for CBG inhibitors provided insight an 
additional scaffold based on benzoic acids and which is capable of mimicking peptide 
interactions with the acidic region. These benzoic acid capped peptides were substituted 
on the Ncap with basic functionality and were found to possess potent activity against 
CDK2/cyclin A
75
. Based on SAR results and preliminary activities described in chapters 
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3 and 4 and the resulting scope for potency improvement, the benzoic acid derivative 
precedent was further investigated. Potential N-capping groups based on this scaffold 
were therefore designed to present groups with the capability of retaining interactions 
with the secondary pocket while including functionality to make ion-pairing interactions 
with acidic region.  The REPLACE strategy therefore was further utilized in the design of 
FLIPs which have increased potency through more complete interactions with the cyclin 
groove
49
. In this series design, synthesis and optimization of benzoic acid derivative N-
caps (ligated to RLIF) was undertaken through application of REPLACE. As before, their 
potential anti-cancer activity was assessed through use of the FP assay to measure 
competitive binding to CDK2/cyclin A and CDK4/cyclin D
57
. Optimization studies of N-
capping groups were conducted based on SAR results and docking analysis. Promising 
compounds were then further tested for anti-proliferative activity on cancer cells through 
cell culture experiments
74
. 
5.2 Results 
5.2.1 Synthesis of N-caps 
 The synthesis of benzoic acid derivatives with substitutions at 3-position and/or 4-
position was undertaken (figure 5.1). Based on computational studies, it was 
hypothesized that substituents at the 3-position would make complementary interactions 
with the secondary hydrophobic pocket. In addition, functional groups incorporated at the 
4-position were designed based on their predicted ion-pairing thus mimicking the 
contacts of the critical arginine. To examine SAR of the 3 position in the benzoic acid 
capping group, a number of alkoxy derivatives were generated by reaction of 3-hydroxy 
benzoic acid with the appropriate alkyl halide. Alkylation of the hydroxyl also results in 
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concomitant alkylation of the acid and therefore the corresponding ester was base 
hydrolyzed to generate the 3-ethoxy and 3-propoxy benzoic acids as desired products (21 
a-b) (scheme 5.1)
76
. 
 
 Figure 5.1 Core structures of benzoic acid derivatives 
Scheme 5.1 Synthesis of 3-alkoxy benzoic acid derivatives
76
 
 
Two commercially available N-caps included 4-(piperazin-1-yl) and 3-(piperidin-
4-yloxy)benzoic acids were obtained as their free amines. In order to append these to the 
peptide as capping groups, the amino groups were first Boc protected using a standard 
method. The desired protected N caps were obtained in approximately 50% yield (22)
77
. 
The Boc protection reaction is shown in scheme 5.2. 
Scheme 5.2 Synthesis of Boc protected 4-piperazinyl benzoic acid
77
 
 
Further analogs in the piperidinyloxybenzoic acid series were synthesized by 
Mitsunobu reaction
78
. These include the 4-piperidinyloxy (26a), 3-methoxy-4-
piperidinyloxy (26b) and 3,5-bis piperidinyloxy derivatives (26c). These compounds 
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were synthesized to study their ion-pairing interactions of the piperidinyl N-atom with 
acidic regions and van der Waals interactions of substituents at 3-position with second 
pocket. The Mitsunobu reaction and subsequent ester hydrolysis are outlined in scheme 
5.3.  
Scheme 5.3 Synthesis of 4-piperidinyl oxy benzoic acid derivatives
78
  
 
The majority of the N-caps based on the benzoic acid scaffold were designed to 
incorporate a piperazinemethyl group as a substituent at the 4-position. Synthesis of 4-
(piperazin-1-ylmethyl)benzoic acid and its derivatives were carried out by reductive 
amination reactions in which an aldehyde is converted to amine through reduction of an 
imine intermediate
79
. This reaction was carried out with 4-formyl benzoic acid precursors 
and the required amine with sodium triacetoxyborohydride as reducing agent (scheme 5.4 
to 5.9). The synthesis of the 4-(piperazin-1-ylmethyl) analogs, 27a and 27b were 
accomplished using 4-formyl benzoic acid precursors. It was observed that the 3-
hydroxyl substitution helped the reaction to go to completion overnight whereas the 
reaction in 4-formyl benzoic acid required 24 hours to complete (27a-b). The 
intermediate compound 4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-
107 
 
hydroxybenzoic acid (27a) was then used as starting material for the synthesis of the 
derivatives alkylated on the 3-hydroxyl  (28a and 28b) (scheme 5.4).  
Scheme 5.4 Synthesis of 3-alkoxy-4-piperazinylmethyl benzoic acid derivatives
79,76
  
When 
compounds containing a substituted piperazine (i.e. 4-((4-(1-methylpiperidin-4-
yl)piperazin-1-yl)methyl) or  (R or S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-
yl)methyl)) were appended using reductive amination, difficulties  occurred in recovery 
of the resulting product during  aqueous work up. Hence the starting material was 
benzylated with (bromomethyl)benzene using sodium hydride
80
. Using the benzylated 
precursor, the reductive amination product was easily recovered from the organic layer. 
To obtain the final product, the benzyl group was removed by hydrogenation
81
 (scheme 
5.5) however was not successful in every case (i.e. with 33a and 33b), and therefore base 
hydrolysis was used (scheme 5.5). By way of a similar procedure to the one used for 
compounds 32 and 33, 4-(((1-(tert-butoxycarbonyl)piperidin-3-
yl)(methyl)amino)methyl)benzoic acid and 4-(((1-(tert-butoxycarbonyl)piperidin-4-
yl)(methyl)amino)methyl)benzoic acid (35a and 35b) were synthesized by reductive 
amination of 4-formyl methyl benzoate with the requisite amine followed by base 
hydrolysis
79
. For the synthesis of 4-(((tert-butoxycarbonyl)(1-(tert-
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butoxycarbonyl)piperidin-4-yl)amino)methyl)benzoic acid (37), Boc protection of the 
amine was required (scheme 5.6)
77
. 
Scheme 5.5 Synthesis of modified piperazinyl benzoic acid derivatives
79,80
  
 
  
Scheme 5.6 Synthesis of piperidinyl amino methyl benzoic acid derivatives 
 
Scheme 5.7 Synthesis of 4- substituted piperazinylmethyl benzoic acid derivatives
79
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Three such derivatives were synthesized from 3-hydroxy-4-formyl benzoic acid by direct 
reductive amination
79
. The recovery and purification of these compounds were successful 
and hence the additional derivatives 39a and 39b were synthesized and purified (scheme 
5.7). Substituents were included on the piperazine ring to imcreasee the hydrophobicity 
of the capping groups. 
Similar to the N-caps mentioned above, alkyl substituents were incorporated into 
(S) methyl piperazine analogs to improve binding affinity as well increase the 
hydrophobicity. Synthesis of (S)-4-((4-alkyl-2-methylpiperazin-1-yl)methyl)benzoic acid 
was carried out by reductive amination of 4-formylmethyl benzoate with tert-butyl (S)-3-
methylpiperazine-1-carboxylate as described previously
79
. Alkylation of the free 
piperazine nitrogen was acheieved by reductive amination with the requisite aliphatic 
aldehyde using similar conditions
76
. As before base hydrolysis of the ester liberated the 
required Ncap product (scheme 5.8). 
Scheme 5.8 Synthesis of (S)-4-((4-alkyl-2-methylpiperazin-1-yl)methyl)benzoic acid 
 
Piperidin-4-ylidenemethyl benzoic acid derivatives were synthesized in the first 
instance by a Wittig reaction of methyl 4-((diethoxyphosphoryl)methyl)benzoate with 
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amino piperidone  to generate 45a and b (Boc protected and methylated respectively). 
The resulting ylidene was then base hydrolyzed to obtain the corresponding free benzoic 
acid, 46a and 46b. The utility of this reaction and the potential SAR information could be 
further extended by high pressure hydrogenation of the ylidine to reduce the double bond 
and obtain  methyl 4-((1-Bocpiperidin-4-yl)methyl)benzoate (47) which after hydrolysis 
generated capping group 48 
82
(scheme 5.9). 
Scheme 5.9 Synthesis of piperidinyl methyl benzoic acid derivatives
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5.2.2 SAR of benzoic acid capped peptides 
5.2.2.1 SAR of 3-susbtituted benzoic acid derivatives 
As described in chapter 4, the phenylacetic acid capped FLIP, 530 (3,5-
diethoxyphenylacetic acid) possessed good affinity for  both CDK2/cyclin complexes. 
Modeling of this analog suggests that the ethoxy group in the 3-position occupies the 
minor hydrophobic pocket providing a structural basis for its reasonable activity
68
. In 
order to probe such modifications in the similar benzoic acid derived capping groups, a 
series of 3-substituted derivatives were docked using the validated LigandFit protocol
55
.  
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Table 5.1 SAR of 3-substitued benzoic acid derivatives for van der Waals 
interactions 
 
 
The results indicated that the inclusion of alkyl or alkoxy groups at the 3-position 
provides good complementarity with the secondary pocket as predicted and that the 
amide carbonyl can form an H-bond with the amide side chain of Gln254. Based on these 
docking results FLIPs were generated in which  RLIF/RLNpfF was N-capped with the 
described derivatives (Table 5.1).  All the FLIPs generated in this series were inactive 
except 5858 which showed moderate inhibition of CDK4/cyclin D.  
5.2.2.2 SAR of 4-Substituted benzoic acid derivatives 
Previous investigations (chapter 4), on furoic acid analogs revealed that presence 
of basic groups resulted in moderate binding activities of CDK2/cyclin A inhibitors 
targeting the CBG. Furthermore the previously reported CGI compounds incorporated 
benzoic acids as Ncaps that were substituted with basic functionality
68
. Based on this 
precedent and the Ncaps described in chapter 4, the design and synthesis of a unique 
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series of benzoic acid derived fragment alternatives was undertaken. These encompassed 
derivatives reported in this previous study and new variants which were computationally 
designed. Substituents appended onto the 4-position included piperazinyl (5850), 
piperazin-1ylmethyl (5566, 5919, 5923, 5920) and guanidomethyl (541). Some of these 
Ncap derivatives included the 3-(piperidin-4yloxy) group (5851) and 3-hydroxy (5920). 
One of the previously reported derivatives incorporated a 4-guanidinomethyl substituent 
(541) and was synthesized for comparison. Each of these N-caps were ligated to RLIF 
except 5566 and 541 which were N-capped to RLNpfF. The SAR results of these 
compounds are shown in table 5.2. 
In this series the most potent compounds are those ligated to RLNpfF which are 2 
fold more potent compared to RRLIF (0.7 µM vs 1.01 µM in CDK2/cyclin A, 2.17 µM 
vs 25.12 µM in CDK4/cyclin D).  The FLIP molecule 541 is the most effective 
compound (CDK2/cyclin A 0.69 µM and CDK4/cyclin D - 15.32 µM) and where the N-
capping group is a benzoic acid substituted with guanidinomethyl group at the 4-position. 
Incorporation of 4-(piperazine-1ylmethyl)benzoic acid as an N-cap (5566) resulted in 
comparable activity to the 35DCPT triazole Ncaps described in chapter 3 with a binding 
IC50 to CDK2/cyclin A of  5.3 µM and to CDK4/cyclin D of 12.87 µM. The 4-(piperidin-
1yloxy)benzamide (5851-31.34µM) and the 4-(piperazine-1yl)benzamide (5850-
35.16µM) FLIPs showed nearly equal potencies in binding to cyclin A in its CDK2 
complex. The piperidinyloxy FLIP 5851 (8.52µM) is 4 fold more potent than its 
piperazinyl counterpart (5850- 23.82 µM) in binding to CDK4/cyclin D. Varying the 
peptide sequence in the 4-piperazinylmethyl benzamide context was undertaken. ALIF 
(5923) is inactive and RLIF (5919) is slightly 2 fold less potent than RLNpfF (5566) in 
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cyclin A. Comparison of 5919 and 5566 again confirmed that the difference in activity is 
because of the more potent peptide sequence RLNpfF. 
Table 5.2 SAR of 3/4 mono and 3,5-disubstituted benzoic acid  
derivatives for ion-pairing interactions 
 
5.2.3 SAR of benzoic acid FLIPs capable of ion-pairing and van der Waals 
interactions 
In order to further extend the SAR of these 4-(piperazine-1yl)benzoic acid 
derivatives and to exploit the unoccupied secondary pocket in this context, alkyl 
substitution of the 3-position was undertaken. The addition of and role of the 3-
subsitution was examined through testing of 5896 (3-methoxy, 4-piperidinyloxybenzoic 
acid) and comparison with its mono 4-substituted counterpart 5851. The potency of the 
bis substituted benzamide FLIP  increased significantly in binding to CDK2/cyclin A (22 
µM  vs 31 µM in cyclin A) but was essentially equipotent towards CDK4/cyclin D (9 µM 
vs 8 µM). Addition of a 3-hydroxyl to this series (5920) results in a 2 fold potency 
SCCP ID R1 R2 PeptideSequence
CDK2/Cyclin A 
IC50 (µM)
CDK4/D1 
IC50 (µM)
5851 H RLIF 31.34±15.71 8.52±4.43
5850 H RLIF 35.16±10.17 23.82
5566 H RLNpfF 5.30±0.99 12.87±1.67
541 H RLNpfF 0.69±0.34 15.32±5.09
5919 H RLIF 12.89±2.99 11.70±5.92
5923 H ALIF >100 51.49±21.34
5920 OH RLIF 4.56±0.74 10.41±0.61
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enhancement compared to 5919 for CDK2/cyclin A (IC50 - 4.56 µM) however does not 
significantly improve activity towards CDK4/cyclin D (CDK4/cyclin D, IC50 -10.41 µM). 
Incorporation of a 3-ethoxy substituent into the FLIP (5922) resulted in similar activity 
compared to 5920 in cyclin A and 2 fold better activities in cyclin D.  Methylation of the 
free piperizinyl N-atom (5921) resulted in slightly diminished potency compared to 5920. 
Further benzoic acid derived capping group modifications were investigated in the 
RβLNMeF context described in chapter 5 so as to improve compound stability and cell 
permeability. In this series (table 5.3), the 4- (piperidin-4yl)oxybenzoic acid derivative 
(5965) is less active in the binding assay compared to the same N-cap ligated to RLIF 
(5851) in CDK2/cyclin A(40 µM (5965) vs 31 µM (5851)). Comparable results are seen 
for 5966 (RbLNMeF-NH2) vs 5920 (RLIF) in both cyclins where the N-cap is 3-hydroxy-
4-(piperazin-1-ylmethyl)benzamide. The RβLNMeF counterpart (5968) to the 3-ethoxy, 
4-(piperazin-1yl)benzamide Ncap (5968) has diminished potency for  both cyclin A 
(22.61µM) and D (18.64 µM). Among FLIPs containing modified versions of the 
piperazine ring system, 5967 (4-((4-(1-methylpiperidin-4-yl)piperazin-1-
yl)methyl)benzamide is the most potent followed by 5970 ((S)-4-((2-methylpiperazin-1-
yl)methyl) benzamide) and 5969 ((R)-4-((2-methylpiperazin-1-yl)methyl) benzamide). 
These compounds are unique in this series as they have respectable potency, lower 
activity towards CDK4/cyclin D and incorporate more drug-like features. The results are 
shown in table 5.3. 
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Table 5.3 SAR of benzoic acid FLIPs capable of ion-pairing and 
 van der Waals interactions 
 
 
Due to the introduction of the non-natural C-terminus and more drug-like Ncaps, 
several FLIPs from this series (Table 5.4) were tested for anti-proliferative activity in 
U2OS and DU145 cells
52,54
. So as to assess their drug-like character and to predict which 
modifications might lead to optimization of pharmaceutical properties, their clog P and 
tPSA were calculated. The resulting parameters were then compared with 5963 (35DCPT 
RβLNMeF) and 5964 (35DCPT- RβL3-TA) which were both shown to have respectable 
growth inhibitory activity. For the most part the benzoic acid derived FLIPs were inactive 
with the exception of 5970 which exhibited very weak anti-proliferative activity. The N-
caps in 5969 and 5970 had total low polar surface area (tPSA) of 3.35 (<140 for orally 
available drug molecules) and a positive value of clog P (2.71) 
65,66
 (table 6.4). Due to its 
SCCP ID R1 R2 PeptideSequence
CDK2/Cyclin A 
IC50 (µM)
CDK4/D1 
IC50 (µM)
5922 RLIF 5.95±2.53 5.14±1.47
5921 H RLIF 7.92±1.39 11.31±1.48
5896 OCH3 RLIF 22.42±9.66 9.36±6.56
5965 H RbLNMeF-NH2 40.38±17.76 30.99±1.18
5966 OH RbLNMeF-NH2 7.42±1.69 11.76±1.01
5968 RbLNMeF-NH2 22.61±1.89 18.64±9.72
5967 H RbLNMeF-NH2 8.32±0.36 48.89±40.36
5969 H RbLNMeF-NH2 22.28±5.22 45.45±0.47
5970 H RbLNMeF-NH2 13.39±4.35 >100
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weak cellular activity, it was hypothesized that modifications that increase 
hydrophobicity would potentially improve cellular permeability and potency. Therefore 
derivatives of 4-piperidin-1ylmethylbenzoic acid were designed based on addition of 
alkyl groups to increase the lipophilicity. The clogP values were used as a guideline to 
assess effective modifications. The clog P values for the 35DCPT N-capped FLIP (5964) 
were used as a target value for further modification of N-caps. 
Table 5.4 Cellular activity and PSA and clogP of selected 
 benzoic acid derivatives 
 
Additional benzoic acid derivatives were designed based on clog P and PSA using 
the corresponding values of 35DCPT as a reference.  The 4-substituents incorporated 
were piperazinylmethyl or piperidinyl derivatives, were ligated to RβL3-TA and tested in 
the binding assay and for anti-tumor activity on DU145 cancer cell lines. These 
Ncap ID
CDK2/Cyclin 
A(µM)
U2OS(µM) PSA clog P
5963 6.49±0.27 30.7±2.7 27.96 2.9
5964 7.91±5.08 18.3±1.5 27.96 2.9
5965 31.08±14.4 >100 25.84 2.13
5966 9.22±6.15 >100 40.08 1.47
5967 10.45±3.58 >100 12.12 3.13
5968 22.48±1.33 >100 29.08 2.64
5969 18.42±4.59 >100 19.85 2.71
5970 4.85 67.3 19.85 2.71
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compounds showed good to moderate activity against CDK2/cyclin A but none of them 
were active in the cellular assay. The results are shown in table 5.5. 
Table 5.5 Benzoic acid derivatives tested in cancer cells. 
 
 
Several other N-caps were designed based improved binding results and calculated 
physicochemical properties (clogP and PSA) in order to optimize drug-likeness (table 
5.6). FLIPs containing the capping groups NC-8, 9 and 10 were designed on the basis that 
improved hydrophobicity will result in greater cell permeability and anti-tumor activity. 
 
 
 
 
 
 
SCCP ID R1 R2 PeptideSequence
CDK2/Cyclin A 
IC50 (µM)
CDK4/D1 
IC50 (µM)
Du145 
IC50 (μM)
6033 H R-bL-3TA 17.44±13.39 74.28±4.45 >100
6034 H R-bL-3TA 6.78±2.72 45.60±13.69 >100
6031 H R-bL-3TA 9.16±8.74 >100 >100
6032 H R-bL-3TA 26.02±7.13 69.91±7.07 >100
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Table 5.6 Benzoic acid derivatives designed to improve cell permeability. 
 
5.3 Discussion and conclusions 
Several N-capping groups scaffolds have been identified however non are optimal 
in terms of mimicking the majority of the interactions of N-terminal tetrapeptide of 
HAKRRLIF. Even 35DCPT, the most effective N-cap only practically interacts with this 
region and hence there is a need for improvement. A previously published study 
described benzoic acid capped peptides with a chlorophenylcyclohexylamine replacement 
ID N-cap PSA clogP
NC-1 21.05 2.29
NC-2 21.05 2.29
NC-3 33.22 2.95
NC-4 40.08 1.99
NC-5 27.91 2.03
NC-6 32.35 2.41
NC-7 32.35 2.41
NC-8 7.68 2.41
NC-9 7.68 4.32
NC-10 16.61 3.33
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for the phenylalanine. These derivatives included basic substituents which when 
incorporated into cyclin groove inhibitors resulted into potent compounds when tested in 
CDK2/cyclin A ELISA using retinoblastoma protein as substrate for competitive 
binding
75
 (Figure 5.2). This suggested that the benzoic acid scaffold would be an 
effective one for the presentation of the required functionality to interact more completely 
with the cyclin groove by including contacts with the secondary pocket while also 
making ion-pairing interactions with the acidic residues. As described in chapter 3, 
previous studies demonstrated that FLIP molecules containing 3,4 
diethoxyphenylacetamido group as N-cap (530) were good inhibitors of CDK2/cyclin A 
(6.5µM) and CDK4/cyclin D (25.5µM). Incorporation of basic substituents including 
piperazinyl and alkyl amines onto heterocyclic scaffolds (5-((4-methylpiperazin-1-
yl)methyl)furan-2-carboxamide-RLIF, 5589, 5-((diethylamino)methyl)furan-2-
carboxamide-RLIF - 5581) resulted in moderate activity in both CDK2/cyclin A and 
CDK4/cyclin D
68
. Supportive docking results suggest that ion-pairing interactions with 
the negatively charged residues contributed to binding. Based on this result and literature 
reviews, benzoic acid derivatives were explored as N-capping groups. It was 
hypothesized that through effective substitutions on the 3,4 positions of benzoic acid core 
structure, ion-pairing, hydrogen bonding and van der Waals interactions might be 
retained.  
 
Figure 5.2 CDK2/cyclin A inhibitors developed by Genentech Inc.  
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In the first steps to exploiting the potential of the benzoic acid scaffold, 3-alkoxy 
derivatives were designed so as to build on the success of 3,5-diethoxyphenylacetic acid 
as an Ncapping group. Although docking studies were undertaken with 3- alkyloxy or 
aryl oxy substituted benzoic acids (Overlays of 3-substituted benzoic acid derivatives are 
shown in figure 5.3), none of these FLIPs had significant activity in the FP binding assay 
with the exception of 3-ethoxybenzamido substituted FLIP which had marginal affinity 
for CDK4/cyclin D. The observed inactivity of this FLIP series could be because of 
weaker van der Waals interactions resulting from too much flexibility of the groups 
without the ion-pairing interactions to stabilize binding. For sufficient activity, N-capped 
peptides require more extensive interactions that are made by the potent CGI peptides 
including ion-pairing and H-bond contacts. In order to improve the affinity of these 
Ncapped peptides, and due to the synthetic versatility of the benzoic acid scaffold, 
additional substituents were appended at the 4 position to include groups capable of ion-
pairing with the cyclin groove.  
 
Figure 5.3 Overlays of 3-susbtituted  
benzoic acid derivatives 
 
Overlay of docked poses of 3-susbtituted benzoic acid shows van der Waals 
interaction at the secondary pocket and hydrogen bonding with Gln 254. 
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In the first instance, single 4-substituted benzoic acids were generated for 
incorporation as capping groups. Inclusion of basic groups (guanidomethyl (541), 
piperazin1-yl (5850), piperidin-4yloxy (5851) and 4-methylpiperazin-1ylmethyl (5919) 
shown in table 6.1 resulted in significant improvement in the activity compared to the 3-
alkyl analogs. The guanidinomethyl substitution which has been previously reported, was 
generated as a RLNpfF FLIP and was the highest potency cyclin groove inhibitor in this 
series (0.69µM). The effectiveness of this compound is due to its very strong electrostatic 
interaction of the positively charged guanidine with the acidic region (Glu220, Glu224). 
Both the piperidin-4yloxymethyl (5851) and piperazinyl (5850) are similarly potent in 
binding to cyclin A in complex with CDK2 however 5851 exhibits higher activity for 
CDK4/cyclin D. The better activity in cyclin D could due to the proximity of piperidinyl 
group with Glu70 and GLu66. RRLNpfF is a better CBG inhibitor compared to RRLIF 
by 2 fold increased potency. The p-fluoro substituent on the phenylalanine ring enables 
increased hydrophobic contacts in the primary pocket
69
.  The increased binding of the 
RLNpfF peptide was confirmed by the comparison of 5566 and 5919 since both of these 
FLIPs have (4-piperazin-1ylmethyl)benzoic acid as N-cap. When ligated to RLNpfF 
(5566) has 2.5 fold better potency in cyclin A compared to the one ligated to RLIF 
(5919). Incorporation of a methoxy or a hydroxyl substituent at 3 position in 5896 and 
5920 improves cyclin A activity compared to the mono substituted counterparts (5851, 
5919) (figure 5.4). Alkoxy or hydroxyl substitution provides additional hydrophobic 
complementarity with secondary pocket in addition to H-bonding interactions of the OH 
with Trp217. The activity profiles of these two compounds confirms the hypothesis that 
having a basic group at 4 position and an alkyl group at 3 position improves the activity 
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of benzamide FLIPs through ion-pairing and van der Waals interactions. Based on 
improvement in the activity profiles of 3,4-disubstituted benzoic acid N-caps,  5896 and 
5920, next generation fragment alternatives included modifications on the piperazine 
moieties for additional hydrophobic interactions. These compounds were designed with 
alkoxy or hydroxyl substituents at 3-position and piperazine with additional alkyl groups 
at the 4 position of benzoic acid as shown in scheme 5.10. 
 
 
 
 
 
 
Figure 5.4 Docked pose of 5920 in CDK2/cyclin A 
Examination of the binding mode of  5920 reveals that N4 of the piperazine-
1ylmethylbenzoic acid  Ncap forms  ion-pairing interactions with Glu224, the 
carbonyl contributes to an H-bond with Gln 254 and 3-hyrdoxyl can H-bond to 
Trp217. 
 
Scheme 5.10 Design and optimization of benzoic acid derivatives for interaction with 
the secondary hydrophobic pocket.  
 
Glu224 
Gln254 
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Docking studies were carried out on a series of benzoic acid derivatives with 3-
alkoxy-4-(piperazine-1ylmethyl) groups.  The docked poses were prioritized based on 
their PLP1 score and further based on expected complementarity with the key acidic 
residues of the CBG (Glu220, Glu224), and with the secondary pocket. For the most part, 
results obtained in testing the synthesized FLIP compounds were in accordance the 
highly ranked docked poses. The design hypothesis was confirmed in that 3,4-
disubstituted benzamido FLIPS and those with a modified piperazine ring possess 
improved activity compared to previous series. The presence of an ethoxy group at 3-
position provides increased van der Waals contacts however the complementarity of the 
propoxy substitution is more optimal as was observed through increased binding 
observed with 5922 and 5968. As described in chapter 4, FLIPs 5963 (35DCPT- 
RβLNMeFNH2) and 5964 (35DCPT- RβL3TA) provided proof of concept for cell 
permeability and therefore this sequence was employed in the context of benzoic acid 
Ncap modification to compare activities with 35DCPT and examine cell permeability.  
Modifications to the piperazine ring (5967, 5969 and 5970) results in decreased binding 
to CDK4/cyclin D and shows selectivity for CDK2/cyclin A. Since these contain 
modified piperazine groups that have increased size, they can be more easily 
accommodated in the cyclin A groove relative to cyclin D which has a narrower 
secondary pocket. Although 5969 and 5970 are stereoisomers there is a significant 
difference in their activity. This can be explained through structural analysis where it was 
observed that the piperazine-2-methyl group of 5969 points out of the minor pocket 
however in 5970, the methyl group interacts efficiently with the secondary pocket 
resulting in the increased binding affinity for this analog (figure 5.5).  
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Figure 5.5 Binding modes of 5969 and 5970.  
Docked poses of 5969 and 5970 showing the orientation of 3-methyl substituent of 
piperazine. In 5969 it is pointing above the second pocket and in 55970 it is 
contacting with the second pocket 
 
As the FLIP molecules in this series were considered to potentially have more 
drug-likeness and stability they were tested for anti-tumor activity in a MTT assay. For 
the most part this series were inactive in both U2OS and DU145 cell lines with the 
exception of 5970 which showed marginal activity. To determine the lack of cellular 
activity compared to 5964, the physicochemical properties that determine drug likeness 
(including hydrophobicity and polar surface area) were calculated for these compounds to 
compare with the 35DCPT capping group. An additional series of benzoic acid 
derivatives were designed based on the FP results and physicochemical properties of 
35DCPT. Further experiments will examine the effects of increased hydrophobicity on 
cellular anti-proliferative activity.  
The main objective of the work described in this chapter was to more completely 
mimic of the interactions of CGI peptides through optimization of benzoic acid based N-
caps.  From the SAR results obtained, this objective has been achieved with appropriately 
modified FLIPs in which the ion-pairing, hydrophobic and hydrogen bonding interactions 
were retained.  Based on the physicochemical properties of 35DCPT, several analogs 
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were designed to have similar hydrophobicity and PSA characteristics. Although the 
initial analogs were in active in cellular studies, further analogs were proposed to address 
this issue and improve drug-like characteristics. In summary,  the extensive SAR data 
obtained for optimized benzoic acid Ncapped peptides further validates REPLACE 
strategy and suggests how these FLIPS can be further modified and improved for the 
development non-ATP competitive CDK inhibitors.   
5.4 Experimental section 
5.4.1 Materials and methods 
All solvents and reagents were used as obtained. 
1
H NMR and 
13
C NMR spectra 
were recorded with a Varian Mercury 300 and 400 Spectrometer, respectively. Mass 
spectra were measured with Micromass QTOF:  Tandem quadruple-time of flight mass 
spectrometer electrospray ionization (ESI) and VG 70S:  Double-focusing magnetic 
sector mass spectrometer (EI). Analytical purities of evaluated compounds were >95% 
unless stated otherwise. The following analytic method (unless stated otherwise) was 
used on a Waters Alliance 2695 HPLC with a 2996 diode-array detector and equipped a 
C18 (2) 100 A, 250 x 4.6mm, 5µ column (Phenomenox Luna). A gradient from 100% 
water (0.1% trifluoroacetic acid) to 60% acetonitrile (0.1% trifluoroacetic acid) was run 
over 30 mins and held for 4 mins. The chromatograms were extracted at 226 and 254 nm. 
Synthesis of 3-alkoxy benzoic acid derivatives
76
 
Step 1: Synthesis of ethyl 3-ethoxybenzoate (20a) 
3-hydroxy benzoic acid (0.69g, 5mmol), ethoxy bromide (0.25g, 23mmol) and 
potassium carbonate (0.13g, 16.5mmol) were refluxed in 5ml of DMF for 12-18hrs. The 
reaction was monitored by TLC (Ethylacetate: Hexanes= 35:65), after the reaction was 
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complete, the reaction mixture was cooled to room temperature; water was added to 
dissolve potassium carbonate. The aqueous layer was extracted with ethyl acetate and the 
combined organic layers were washed with saturated sodium bicarbonate, brine, dried 
over sodium sulfate and evaporated to get reddish oil (0.29g, 30%). 
ethyl 2-(3-ethoxyphenyl)acetate: 1H NMR (dimethyl sulfoxide-D6, 300MHz) δ (ppm) 
7.18(s,1H), 7.13 (t. J=7.71Hz, 1H), 6.75-6.78 (d, J=8.88Hz, 2H), 6.70-6.73 (d, J=8.67Hz, 
2H), 1.31 (t, J=7.11Hz, 3H), 1.16 (t, J=7.29Hz, 3H) GC MS- 208 
Step 2: Synthesis of 3-ethoxybenzoic acid (21a) 
The ethyl 3-ethoxybenzoate (0.97g, 5mmol) obtained from step 1 was treated with 
sodium hydroxide (2.8g, 70mmol) and a solution of 15ml ethanol and 15ml water. The 
reaction mixture was refluxed for two hours and the reaction was monitored by TLC 
(35% ethyl acetate in hexanes). After the completion of reaction, the reaction mixture 
was cooled, the alcohol was evaporated and diluted with water. The reaction mixture was 
acidified with 1N hydrochloric acid and stirred to precipitate the product as white solid 
(0.67g, 81.2%) 
2-(3-ethoxyphenyl)acetic acid :
1
H NMR (chloroform-D3, 500MHz) δ (ppm) 7.256 (t, 
J=7.75Hz, 1H) 6.8753 (d, J=7.65Hz, 1H), 6.8507(s, 1H), 6.8319 (d, J=2.2Hz, 1H), 4.0636 
(q, J=7.0Hz, 2H), 3.636 (s, 1H), 1,4296 (d, J=55.57Hz, 3H) 
13
C NMR (chloroform-D3, 500MHz) δ (ppm) 177.15, 159.14, 134.61, 129.6, 121.55, 
115.65, 113.41, 63.41, 41.01, 31.16, 14.80 GC MS-108 
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Synthesis of 3-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)benzoic acid and 4-(4-
(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid (22)
77
 
To a solution of 3-(piperidin-4-yloxy) benzoic acid (0.12g, 0.5 mmol) and 
potassium carbonate (0.13g, 1mmol) in 1mL of water di-tert-butyl dicarbonate (0.11g, 
0.5 mmol) was added as a solution in 0.6ml tetrahydrofuran, dropwise at 0 °C. After the 
addition was completed, the reaction mixture was allowed to come to room temperature 
and stirred for 4 h. THF was removed in vacuum and the aqueous phase was washed with 
ether. The aqueous phase was separated and adjusted to pH 2 with 1 N hydrochloric acid, 
and extracted with ethyl acetate. The combined organic extracts were concentrated to get 
3-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)benzoic acid (0.15 g, 49.5%) as a white 
solid. 
1H NMR (chloroform-D3, 400MHz) δ (ppm) 7.70 (d, J=7.17Hz, 1H), 7.61(s,1H), 7.37(t, 
J=8.34Hz, 1H), 7.15 (d, J=8.64, 1H), 4.55 (s,1H), 3.70(q, 2H), 3.36(q, 2H), 1.93(q, 2H). 
1.77(q, 2H), 1.46 (s,9H) 
13
C NMR (chloroform-D3, 400MHz) δ (ppm) 170.89, 157.29, 154.89, 130.65, 129.74, 
122.94, 122.26, 116.69, 79.75, 72.45, 28.45 
ES+344 
Synthesis of 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid (23)
77
 
To a solution of sodium salt of 4-(piperazin-1-yl)benzoic acid (0.36g, 1.5 mmol) 
and potassium carbonate (0.20g, 1.5mmol) in 3mL of water di-tert-butyl dicarbonate 
(0.32g, 1.5 mmol) was added as a solution in 1.8ml tetrahydrofuran, dropwise at 0 °C. 
After the addition was completed, the reaction mixture was allowed to come to room 
temperature and stirred for 4 h. THF was removed in vacuum and the aqueous phase was 
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washed with ether. The aqueous phase was separated and adjusted to pH 2 with 1 N 
hydrochloric acid, and extracted with ethyl acetate. The combined organic extracts were 
concentrated to get 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid (0.13 g, 45%) 
as a white solid. 
1H NMR (chloroform-D3, 400MHz) δ (ppm) 7.98(d, J=8.10Hz, 2H), 6.87(d, J=8.67Hz, 
2H), 3.58(s, 4H), 3.33 (s,4H), 1.48 (2,9H) 
13
C NMR (chloroform-D3, 400MHz) δ (ppm) 170.86, 154.68, 154.44, 132.03, 118.92, 
113.78, 80.21, 47.35, 28.42 
ES+307 
Synthesis of 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)benzoic acid
78
 
Step 1. Synthesis of 3-methoxybenzoic acid methyl ester (24)
76
 
To a solution of vanilic acid (0.67g, 4mmol) in 9ml of anhydrous methanol 
0.25ml of Conc. Sulfuric acid (3.0 mL) was added and the mixture was refluxed 
overnight. The reaction mixture was cooled to room temperature, the solvent was 
evaporated and the residue was dissolved in ethyl acetate. The organic layer was washed 
with 5% sodium bicarbonate, water and brine. Then it was dried over sodium sulfate, 
filtered, and concentrated to get a white solid (0.49 g, 68.2%) 
Step 2: Synthesis of tert-butyl 4-(4-(methoxycarbonyl)phenoxy)piperidine-1-carboxylate 
(25a)
78
 
4-Hydroxymethylbenzoate (0.30g, 2mmol) and triphenylphosphine (2.62g, 
10mmol) were dissolved in 30 mL of dry THF at 0 °C. To the stirred mixture a solution 
of N-(tertbutyloxycarbonyl)piperidin-4-ol (1.15g, 10mmol) and DIAD(2.02g, 10mmol) 
20 mL of dry THF was added drop wise over a period of 2 h,. The reaction mixture was 
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stirred for 5 days at room temperature and monitored by TLC (Ethylacetate: Hexanes-
35:65) to see the consumption of starting material. After the reaction was completed, the 
reaction mixture was diluted with 50 mL of ethyl acetate. The organic phase was washed 
with saturated aqueous sodium bicarbonate solution, dried over sodium sulfate and 
concentrated to give a semisolid. This material was suspended in 100-200 mL of 
hexane/ethyl acetate (9:1), stirred, and filtered to remove triphenylphosphine oxide. 
Evaporation of the filtrate under reduced pressure yielded oil that was purified by Flash 
column (hexane/ethyl acetate 6.5:3.5) to give oil that solidified on standing (0.23g, 70%). 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.97(d, J=8.7Hz, 2H), 6.9 (d, J=8.7Hz, 2H), 
4.55(m, 1H), 3.88(s,3H), 3.68(m,2H), 3.36(m,2H), 1.92(m,2H), 1.77(m,2H), 1.46(s,9H) 
EI+335 
di-tert-butyl 4,4'-((5-(methoxycarbonyl)-1,3-phenylene)bis(oxy))bis(piperidine-1-
carboxylate) (25c) 
1
H NMR (methanol-d4, 300 MHz) δ (ppm) 7.16(s, 2H), 6.78(s, 1H), 4.59(s, 2H), 4.09(q, 
J= 7.35Hz, 2H), 3.88(s, 3H), 3.69(s, 3H), 3.36(s, 3H), 1.92(s, 2H), 1.66(s, 2H), 1.46(s, 
18H) ES+535 
Step 3: Synthesis of 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)benzoic acid  (26a) 
1
H NMR (chloroform-D3, 500MHz) δ (ppm) 8.03 (d, J=8.73Hz, 2H), 6.93(d, J=9.0Hz, 
2H), 5.58(m,1H), 3.69(m, 2H), 3.73(m,2H), 1.93(m,2H), 1.85(m,2H), 1.47(s,9H) 
EI+321 
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4-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)benzoic acid (26b) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.71 (d, J=8.4Hz, 1H). 7.6(s, 1H), 6.93 (d, 
J=8.49Hz, 1H), 4.56(m,1H), 3.78(m,2H), 3.292(m,2H), 1.95(m,2H), 1.81(m,2H), 
1.46(s,9H) 
EI+365 
13
C NMR (chloroform-D3, 400MHz) δ (ppm) 171.22, 154.84, 151.48, 150.06, 124.21, 
122.28,114.45, 113.37, 79.77, 73.90, 56.09, 28.45 
EI+351 
3,5-bis((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)benzoic acid (26c) 
1H NMR (methanol-d4, 300 MHz) δ (ppm) 7.16(s, 2H), 6.65(s, 1H), 4.63-4.51(m, 2H), 
4.09(d, J=12.3Hz, 1H), 3.77-3.65(m, 4H),  3.39-3.32(m, 3H), 2.79(s, 1H), 1.91(s, 3H), 
1.73-1.57(m, 4H), 1.46(s, 18H) ES+521 
Synthesis of 4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-hydroxybenzoic 
acid
23
(27a)
79
 
To a solution of 4-Formyl-3-hydroxy benzoic (0.16g, 1mmol) and 1-Boc-
Piperazine (0.18g, 1mmol) in 25ml of dichloromethane was added sodium triacetoxy 
borohydrate (0.21g, 1.4mmol). The reaction mixture was stirred overnight at RT and the 
reaction was monitored by TLC (ethylacetate:hexanes-35:65). After the reaction was 
completed the reaction mixture was quenched with 2N sodium hydroxide and the reaction 
mixture was stirred for 10mins. The reaction mixture was diluted with dichloromethane 
and 2N sodium hydroxide. The layers were separated; the aqueous layer was acidified to 
pH4 to precipitate the product. The product was filtered off to get a white solid (0.33g, 
80.2%). 
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1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.69 (d, J=7.17Hz, 1H), 7,64(s,1H), 7.31(d, 
J=7.74Hz, 1H), 4.34(s,2H), 4.25(d, J=15.33, 2H), 3.67(d, J=10.95Hz), 3.43(m,2H), 
2.98(m,2H), 1.48(s,9H) 
ES+ 337 
tert-butyl 4-(2-ethoxy-4-(ethoxycarbonyl)benzyl)piperazine-1-carboxylate (28a) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.61(d, J=7.47Hz, 1H), 7.5 (s,1H), 7.45(d, 
J=8.13Hz, 1H), 4.36(q, J=6.27, 2H), 4.09(q, J=7.68Hz, 2H), 3.63(s,2H), 3.45(s,3H), 
2.65(s,2H), 2.46(s, 3H), 1.44(s,9H), 1.42-1.35(m,6H) 
EI+392 
tert-butyl 4-(2-propoxy-4-(propoxycarbonyl)benzyl)piperazine-1-carboxylate (28b) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.63(d, J=5.31Hz, 1H), 7.52(s,2H), 4.27(t, 
J=5.91Hz, 2H), 4.0(t, J=6.87Hz, 2H), 3.75(s, 4H), 3.52(s, 4H), 2.55(s,4H), 1.87-1.75(m, 
4H), 1.44(s,9H), 1.04(q, J=7.74Hz, 6H) 
EI+420 
4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-ethoxybenzoic acid (29a) 
1
H NMR (Dimethyl sulphoxide- D6, 300MHz) δ (ppm) 7.67(s, 2H), 7.62(s, 1H), 4.4(s, 
2H), 4.22(q, J=6.39Hz), 4.07(s,2H), 3.41(s,2H), 3.16(s,4H), 1.46(s,9H), 1.30-1.22(m,3H), 
EI+365 
4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-propoxybenzoic acid (29b) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.57(s, 2H), 7.53(s,1H), 4.01(t, J=6.69Hz, 
2H), 3.89(s,2H), 3.65(s,4H), 2.81(s,4H), 1.84(q, J=8.01Hz, 2H), 1.44(s, 9H), 1.05(t, 
J=7.32Hz, 3H), 
ES+379 
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Synthesis of 4-((4-(1-methylpiperidin-4-yl)piperazin-1-yl)methyl)benzoic acid/(R) 
and (S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)benzoic acid 
Step 1: Synthesis of benzyl 4-formylbenzoate
76
 (30) 
To a sample of 4-Formyl benzoic acid (0.75g, 5mmol) dry dimethyl formamide 
(15 mL) was slowly added with stirring 60 wt % NaH in mineral oil (0.14g, 6mmol). The 
reaction solution was stirred for 45 min, benzyl bromide (0.10g, 6 mmol) was added 
dropwise, and the reaction solution was stirred for an additional 5 h and monitored by 
TLC (ethylacetate:hexanes-35:65 with few drops of acetic acid). After the completion of 
the reaction, and the reaction solution was poured into 1N HCl (27mL) and extracted 
with ethyl acetate. The combined organic extracts were washed with saturated sodium 
bicarbonate and brine, dried over sodium sulfate, and concentrated to get a crude a yellow 
oil which was purified by flash chromatography (Biotage SP4) using a SNAP 100g 
column with a gradient run starting from 6% ethylacetate: 94% hexanes to 35% ethyl 
acetate and 65% hexanes over 15 column volumes to yield a white solid (0.62g, 51.6%). 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 10.1(2,1H), 8.23(d, J=8.04Hz), 2H), 9.95(d, 
J=7.922Hz, 2H), 7.47-7.311(m, 5H), 5.39(s,2H) 
EI+240 
Step 2: Synthesis of benzyl 4-((4-(1-methylpiperidin-4-yl)piperazin-1-yl)methyl)benzoate 
(31c)
79
 
To a solution of benzyl 4-Formyl benzoate (0.24g, 1mmol) and 1-(1-
methylpiperidin-4-yl)piperazine (0.18g, 1mmol) in 25ml of dichloromethane was added 
sodium triacetoxy borohydrate (0.21g, 1.4mmol). The reaction mixture was stirred 
overnight at RT and the reaction was monitored by TLC (ethylacetate:hexanes-35:65). 
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After the reaction was completed the reaction mixture was quenched with 2N sodium 
hydroxide and the reaction mixture was stirred for 10mins. The reaction mixture was 
diluted with dichloromethane and 2N sodium hydroxide. The layers were separated; the 
organic layer was evaporated to get the crude product. The crude material was then 
purified by flash chromatography (Biotage SP4) using a SNAP 25g column with a 
gradient run starting from 6% ethylacetate: 94% hexanes to 25% ethyl acetate and 75% 
hexanes over 10 column volumes to yield a white solid (0.34g, 85.3%). 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 8.01(d, J=7.80Hz, 2H), 7.45-7.33(m, 7H), 
5.35(s,2H), 3.53(s,2H), 2.89(s,3H), 2.57(s,3H), 2.47(s,3H), 2.24(s,3H), 1.91(t, 
J=10.98Hz, 2H), 1.78(d, J=12.78, 2H), 1.64-1.50(m, 4H) 
ES+408 
(R)-tert-butyl 4-(4-((benzyloxy)carbonyl)benzyl)-3-methylpiperazine-1-carboxylate (31a) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 8.02(d, J=7.77Hz, 2H), 7.48-7.29(m, 7H), 
5.35(s,2H), 4.01(d, J=14.28Hz,1H), 3.74(s, 1H), 3.62(d, 15.09Hz, 1H), 3.24(d, 
J=12.95Hz, 1H), 3.07(t, J=11.10Hz, 1H), 2.87(s,1H), 2.59(d, 12.72Hz, 1H), 2.43(s, 1H), 
2.09(d, J=12.7Hz, 1H), 1.44(s,9H), 1.10(d, J=6.3Hz, 3H) 
ES+425 
(S)-tert-butyl 4-(4-((benzyloxy)carbonyl)benzyl)-3-methylpiperazine-1-carboxylate (31b) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 8.07-8.00(m, 2H), 7.45-7.33(m, 7H), 
5.35(s,2H), 3.99(d, J=13.53Hz, 1H), 3.61(d, J=13.53Hz, 1H), 3.23(d, J=13.53Hz, 1H), 
3.07(d, J=12.78Hz, 1H), 2.92(d, J=8.25Hz, 1H), 2.75(d, J=9.03Hz, 1H), 2.59(d, 
J=12.03Hz, 1H), 2.49-2.30(m,1H), 1.76(s,1H), 1.44(s,9H), 1.09(d, 6.09Hz, 3H) 
ES+425 
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Step 3a: Synthesis of Synthesis of 4-((4-(1-methylpiperidin-4-yl)piperazin-1-
yl)methyl)benzoic acid (32)
80
 
The product obtained from step 1 (0.24g, 0.5mmol) was treated with Palladium 
over activated carbon (24mg, 10%) in the presence of methanol. The reaction mixture 
was stirred while hydrogen gas was passed from a balloon. The reaction was continued 
for 12 hours and monitored by TLC (ethylacetate:hexanes-35:65). After the reaction was 
completed, methanol was evaporated and the reaction mixture was dissolved in water. 
The palladium catalyst was filtered off using 0.45u filter. The aqueous layer was 
evaporated to get the desired product as white solid (0.15g, 99%). 
1
H NMR (methanol-d4, 400 MHz) δ (ppm) 8.18(s,2H), 7.72(s,2H), 3.97(s,2H), 
3.76(s,2H), 2.23(t, J=13.68Hz, 2H), 3.09(s,3H), 2.98(d, J=19..3Hz, 9H), 2.45(d, 
J=16.01Hz, 2H, 2.08-1.92(m, 2H) 
13
C NMR (methanol-d4, 400 MHz) δ (ppm) 130.18, 129.0, 61.75, 58.74, 53.94, 52.06, 
48.20, 43.21, 25.89 
ES+318 
Step 3b: Synthesis of (R)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-
yl)methyl)benzoic (33 a)
76 
The SM (0.44g, 1.1mmol), 4ml of 1N NaOH, 3ml of water and 3ml of alcohol 
were refluxed at 100
o
C for 2 hours. The reaction was monitored by TLC 
(ethylacetate:hexanes-35:65). After the completion of reaction, the aqueous solution was 
evaporated completely. The residue was dissolved in methanol, white solid that was not 
soluble in methanol was filtered off. The methanol was evaporated to get a reddish brown 
solid (0.27g, 73.5%). 
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(R)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)benzoic acid (33a) 
1
H NMR (methanol-d4, 400 MHz) δ (ppm) 7.61(d, J=8.32Hz, 2H), 7.13(d, J=7.52Hz, 
2H) 3.92(d, J=17.6Hz, 2H), 3.25-3.12(m, 4H), 3.10-2.98(m, 1H), 2.94-2.80(m, 2H), 
1.29(s, 9H), 1.14(d, J=6.44Hz, 3H) 
13
C NMR (dimethylsulfoxide-D6, 500MHz) δ (ppm) 170.84, 168.96, 142.41, 134.18, 
129.56, 79.7, 60.24, 57.48, 54.74, 28.51, 
ES+335 
(S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)benzoic acid (33b) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.96(d, J=8.04Hz, 2H), 7.43(d, J=8.04Hz, 
2H), 4.077(d, J=13.5Hz, 2H), 3.80-3.53(m,2H), 3.12(t, J=22.74Hz, 2H), 2.9(s, 1H), 2.73-
2.62(m, 1H), 2.50(s,1H), 2.15(t, J=10.11Hz, 1H), 1.44(s,9H), 1.16(d, J=6.57, 3H) 
13
C NMR (dimethylsulfoxide-D6, 500MHz) δ (ppm) 172.78, 169.26, 154.23, 142.99, 
141.21, 136.43, 129.47, 128.48, 128.38, 127.06, 126.87, 79.14, 63.33, 57.54, 54.70, 28.67 
ES+335 
Synthesis of 4-(((1-(tert-butoxycarbonyl)piperidin-4-yl)(methyl)amino)methyl)benzoic 
acid (16a) and 4-(((tert-butoxycarbonyl)(1-(tert-butoxycarbonyl)piperidin-4-
yl)amino)methyl)benzoic acid (37) 
Step1: tert-butyl 4-((4-(methoxycarbonyl)benzyl)(methyl)amino)piperidine-1-carboxylate 
(34a) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.98(d, J=8.19Hz, 2H), 7.39(d, J=7.92Hz, 
2H), 4.16(s,2H), 3.9(s,3H), 3.67(s,2H), 2.71-2.56(m,3H), 2.21(s,3H), 1,81(d, J=12.39Hz, 
2H), 1.56-1.50(m,2H), 1.44(s,9H) ES+363 
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tert-butyl 4-((4-(methoxycarbonyl)benzyl)amino)piperidine-1-carboxylate (34c) 
1
H NMR (methanol-d4, 300 MHz) δ (ppm) 7.99(d, J=7.86Hz, 2H), 7.40(d, J=8.43Hz, 
2H), 4.03(s,2H), 3.90(s,5H), 3.59(s,2H), 2.80(s,1H), 2.03(s,1H), 1.86(d, J=12.15Hz, 2H), 
1.44s, 9H) ES+349 
Step 2: Synthesis of 4-(((1-(tert-butoxycarbonyl)piperidin-4-
yl)(methyl)amino)methyl)benzoic acid (35a)
76
 
The SM (0.24g, 0.648 mmol), 4ml of 1N NaOH, 3ml of water and 3ml of alcohol 
were refluxed at 100
o
C for 2 hours. The reaction was monitored by TLC 
(ethylacetate:hexanes-35:65). After the completion of reaction, the aqueous solution was 
evaporated completely to get a white solid (0.1g, 80%). The crude mixture was purified 
by semi-prep HPLC
22
. 
1
H NMR (methanol-d4, 300 MHz) δ (ppm) 7.99(d, J=7.68Hz, 2H), 7.47(d, J=8.19Hz, 
2H), 4.22(d, J=13.34Hz, 2H), 4.08(s, 2H), 3.13(t, J=10.68Hz, 1H), 2.78(t, J=14.01, 2H), 
2.50(s, 3H), 2.02(d, J=14.01Hz, 2H), 1.63(q, J=12.0Hz, 2H), 1.45(s, 9H) ES+349 
Step 2a: Synthesis of tert-butyl 4-((tert-butoxycarbonyl)(4-
(methoxycarbonyl)benzyl)amino)piperidine-1-carboxylate (36)
77
 
The starting material (0.34g, 1.16mmol), and potassium carbonate (0.13g, 
1.16mmol) were dissolved in water and methanol to get a clear solution. The reaction 
mixture was stirred in an ice bath. The di-tert-butyl dicarbonate (0.50g, 2.32mmol) was 
dissolved in THF and added drop wise into the reaction mixture. The reaction mixture 
was allowed to come to room temperature and then it was stirred overnight. The 
consumption of the starting material was monitored by TLC (100% Ethylacetate). After 
the reaction was completed, the solvents were evaporated and the crude mixture was 
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separated by flash chromatography using a gradient of 12-100% Ethylacetate in 5 column 
volumes. The product was obtained as a white solid (0.4g, 77%) 
20
.  
1
H NMR (methanol-d4, 300 MHz) δ (ppm) 7.97(d, J=7.92Hz, 2H), 7.35(d, J=8.67Hz, 
2H) 4.47(s, 2H), 4.09(d, J=11.85Hz, 2H), 3.34(s,3H), 2.74(s,2H), 1.61(s,4H), 1.41(s, 
18H) ES+449 
Step 3: Synthesis of 4-(((tert-butoxycarbonyl)(1-(tert-butoxycarbonyl)piperidin-4-
yl)amino)methyl)benzoic acid (37)
76
  
The SM (0.44g, 1mmol), 3ml of 1N NaOH, 3ml of water and 3ml of alcohol were 
refluxed at 100
o
C for 2 hours. The reaction was monitored by TLC (ethylacetate:hexanes-
35:65). After the completion of reaction, the organic solvents were evaporated 
completely. The aqueous layer was neutralized to pH 7.0 with 1N NaOH to get a white 
solid which was filtered off (0.3g, 69.0%). 
1
H NMR (methanol-d4, 300 MHz) δ (ppm) 7.95(d, J=7.80Hz, 2H), 7.31(d, J=7.29Hz, 
2H), 4.47(s,2H), 4.09(d, J=13.89Hz, 2H), 2.72(s,2H), 1.61(s,5H), 1.42(18H) ES+435 
Synthesis of (S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)-3-
hydroxybenzoic acid (38a-c, 39a-b)
79
 
To a solution of 4-Formyl-3-hydroxy benzoic (0.16g, 1mmol) and (S)-tert-butyl 2-
methylpiperazine-1-carboxylate (0.45g, 2mmol) in 25ml of dichloromethane was added 
sodium triacetoxy borohydrate (0.59g, 2.8mmol). The reaction mixture was stirred for 2 
days at RT and the reaction was monitored by TLC (ethylacetate:hexanes-35:65). After 
the reaction was completed the reaction mixture was quenched with water and the 
reaction mixture was stirred for 10mins. The layers were separated; the aqueous layer 
was evaporated to get the crude product which was purified by flash chromatography.  
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1
H NMR (methanol-d4, 300 MHz) δ (ppm) 7.45(d, J=7.83Hz, 1H), 7.38(s,1H), 7.17(d, 
8.52, 1H), 4.27(d, J=14.07Hz, 1H), 3.75-3.60(m,3H), 3.52(s,1H), 3.09(s,1H), 2.85(d, 
J=12.39Hz, 1H), 1.45(s,9H), 1.21(d, J=6.03Hz, 3H) ES+351 
3-hydroxy-4-((4-methylpiperazin-1-yl)methyl)benzoic acid (38b) 
1
H NMR (methanol-d4, 300 MHz) δ (ppm) 7.42(d, J=8.01Hz, 1H), 7.38(s,1H), 7.16(d, 
J=7.89Hz, 1H), 3.80(s, 2H) 2.79(d, J=25.89Hz, 8H), 2.51(s, 3H) ES+251 
3-hydroxy-4-((4-(1-methylpiperidin-4-yl)piperazin-1-yl)methyl)benzoic acid (38c) 
1
H NMR (methanol-d4, 300 MHz) δ (ppm) 7.44(d, J=8.13Hz, 1H), 7.41(s, 1H), 7.34(d, 
J=8.13Hz, 1H, 4.32(s,2H), 3.52(d, J=12.0, 2H), 3.42(s, 4H), 3.27(s, 4H), 2.95(t, J=12.45, 
2H), 2.73(s, 3H), 2.24(d, J=12.87Hz, 2H), 1.75(q, J=20.97Hz, 2H) ES+334 
4-((4-ethylpiperazin-1-yl)methyl)benzoic acid (39a) 
1
H NMR (methanol-d4, 300 MHz) δ (ppm) 7.91(d, J=6.78Hz, 2H), 7.35(d, J=7.08Hz, 
2H), 3.65(s, 2H), 3.02(s, 3H), 2.92(q, J=5.10, 3H),  2.68(s, 4H), 1.24(t, J=6.87, 3H), 
ES+248.33 
4-((4-propylpiperazin-1-yl)methyl)benzoic acid (39b) 
1
H NMR (chloroform-D3, 300 MHz) δ (ppm) 7.86(d, J=7.47, 2H), 7.21(d, J=8.04Hz, 
2H), 3.77(s, 2H), 2.91(s, 3H), 2.71(s, 4H), 2.60(m, 3H), 1.68(m, 2H), 0.90(t, J=6.75Hz, 
3H) ES+262.35 
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Synthesis of (S)-tert-butyl 4-(4-(methoxycarbonyl)benzyl)-3-methylpiperazine-1-
carboxylate 
Step 1: Synthesis of (S)-tert-butyl 4-(4-(methoxycarbonyl)benzyl)-3-methylpiperazine-1-
carboxylate (40)
79
 
To a solution of 4-Formyl methylbenzoate (0.16g, 1mmol) and (S)-tert-butyl 3-
methylpiperazine-1-carboxylate (0.20g, 1mmol) in 25ml of dichloromethane was added 
sodium triacetoxy borohydrate (0.21g, 1.4mmol). The reaction mixture was stirred 
overnight at RT and the reaction was monitored by TLC (ethylacetate:hexanes-35:65). 
After the reaction was completed the reaction mixture was quenched with 2N sodium 
hydroxide and the reaction mixture was stirred for 10mins. The reaction mixture was 
diluted with dichloromethane and 2N sodium hydroxide. The layers were separated; the 
organic layer was evaporated to get the crude product. The crude material was then 
purified by flash chromatography (Biotage SP4) using a SNAP 25g column with a 
gradient run starting from 6% ethylacetate: 94% hexanes to 25% ethyl acetate and 75% 
hexanes over 10 column volumes to yield a white solid (0.34g, 85.3%). 
Step 2: Synthesis of (S)-methyl 4-((2-methylpiperazin-1-yl)methyl)benzoate (41)
56
 
The product from step 1 (S)-tert-butyl 4-(4-(methoxycarbonyl)benzyl)-3-
methylpiperazine-1-carboxylate (0.35g, 1mM) was stirred with 20% trifluoroacetic acid 
in 5ml of dichloromethane for 2hrs. The reaction was monitored by TLC 
(ethylacetate:hexanes-35:65). After the reaction was completed the reaction mixture was 
evaporated and the concentrated crude material was purified by flash chromatography 
(Biotage SP4) using a RP SNAP 10g column with a gradient run starting from 0% 
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Acetonitrile : 60% water over 10 column volumes to yield a reddish semi solid (0.22g, 
90%). 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 8.50(d, J=7.92Hz, 2H), 7.90(d, J=7.17Hz, 
2H), 4.41(s,3H) 3.74(q, J=12.51Hz, 2H), 3.58(t, J=11.74Hz, 3H), 3.43(m,2H), 3.319m, 
1H), 3.04(t, J=11.79Hz, 1H), 1.75(s, 3H)  ES+248.15
 
Step 3: (S)-methyl 4-((4-ethyl-2-methylpiperazin-1-yl)methyl)benzoate (42a)
79
 
To a solution of (S)-methyl 4-((2-methylpiperazin-1-yl)methyl)benzoate (0.24g, 
1mmol) and acetaldehyde (0.44g, 10mmol) in 25ml of dichloromethane was added 
sodium triacetoxy borohydrate (0.21g, 1.4mmol). The reaction mixture was stirred 
overnight at RT and the reaction was monitored by TLC (ethylacetate:hexanes-35:65). 
After the reaction was completed the reaction mixture was quenched with 2N sodium 
hydroxide and the reaction mixture was stirred for 10mins. The reaction mixture was 
diluted with dichloromethane and 2N sodium hydroxide. The layers were separated; the 
organic layer was evaporated to get the crude product. The crude material was then 
purified by flash chromatography (Biotage SP4) using a RP SNAP 10g column with a 
gradient run starting from 0% acetonitrile: 25% water, to 25% acetonitrile:75% water for 
3 column volumes, the gradient was held at 25% acetonitrile:75% water for 5 column 
volumes and then proceeded till 100% acetonitrile over 4column volumes to yield a white 
semi solid (0.16g, 60%). 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.92(d, J=7.17Hz, 2H), 7.30(d, J=7.65Hz, 
2H), 3.84(s, 3H), 3.33(d, J=12.48Hz, 2H), 3.13(m,2H), 2.96(q, J=5.25Hz, 2H), 2.86(s, 
1H), 2.68(m,2H), 2.50(m,2H), 1.26(t, J=7.41Hz, 3H), 1.16(d, J=5.94Hz, 3H) ES+276.18 
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 (S)-methyl 4-((4-propyl-2-methylpiperazin-1-yl)methyl)benzoate (42b) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.98 (d, J=7.74Hz, 2H), 7.37(d, J=7.98Hz, 
2H), 3.91(s,3H), 3.31(d, J=10.59Hz, 2H), 3.17(d, J=13.89Hz, 1H), 2.88(m,1H), 
2.76(m,3H), 2.52(m,4H), 1.72(m, 2H), 1.20(d, J=7.26, 3H), 0.96(t, J=8.82, 3H) 
ES+290.41 
Synthesis of (S)-4-((4-ethyl-2-methylpiperazin-1-yl)methyl)benzoic acid (43a)
76
 
Step 4: (S)-methyl 4-((4-ethyl-2-methylpiperazin-1-yl)methyl)benzoate (0.27g, 
1mmol), 4ml of 1N NaOH, 3ml of water and 3ml of alcohol were refluxed at 100
o
C for 2 
hours. The reaction was monitored by TLC (ethylacetate:hexanes-35:65). After the 
completion of reaction, the aqueous solution was evaporated completely. The residue was 
purified flash chromatography (Biotage SP4) using a RP SNAP 10g  column with a 
gradient run starting from 0% acetonitrile: 25% water over 10 column volumes, the 
gradient was held at 25% acetonitrile:75% water for 3column volumes and then 
proceeded till 60% acetonitrile over 4column volumes to yield a white solid (0.17g, 65%) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.89(d, J=7.50Hz, 2H), 7.32(d, J=7.08Hz, 
2H), 2.89(m,2H), 2.75(m,2H), 2.52(m,4H), 2.23(m,2H), 2.08(m,1H), 1.21(d, J=7.20Hz, 
3H), 1.11(t, J=7.20Hz, 3H) ES+262.17 
(S)-4-((2-methyl-4-propylpiperazin-1-yl)methyl)benzoic acid (43b) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 8.00(d, J=7.86Hz, 2H), 7.40(d, J=8.22Hz, 
2H), 3.92(s,2H), 3.44(s, 1H), 3.22(m,2H), 2.91(m,3H), 2.78(m, 3H), 1.77(m,2H), 1.29(d, 
J=6.81Hz, 3H), 0.97(t, J=7.23Hz, 3H) ES+276.38 
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Synthesis of 4-((1-substituted piperidin-4-ylidene)methyl)benzoic acid
82
 
Step 1: Synthesis of methyl 4-((diethoxyphosphoryl)methyl)benzoate (44) 
A mixture of methyl 4-(bromomethyl)benzoate (1.39 g, 5mmol) and triethyl phosphite 
(1.08g, 5.5 mmol) were stirred at 150°C for 24 h in an oil bath. The mixture was purified 
by reverse phase flash chromatography with a gradient of 100% water, 0% acetonitrile 
for 3 column volumes, the gradient was slowly changed to 40% water in 2 column 
volumes and held at 40% water for 2 column volumes. Then the gradient was slowly 
chaged to 0% water, 100% acetonitrile in 3 column volumes. The product was obtained 
as a colorless oil (yield-1.11 g, 78%). 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.96(d, J=8.22Hz, 2H), 7.34(d, J=7.98Hz, 
2H), 3.99 (t, J=7.14Hz, 2H), 3.88(s,3H), 3.21(s,1H), 3.14(s,1H), 1.21(t, J=6.42Hz, 6H) 
ES+286.28 
Step 2: methyl 4-((1-methylpiperidin-4-ylidene)methyl)benzoate (45a)
 82
 
The product 25 (0.29g, 1 mmol) step 1obtained from step 1 is stirred with THF (1.7 ml) 
in an ice bath. To this 15-crown-5 (0.018 g, 0.08 mmol) and NaH (60% in oil, 0.04g) was 
added and stirred for 30 mins at 0°C.  a solution of 1-methylpiperidin-4-one (0.09 g, 0.83 
mmol) dissolved in about 1ml of THF was added drop by drop to ice cold stirring mixture 
for about 20 mins while maintaining the temperature of the mixture at 0°C. After the 
addition of 1-methylpiperidin-4-one, the reaction was stirred at room temperature. 
Reaction was monitored with TLC (50% Ethylacetate: 50% Hexanes) for completion. 
After the reaction is complete the reaction mixture was poured in ice water and further 
partitioned with ethylacetate. Ethylacetate layer was collected and washed with saturated 
sodium bicarbonate followed by brine and finally dried over magnesium sulfate. The 
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crude product was purified in purified by flash chromatography (Biotage SP4) using a 
SNAP 100g column with a gradient 0% to 40% ethylacetate for 5 column volumes, the 
concentration of ethyl acetate at 40%  was kept constant for 2 column volumes and then 
increased to 100% in 5 column volume. The purified product was obtained as white 
powder (yield- 0.23g, 94%). 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.97(d, J=7.83Hz, 2H), 7.26(d, J=2.978Hz, 
2H), 6.30(s, 1H) 3.90(s,3H), 3.21(s,1H), 2.51(m,4H), 2.40(m,4H), 2.29(s, 3H)  
ES+245.14 
tert-butyl 4-(4-(methoxycarbonyl)benzylidene)piperidine-1-carboxylate (45b) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.98(d, J=7.92Hz, 2H), 7.24(d, J=6.60Hz, 
2H), 6.36(s, 1H) 3.90(s,3H), 3.51 (t, J=5.97Hz, 2H), 3.40 (J=5.43, 2H), 2.45(t, J=5.40Hz, 
2H), 2.35(t, J=2.28Hz, 2H), 1.47(s, 9H)  
ES+331.41 
4-((1-methylpiperidin-4-ylidene)methyl)benzoic acid (46a) 
1
H NMR (D2O, 300MHz) δ (ppm) 7.95(d, J=7.53Hz, 2H), 7.27(d, J=7.53Hz, 2H), 
6.57(s,1H), 3.30(s,2H), 3.20(s,1H), 2.85(s,3H), 2.78(t, J=5.55Hz, 2H), 2.70(t, J=5.58Hz, 
2H) ES+231.29 
4-((1-(tert-butoxycarbonyl)piperidin-4-ylidene)methyl)benzoic acid (46b) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 8.54(d, J=7.86Hz, 2H), 7.77(d, J=7.328Hz, 
2H), 6.87(s, 1H), 4.01(t, J=6.21Hz, 2H) 3.91(t, J=6.66Hz, 2H), 2.96(t, J=2.88Hz, 2H), 
2.85(t, J=6.18Hz, 2H), 1.96 (s, 9H) ES+331.41 
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tert-butyl 4-(4-(methoxycarbonyl)benzyl)piperidine-1-carboxylate (47)
 82
 
The product 26b ( 0.31 g, 1 mmol) was dissolved in MeOH/THF (1:1, 3 mL) and 
hydrogenated at 780 psi over 10% Pd/C(water 50%, 0.02 g) at 70°C for 18 h. The 
reaction mixture was filtered to remove Pd/C and concentrated in rotatory evaporator and 
dried. The residue was purified by flash chromatography (Biotage SP4) using a SNAP 
100g column with a gradient 0% to 60% ethylacetate for 5 column volumes, the 
concentration of ethyl acetate at 60%  was kept constant for 2 column volumes and then 
increased to 100% in 5 column volume. The purified was product obtained as white 
powder (yield- 0.32g, 98%) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 7.88(d, J=8.16Hz, 2H), 7.13(d, J=8.13Hz, 
2H), 4.02(m, 2H), 3.83(s,3H), 2.52(m, 4H), 1.52(s,4H), 1.37(s, 9H), 1.10 (m,2H) 
ES+233.31 
4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)benzoic acid (48) 
1
H NMR (chloroform-D3, 300MHz) δ (ppm) 8.36(d, J=8.07Hz, 2H), 7.58(d, J=9.18Hz, 
2H), 4.42(d, J=14.58Hz, 2H) 2.96(m, 4H), 1.94(d, J=13.86Hz, 2H), 1.79 (s, 9H) 
ES+319.40 
5.4.2 Fluorescence Polarization Binding Assay  
CDK4D1 FP assay: This assay was performed using black 384-well plates using 
a previously described procedure
55
 with the following modifications. To each well were 
added: 5 µl CDK4D1 (0.3 µg/well purified recombinant human kinase complex from 
Invitrogen), 5 µl compound solution, 5 µl 30 nM fluoresceinyl-Ahx-Pro-Val-Lys-Arg-
Arg-Leu-(3ClPhe)-Gly tracer peptide. Compounds and kinase complexes were diluted 
using assay buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, 1mM 
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dithiothretiol (DTT). Plate was centrifuged for 1 min at 500 rpm and then incubated with 
shaking for 45 min at room temperature. Fluorescence polarization was read on DTX880 
multimode detector (Beckman Coulter, Brea, CA) fitted with 485 nm/535 nm 
excitation/emission filters and a dichroic mirror suitable for fluorescein. Relative mp was 
calculated for each concentration tested using the equation showing below. IC50 values 
were determined by logarithmic regression by correlating relative mp and testing 
concentrations. 
Relative mp = 
mP(compound)-mP(DMSO, protein, tracer)
mP( DMSO, protein)-mP(DMSO, protein, tracer)
 
CDK2A2 FP assay This assay was performed using black 384-well plates. To 
each well were added: 5 µl CDK2A2 (0.3 µg/well purified recombinant human kinase 
complex), 5 µl compound solution, 5 µl 30 nM fluoresceinyl-Ahx-Pro-Val-Lys-Arg-Arg-
Leu-Phe-Gly tracer peptide. Compounds and kinase complexes were diluted using assay 
buffer (25 nM HEPES pH 7, 10 nM NaCl, 0.01% Nonidet P-40, 1mM dithiothretiol 
(DTT). Plate was centrifuged for 1 min at 500 rpm and then incubated with shaking for 
45 mins at room temperature. Fluorescence polarization was read on DTX880 multimode 
detector (Beckman Coulter, Brea, CA) fitted with 485 nm/535 nm excitation/emission 
filters and a dichroic mirror suitable for fluorescein. Relative mp was calculated for each 
concentration tested using the equation showing below. IC50 values were determined by 
logarithmic regression by correlating relative mps and testing concentrations. 
5.4.3 Docking
55
 
All the N-capping groups were docked in the cyclin A/CDK2 crystal structure 
(PDB ID 2UUE) using 1-(3,5- dichlorophenyl)-5-methyl-1H-1,2,4-triazole-3-
carbaldehyde as control ligand. The parameters of the LigandFit (Discovery Studio 3.0, 
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Accelrys) were PLP1 energy grid, minimization sphere “on”, number of poses 10. All the 
docked poses analyzed with PLP1 scoring function, hydrogen bonding and were 
subjected to visual analysis for complementarity with second pocket. 
5.4.4 Cell culture
79
 
U2OS osteosarcoma cells and DU145 human prostate cancer cells were obtained 
from ATCC (Manassas, VA). All cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM , Fisher Scientific) supplemented with 10% Fetal Bovine Serum (FBS, 
USA Scientific) and 100µg/ml of Streptomycin (strep)/ 100 U/ml of Penicillin (pen). 
Cells were incubated at 37ºC with 5% CO2. 
5.4.5 Viability assay 
Cells were seeded in 96-well plates at (2 × 10
3 
cells/ml) and allowed to adhere 
overnight in DMEM growth media containing 10% NU serum and 1% Pen/Strep. The 
compounds 5965, 5966, 5967, 5968 and 5970 were dissolved in DMSO and added in a 
dose dependent manner (1 µM to 100 µM). The diluted compounds were added to the 
cells in triplicate and incubated for 72 hours at 37
o
C with 5% CO2. The cell viability was 
determined using MTT (3-(4,5-Dimethylthiazol-2YI)-2,5-Diphenyl tetrazolium 
Bromide)  assay
4
.  Absorbance readings were obtained using a DTX880 multimode 
detector fitted with 595nm filter. Cell viability results were represented as the ratio of the 
absorbance reading in treated vs. untreated cells. IC50 values were obtained using a 
nonlinear regression line with 5.0 Graghpad Prism. Experiments performed in triplicates.
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CHAPTER 6 
OUTLOOK FOR THE FUTUTRE DVELOPMENT OF NON-ATP COMPETITVE 
COMPOUNDS AS CELL CYCLE SPECIFIC CDK INHIBITORS 
 
CDK inhibitors comprise an important class of anticancer agents. CDKs play a 
critical role in cell cycle and CDKs are deregulated in majority of human tumors
40
. 
Although there are several drugs in development in this category with interesting 
preclinical activity none have yet been approved by the FDA for clinical use
41
. For the 
most part, CDK inhibitors that have been investigated in clinical studies lack selectivity 
towards cell cycle CDK targets and have side effects as a result of their cross-reactivity
42
. 
The main goal of this project is to develop non-ATP competitive inhibitors targeting cell 
cycle CDKs. This is achieved by targeting CBG which is unique to cyclin A, D and E so 
as to avoid inhibition of transcriptional CDKs. Antagonizing protein-protein interactions 
at this site leads to selective inhibition of CDK2 and CDK4 that form complexes with the 
cyclins A, D and E which can lead to tumor specific killing of cancer cells with 
deregulated CDK/Cyclin/Rb/E2F1 pathways. Potent peptidic inhibitors have been 
identified in cell permeable forms that have significant anti-tumor activity.  In this study, 
a  novel strategy called REPLACE has been exploited to iteratively convert optimized 
peptidic inhibitors which in general do not make good drugs of CDK2/cyclin A as 
pharmaceutically appropriate compounds. Targeting protein-protein interactions (PPI) in 
drug discovery is highly challenging as these typically involve a large shallow contact
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 interface comprised ofnumerous and diffuse contacts
83
. Furthermore, peptidic 
compounds which inhibit PPI’s that are amenable to drug discovery are problematic due 
to their metabolic instability, cell permeability and poor bioavailability
48
. Current 
strategies that have been applied for the development of PPI inhibitors include design of 
proteomimetics and fragment based design
84,85
. REPLACE is an iterative strategy 
comprised of computational prediction, synthetic organic chemistry and biological 
evaluation used to convert peptidic inhibitors into FLIPs and ultimately non-peptidic 
drug-like compounds. Using REPLACE, fragment alternatives are designed and 
identified to mimic the interactions of binding determinants of a peptidic inhibitor. The 
combination of structural analysis along with synthetic methodologies and biological 
evaluation results in the efficient design of molecules that interact with hot spots (sites of 
critical interaction) and complement the large contact surface area of the PPI binding site. 
REPLACE overcomes the disadvantages of conventional fragment based design since the 
peptide acts as an affinity and solubility scaffold. Also the iterative nature of REPLACE 
means that the inhibitor is gradually converted in several steps therefore minimizing the 
possibility of complete potency loss through conformation change. PLAs are optimized in 
the context of the peptide prior to further truncation. In this study REPLACE has been 
exploited to generate more drug-like inhibitors that selectively inhibit cell cycle 
CDK/cyclin complexes and possess significant anti-proliferative activity. Capped 
peptides have been identified as more drug-like mimics of the lead octapeptide. Key 
fragment alternatives discovered include N-caps based on (i) phenyl heterocyclic 
carboxylic acids
63
, (ii) furan and thiazole carboxylic acids substituted with alkylamino 
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groups
68
 and (iii) pyridine carboxylic acids modified with alkoxy or basic groups
68
, (iv) 
phenylacetic acid derivatives
68
 and (v) benzoic acid derivatives.  
The first stage of the REPLACE
49
 strategy was identification of fragment 
alternatives for key peptide determinants using high-throughput docking. LigandFit
55
, a 
shape based docking method was employed for evaluating binding of fragments in the 
cyclin groove. LigandFit
55
 generates poses that have high complementarity with a 
binding site through the use of Monte Carlo conformational search methods in 
conjunction with a shape based comparison filter. Use of a LigandFit protocol with the 
PLP1 energy grid and a minimization step to refine generated poses, was shown to 
reproduce known binding modes of previously determined N-capping groups. An 
accurate prediction of the binding affinity of the generated poses was provided by using 
the PLP1 scoring function which was shown to obtain the best results since it takes into 
account hydrogen bonding between the ligand and receptor. Specific H-bonds and ion-
pairing interaction of CGI ligands with the cyclin groove have been shown to be 
important determinants of high affinity binding. Potential fragment alternatives for the N-
terminus were synthesized or obtained from commercial sources and then used to 
generate FLIP molecules through coupling to an assembled peptide on a solid support
56
. 
The ability of FLIPs to recapitulate the affinity of the native peptide is determined in a 
competitive binding assay using a known cyclin groove inhibitory peptide which is 
fluorescently labeled
57
. This assay has an important advantage which shows the inhibition 
of CDK2/cyclin A and CDK4/cyclin D complexes through specific binding of FLIPs on 
target (CBG). After confirmation of the ability of FLIPs to bind with sufficient avidity to 
the CBG, the potency of the peptide-fragment hybrids can then be further refined through 
150 
 
modifications to the N-capping groups. Initial studies examined the SAR of phenyl 
heterocyclic carboxylic acids as N-capping groups with these being designed to retain H-
bond interactions (Trp217 and Gln 254) and hydrophobic complementarity with 
secondary pocket
63
. Subsequent to this, additional Ncap scaffolds were pursued in order 
to provide charge-charge interactions with the acidic regions of CBG in addition to the H-
bond and minor pocket complementarity. To achieve this furoic and picolinic acid based 
derivatives were exploited and found to be moderately effective
68
. Benzoic acid based N-
caps easy to synthesize and were used to generate diverse SAR providing interactions 
with multiple subsites of CBG with the aim of improving previously developed scaffolds. 
Through the N-cap development and optimization critical interactions important for 
binding at the CBG was studied. The critical N-terminal residue Arg was replaced so as 
to reduce the charge of the overall compound and also to improve metabolic stability of 
the FLIP molecule.  
After identification of more optimal Ncaps, in order to make the rest of the 
peptidic cyclin groove inhibitor more drug-like, REPLACEments for C-terminal motif 
interacting with the major hydrophibic pocket were investigated.  Non-natural residues  
(β-Leu for Leu and Ile, NMePh/3TA for Phe) were incorporated to improve metabolic 
stability of the FLIPs along with retaining interactions at the primary pocket
71,72
. Along 
with metabolic stability, modification with a C-terminal amide functionality improved 
physicochemical properties such as clogP and polar surface area that contribute to drug 
like characteristics. After identifying a more optimal C-terminal motif, these were then 
combined with the most effective Ncap to generate FLIPS which should have greater 
metabolic stability and cell permeability. After confirming their binding activity, the 
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more drug like inhibitors were further tested for their anti-proliferative activity in cancer 
cell lines that harbor deregulated CDK/Cyclin/Rb/E2F1 pathways
52,54
. The effects on cell 
cycle distribution for the lead CGI compound, SCCP5964 were determined by FACS 
analysis and revealed that this molecule induces a G1 arrest, an observation consistent 
with the inhibition of cell cycle CDKs.  
  Overall significant progress has been achieved in further validating the 
REPLACE strategy in the generation of more drug-like cyclin groove inhibitors that are 
cell permeable and have anti-proliferative activity. These are the first reported CGI 
compounds that are innately drug-like and have anti-tumor activity. These compounds 
therefore form a novel class of CDK inhibitors with their unique capability to specifically 
inhibit cell cycle specific CDKs unlike clinically investigated compounds that target ATP 
binding pocket.  The REPLACE strategy has been successfully employed in the iterative 
conversion of peptidic inhibitors into more drug like compounds with anti-tumor activity 
consistent with on target inhibition demonstrating their potential for drug development. 
These compounds therefore have significant potential for further development as anti-
tumor therapeutics that show specificity towards cancer cells and potentially reduce the 
toxicities observed with ATP competitive compounds. 
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APPENDIX A 
 CHARACTERIZATION DATA OF REPRESENTATIVE N-CAPS  
 
 
Figure A.1 MS: 1-(3-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid 
 
  
Figure A.2 NMR: 1-(3-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid
164 
 
 
 
Figure A.3 
13
CNMR: 1-(3-chlorophenyl)-5-methyl-1H-1,2,4-triazole-3-carboxylic acid  
 
 
Figure A.4 MS-1-(4-chlorophenyl)-5-methyl-1H-pyrazole-3-carboxylic acid 
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Figure A.5 NMR- 1-(4-chlorophenyl)-5-methyl-1H-pyrazole-3-carboxylic acid 
 
 
Figure A.6 MS- 5-(3,5-dichlorophenyl)furan-2-carboxylic acid 
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Figure A.7 NMR- 5-(3,5-dichlorophenyl)furan-2-carboxylic acid 
 
 
Figure A.8 MS- 2-(3-propoxyphenyl)acetic acid 
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Figure A.9 NMR- 2-(3-propoxyphenyl)acetic acid 
 
 
Figure A.10 MS: 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid 
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Figure A.11 
1
HNMR: 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid 
 
 
Figure A.12 
12
CNMR: 4-(4-(tert-butoxycarbonyl)piperazin-1-yl)benzoic acid  
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Figure A.13 MS:4-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-3-methoxybenzoic acid 
 
 
Figure A.14 
1
HNMR:4-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)-3-methoxybenzoic 
acid 
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Figure A.15 
13
CNMR:4-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy) 
-3-methoxybenzoic acid 
 
 
Figure A.16 MS: 4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl) 
-3-hydroxybenzoic acid 
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Figure A.17 NMR: 4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-hydroxybenzoic 
acid 
 
Figure A.18 MS: 4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-ethoxybenzoicacid 
172 
 
 
Figure A.19 NMR: 4-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)-3-ethoxybenzoic 
acid 
 
Figure A.20 MS:(S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)benzoic 
acid 
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Figure A.21  NMR:(R)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-
yl)methyl)benzoic acid 
 
 
Figure A.22 MS: 4-(((1-(tert-butoxycarbonyl)piperidin-4-
yl)(methyl)amino)methyl)benzoic acid 
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Figure A.23 NMR: 4-(((1-(tert-butoxycarbonyl)piperidin-4-
yl)(methyl)amino)methyl)benzoic acid 
 
 
Figure A.24 MS: (S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)-3-
hydroxybenzoic acid 
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Figure A.25 NMR: (S)-4-((4-(tert-butoxycarbonyl)-2-methylpiperazin-1-yl)methyl)-3-
hydroxybenzoic acid 
 
 
Figure A.26 MS: 4-((4-propylpiperazin-1-yl)methyl)benzoic acid 
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Figure A.27 NMR: 4-((4-propylpiperazin-1-yl)methyl)benzoic acid 
 
 
Figure A.28 MS (S)-4-((2-methyl-4-ethylpiperazin-1-yl)methyl)benzoic acid 
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Figure A.29 NMR: (S)-4-((2-methyl-4-ethylpiperazin-1-yl)methyl)benzoic acid 
 
 
Figure A.30 MS: 4-((1-methylpiperidin-4-ylidene)methyl)benzoic acid 
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Figure A.31 NMR: 4-((1-methylpiperidin-4-ylidene)methyl)benzoic acid 
 
 
Figure A.32 MS: 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)benzoic acid 
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Figure A.33 NMR: 4-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)benzoic acid 
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APPENDIX B: 
 CHARACTERIZATION DATA OF FLIP MOLECULES 
Table B.1 Analytical data for FLIPs based on phenyl heterocyclic carboxylic acid 
derivatives 
 
FLIP Purity
Column 
Dimensions
Method Flow rate
HPLC 
Retention 
Time
Theoretical 
MW
Observed 
MW
5843 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 23.9 732 732.6
5773 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 22.4 801.77 800.55
5774 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 24.2 767.33 766.5
5762 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 9.0 731.91 731.65
5763 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 11.2 800.8 799.5
5764 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 10.1 766.34 765.55
5771 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 9.4 749.9 749.6
5765 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 10.1 766.35 755.65
5766 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 9.4 761.9 761.55
5767 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 20.4 761.9 761.55
5776 >75% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 23.3 785.7 784.55
5775 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 9.9 751.34 750.45
5768 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 11.4 786.77 787.55
5769 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 22.9 752.3 751.55
5772 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 9.7 735.87 735.65
5770 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 10.4 752.32 751.55
5588 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 21.7 747.9 747.4
5587 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 22.5 731.9 731.4
5760 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 22.2 731.9 731.6
5852 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 19.2 735.69 735.4
5583 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 23.6 769.37 768.3
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Table B.2 Analytical data for FLIPs based on thiazole, furan carboxylic acid, picolinic 
acid, phenylacetic acids  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FLIP Purity
Column 
Dimensions
Method Flow rate
HPLC 
Retention 
Time
Theoretical 
MW
Observed 
MW
5581 >90% 4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min 18.58 726.9 727.4
5585 >90% 4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min 17.94 721.82 721.45
5584 >90% 4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min 21.48 740.95 740.4
5589 >90% 4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min 17.82 753.95 753.45
5586 >90% 4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min 21.83 721.86 721.35
5582 >90% 4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min 21.10 740.95 740.25
5761 >90% 4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min 7.21 735.9 735.55
5845 >90% 4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min 19.68 666.69 666.55
5856 >90% 4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min 19.81 735.69 737.0
5854 >90% 4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min 19.85 709.69 709.45
5855 >90% 4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min 11.71 737.69 737.45
5853 >90% 4.6 × 250 mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1ml/min 22.42 723.69 723.45
182 
 
Table B.3 Analytical data for peptides and FLIPs derived from p21 and p107  
 
 
 
 
 
 
 
 
 
Peptide Purity
Column 
Dimensions
Method Flow rate
HPLC Retention 
Time
Theoretical 
MW
Observed 
MW
540 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 14.97 722.8 722.4
5811 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 16.5 703.88 703.8
5812 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 19.54 704.88 704.45
5831 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 17.68 704.89 704.9
5832 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 17.48 644.81 644.45
5833 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 21.05 618.77 618.4
5871 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 14.81 647.77 647.9
5873 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 18.02 604.74 604.45
5874 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 14.36 590.72 590.45
5875 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 15.15 604.7 605.1
5876 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 14.84 661.5 661.55
5941 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 16.51 618.78 618.25
5925 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 16.8 716.9 717.4
5930 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 16.63 618.72 617.9
5918 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 17.09 703.87 703.4
5877 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 17.69 675 676
5878 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 21.22 681 681.4
5879 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 17.2 689.87 689.6
5815 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 15.71 934.1 934.6
5814 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 13.14 940.14 940
5820 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 11.13 948.12 948.2
5813 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 13.36 953.14 953.9
5816 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 17.1 1046.4 1046.4
444 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 14.84 1040.27 1040.3
5557 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 15.97 1023.22 1023.2
5558 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 13.9 891.03 890.5
5559 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 16.5 980.19 980.1
5564 >90% 4.6X250mm 5-95% acetonitrile(0.05%TFA)/water(0.065%TFA) 1.0ml/min 15.94 1064.31 1064.45
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Table B.4 Analytical data for FLIPs based on benzoic acid derivatives 
 
SCCP ID Purity
Column 
Dimensions
Method Flow rate
HPLC Retention 
Time
Theoretical 
MW
Observed 
MW
5857 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 22.36 651.69 651.4
5858 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 10.3 681.69 681.4
5844 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 12.93 723.92 723.6
5846 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 21.01 743.5 743.55
5882 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 20.66 695.86 695.5
5883 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 22.65 709.89 709.5
5851 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 20.65 749.69 750.45
5850 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 19..79 734.69 736.4
5896 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 21.22 779.5 780.55
5919 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 17.74 749.7 749.4
5923 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 19.52 664.59 664.29
5920 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 17.44 765.7 765.1
5922 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 19.14 808.69 807.5
5921 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 17.99 763.7 763.2
5965 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 19.55 665.69 665.5
5966 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 17.02 680.69 708.5
5968 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 18.81 708.69 708.5
5967 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 17.8 760.69 761.6
5969 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 18.19 678.69 678.75
5970 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 17.87 679.54 678.55
6033 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 16.37 683.94 684.4
6034 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 16.07 697.97 698.3
6031 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 17.14 653.28 653.2
6032 >90% 4.6 × 250 mm 5-65% acetonitrile/water/0.1%TFA 1ml/min 18.28 722.09 721.25
